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Illicit drugs have profound effects on individuals and societies worldwide.  For individuals, drugs jeopardize
health, livelihood and security.  At the national level, their osmotic relationship with crime can make them
both cause and consequence of conflict, weak governance and underdevelopment. Poor countries are particu-
larly vulnerable and need help, as they lack the resources to break out of the vicious circle.  The global dimen-
sion of the drug problem is equally important:  illicit drug markets know no borders and their transnational
nature puts them beyond the reach of any single government, rich or poor.
While the cross-border dimension of drug trafficking has long been understood and translated into a highly
developed system of international cooperation, in recent years the opening of world markets has accentuated
this trait.  More than ever, a multilateral and coordinated response is needed.  In the United Nations Millen-
nium Declaration, Member States resolved to redouble efforts to provide such a response.  A year ago, gov-
ernments reaffirmed their commitment, made at the special session of the UN General Assembly (UNGASS)
in 1998, to make significant progress in countering the world drug problem by the year 2008.  They noted
that the "shared responsibility" (namely, the involvement of countries of origin as well as of destination), could
only be achieved by means of a "balanced approach" (giving demand as much attention as supply), balancing
preventive measures and law enforcement interventions.
This year's World Drug Report shows that though Member States have made significant progress in some areas,
there are others where effective measures are still needed.  Drug abuse remains at an unacceptable level.
There is no easy road to a world less tormented by illicit drugs. If we want to end the suffering, however, we
can together do a lot more than at present:
• First, the drug problem must be tackled in the broader context of human security and sustainable
development. It will take more than counter-narcotics operations (necessary as they may be) to con-
tain the drug problem - the  whole of society must be involved.
• Secondly, responses to the drugs and crime nexus must become more integrated. Criminals expropri-
ate huge sums of money from poor farmers and poor addicts alike. The United Nations Office on Drugs
and Crime (UNODC) recently merged the drugs and crime programmes within one internal struc-
ture and the new UN conventions against transnational organized crime and corruption offer unique
prospects of progress on the drug control front as well.
• Thirdly, drug control programmes must better attune themselves to the dynamics of drug markets: a
better understanding of underlying trends, more robust data, increased research and a deeper scientific
approach to the problem are all required.
I hope that readers will find this 2004 edition of the World Drug Report a useful contribution.
Antonio Maria Costa
Executive Director
United Nations Office on Drugs and Crime
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3The United Nations Office on Drugs and Crime (UNODC) is a global leader in the fight against illicit drugs
and international crime. UNODC has approximately 500 staff members worldwide. Its headquarters are in
Vienna and it has 21 field offices as well as a liaison office in New York. UNODC relies on voluntary contri-
butions, mainly from governments, for 90 per cent of its budget.  The three pillars of the UNODC work pro-
gramme are: 
• Research and analytical work to increase knowledge and understanding of drugs and crime issues and
expand the evidence-base for policy and operational decisions; 
• Normative work to assist States in the ratification and implementation of the international treaties, the
development of domestic legislation on drugs, crime and terrorism, and the provision of secretariat
and substantive services to the treaty-based and governing bodies; and 
• Field-based technical cooperation projects to enhance the capacity of Member States to counteract
illicit drugs, crime and terrorism.  
In 1998 the General Assembly gave UNODC the mandate to publish "comprehensive and balanced informa-
tion about the world drug problem."  Since then, the international community has recognized the importance
of detailed, factual and objective information to the field of international drug control. 
The United Nations Office on Drugs and Crime (UNODC) has published such assessments annually since
1999.  This year UNODC introduces its first two volume edition of the World Drug Report, which merges the
former Global Illicit Drug Trends publication and the World Drug Report. The consolidation of the two reports
is designed to increase the breadth of analytical coverage, while maintaining the annual frequency of statistical
output. The first volume covers market trends and provides in depth long term trend analysis, the second
volume compiles detailed statistics on all of the drug markets. Together they provide the most complete pic-
ture yet of the international drug problem. 
The aim of the present Report remains the same as previous years: to contribute to annual assessments by pre-
senting supply (production and trafficking) and demand statistics and analysis on the evolution of the global
illicit drug problem.  However, by presenting a thorough consideration of the status of the world drug situa-
tion and through the presentation of long term trends, this year's report goes further than ever in providing an
assessment of the world drug situation. 
As in previous years, the present Report is based on data obtained primarily from the annual reports ques-
tionnaire (ARQ) sent by Governments to UNODC in 2003, supplemented by other sources when necessary
and where available. Two of the main limitations herein are: (i) that ARQ reporting is not systematic enough,
both in terms of number of countries  responding and of content, and (ii) that most countries lack the ade-
quate monitoring systems required to produce reliable, comprehensive and internationally comparable data.
National monitoring systems are, however, improving and UNODC has contributed to this process over the
last few years. (For more information on data sources and limitations please consult the Methodology section
at the  end of the report.)
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5This report  has been reproduced without formal editing.
The designations employed and the presentation of the material in this publication do not imply the expression
of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of
any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or
boundaries.  The names of territories and administrative areas are in italics.
The following abbreviations have been used in this report:
ARQ Annual reports questionnaire
ATS         Amphetamine-type stimulants. Amphetamines (amphetamine, methamphetamine 
and related substances) and substances of the ecstasy group (ecstasy, MDMA,
MDEA, MDA etc.)
CICAD       Inter-American Drug Abuse Control Commission
CIS        Commonwealth of Independent States
DEA         Drug Enforcement Administration (United States of America)
DELTA UNODC Database for Estimates and Long-term Trends Analysis
DUMA Drug Use Monitoring in Australia
EMCDDA     European Monitoring Centre for Drugs and Drug Addiction
ESPAD European School Survey Project on Alcohol and other Drugs (Council of Europe)
F.O. UNODC Field Office
ICMP UNODC Global Illicit Crop Monitoring Programme
IDU Injecting drug use
INCB        International Narcotics Control Board
INCSR International Narcotics Control Strategy Report (United States of America)
Interpol/ICPO    International Criminal Police Organization
LSD         lysergic acid diethylamide
NAPOL National Police
PCP         phencyclidine
UNAIDS      Joint and Co-sponsored United Nations Programme on Human
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
WADAT Weighted Analysis on Drug Abuse Trends, referred to as Drug Abuse Trend Index
in this report.
WCO World Customs Organization
WHO         World Health Organization
Govt. Government
u. Unit
lt. Litre
kg Kilogram
ha Hectare
mt Metric ton
Explanatory notes

7This year the United Nations introduces its first two volume edition of the World Drug Report. The first volume
covers market trends and provides in depth trend analysis. The second volume compiles detailed statistics on all of
the drug markets. Together they provide another contribution of the United Nations Office on Drugs and Crime
towards understanding the world drug problem.  
Chapter 1: The world drug problem: A status report
The Policy Landscape
The multilateral drug control system is a very valuable piece of political capital, agreed upon through an incremen-
tal process spanning a century. Its legal framework is provided by the three international drug conventionsa.    Adher-
ence to the conventions is almost universal, and most States Members of the United Nations have ratified them.
The scope of control over drugs has broadened and deepened over the years, having begun with the regulation of
licit production and trade and before extending to the goal of international cooperation against the multi-faceted
problem of illicit drugs.  
Though there has been an epidemic of drug abuse over the last half-century, its diffusion into the general popula-
tion has been contained.  Less than 3% of the global population (or 5% of the population aged 15 and above) - the
annual prevalence rate of drug use today - is certainly evidence of containment, particularly when compared with
the annual prevalence rate of 30% for tobacco.  There are, however, three important caveats.  First, there is no clear
baseline with which to compare this 5% diffusion.  Secondly, though the large majority of the population (95%)
remains untouched by illicit drug use, some very susceptible segments of that population, particularly youth, have
been seriously affected by it.  Thirdly, while it can be argued that a diffusion of the epidemic in the general popu-
lation has been contained, it cannot be argued that the epidemic has been stopped.  Though considerable progress
has been made, the overarching objective of the drug control conventions - restricting the use of psychoactive sub-
stances under international control to medical and scientific use - has not yet been achieved.  
There is a powerful consensus among countries, however, that this is still a reachable goal.  The consensus reaches
across governments and public opinion in the vast majority of countries.  Current levels of illicit drug use, together
with the health consequences and criminal activities associated with it, have consistently been deemed unacceptable
by both policy makers and public opinion.  This is why the multilateral drug control system continues to enjoy
almost universal adherence.   Consideration of such an intensive and extensive level of consensus provides a crucial
sense of perspective for evaluating the paradoxical actions of a small, yet very vocal, number of actors to break ranks
and challenge the spirit of multilateralism. 
Executive Summary
a) The Single Convention on Narcotic Drugs of 1961 (United Nations, Treaty Series, vol. 520, No.7515), the Convention on Psychotropic Substances
of 1971 (Ibid., vol. 1019, No.14956) and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of
1988 (Ibid., vol.1582, No.27627).
The majority of governments, precisely because they still regard the drug conventions as relevant, have made con-
tinuous efforts to achieve better results in bringing the drug problem under control.
The Dynamics of World Drug Markets
What is the current level of drug use in the world?
The total number of drug users in the world is now estimated at some 185 million people, equivalent to 3% of the
global population, or 4.7% of the population aged 15 to 64.  The new estimates confirm that cannabis is the most
widely used substance (close to 150 million people), followed by the ATS (about 30 million people for the amphet-
amines, primarily methamphetamine and amphetamine, and 8 million for ecstasy).  Slightly more than 13 million
people use cocaine, and 15 million use opiates (heroin, morphine, opium, synthetic opiates), including some 9 mil-
lion who take heroin.    
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Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.    
Remark: As drug users frequently take more than one substance (poly-drug use), the world total for all illicit drugs together is not equal
to the sum of the estimates for each individual drug category.
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In terms of health impact, as measured by the demand for treatment services, opiates remain the most serious prob-
lem drug in the world.  They account for 67% of drug treatment in Asia, 61% in Europe and 47% in Oceania.  In
South-East Asia, however, methamphetamine has become the main problem drug in the last decade.  Cocaine still
comes first in the Americas as a whole, but the number of admissions to treatment centres are now higher for heroin
than cocaine in the USA. In Africa, cannabis continues to dominate treatment demand (65%).
How is the drug problem evolving?
The spread of drug abuse may be losing momentum. There is a notable exception however: consumption of cannabis
herb, the most commonly used illicit drug in the world, appears to be spreading at an accelerated pace. During the
last decade, the highest increases, after cannabis, were for the ATS (mainly ecstasy), followed by cocaine and the opi-
ates.
9
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Source: UNODC, Annual Reports Questionnaire Data. Source: UNODC, Annual Reports Questionnaire Data.
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Global drug abuse trends in 2000 
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Global drug abuse trends in 2002 
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The overall number of drug seizures has consistently increased since the early 1990s, but there were signs of stabi-
lization or decline in 2002. Global seizure data for the period 1990-2000 show a decline in the relative importance
of cannabis, the rapid emergence of ATS, an increase of opiates and an increase, followed by a stabilization, of
cocaine.
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Over a 10-year period, the quantities of illicit drugs seized have also increased as a whole. Ecstasy, depressants and
amphetamine-type stimulants show the strongest increases. From 2001 to 2002, however, the quantities seized
remained largely stable, with the exception of ecstasy. In terms of absolute quantities, drug seizures are consistently
dominated by cannabis, followed by cocaine, opiates and then ATS.
The conversion of the quantities of drugs seized into unit equivalents (a typical dose taken by drug users to experi-
ence a 'high') facilitates more meaningful comparisons of seizures across drug categories. The converted figures
reflect the strong increases of the 1990s (from 14 billion doses in 1990, to 26 billion in 2000), and signs of stabi-
lization in 2001/2002. Seizures in unit terms are the highest in the Americas (10.4 billion doses), followed by Europe
(7.4 billion), Asia (5.5 billion), Africa (2.4 billion) and Oceania (0.08 billion).  On a per capita basis, however, the
ranking changes to: the Americas (12.1 units or doses seized per capita), Europe (10.2), Africa (2.9), Oceania (2.6)
and Asia (1.5). The relative importance of the Americas declined over the last two decades, while Europe's increased.
Overall, cannabis remains by far the most frequently seized substance in terms of unit equivalents; in Africa, it
accounted for 99% of all seizures in 2002. The Americas have the highest percentage of seizures of cocaine-type sub-
stances (31% in 2002), while Asia comes first for the proportion of opiates in seizures (43% in 2002). Seizures of
ATS are dominant in Oceania (more than half of all seizures in that region in 2002).
Global illicit production of opium (from which heroin is processed) has remained stable, at around 4,000 to 5,000
metric tons, since the early 1990s, but has become increasingly concentrated in Afghanistan.  Coca cultivation
(cocaine is extracted from the leaves of the coca bush) was stable during most of the 1990s, but has been steadily
decreasing since 1999 (-30% from 1999 to 2003).  There is unfortunately not enough data to establish any mean-
ingful global illicit production trend for cannabis, which is now reportedly cultivated in more than 140 countries
throughout the world.  The situation is somewhat similar for ATS, although the spectacular progression in the
number of seizures of illegal laboratories since the mid-1990s (from less than 1000 in 1995 to about 10,000 in 2002)
is consistent with trends reported for ATS consumption.
The outlook for world drug markets
Taking into account trends in cultivation, production and consumption, the global heroin market has remained
largely stable in 2002, but there are indications of a slight expansion in 2003 and a forecast for a larger one in 2004.
As opium poppy cultivation is increasingly concentrated in Afghanistan, which produced three-quarters of the
world's illicit opium in recent years, the fate of the world heroin market will largely depend on what happens in that
country. The overall stabilization and decline in coca cultivation and cocaine production has been sustained for the
fourth straight year. There is no indication that this trend will be reversed. Vigilant supply reduction efforts con-
tinue in Colombia, Peru and Bolivia. While there have been some setbacks, these efforts are likely to be sufficient
11
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to sustain overall declines in cultivation and production. The cannabis market remains buoyant. In South America
consumption is rising, and the market continues to expand in Western and Eastern Europe as well as in Africa. In
the United Kingdom, Europe's largest cannabis market, use has stabilized at high levels over the last three years.
Although  the market for ATS is expanding and buoyant,  there are some signs that the rate of increase is slowing
down from the rapid increases that characterized virtually every sector of this market over the past ten years. 
Injecting drug use and HIV/AIDS 
Global estimates, provided by UNAIDS and WHO, indicate that by the end of 2003 between 34 and 46 million
people were living with HIV/AIDS. Between 4.2 and 5.8 million people were infected in 2003 alone.  In the same
year, between 2.5 and 3.5 million people died of AIDS. While the bulk of new infections are due to unsafe sexual
behaviour, the use of contaminated injection equipment among injecting drug users continues to fuel the pandemic,
particularly in Eastern Europe, Central, South and South East Asia and Latin America. According to a review of the
Reference Group on the Prevention and Care of HIV/AIDS Among Injecting Drug Users in 2003, information on
the size of the injecting drug user population is available for 130 countries and territories, and data on the associa-
tion of HIV infection with injecting drug use is available for 78. The group estimated that there are approximately
13 million injecting drug users worldwide, of which 8.8 million are in Eastern Europe, Central, South and South-
East Asia, 1.4 million in North America, and 1 million in Latin America.
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Conceptual advances in drug control 
Despite favourable comparison with the public health disaster created by the largely uncontrolled tobacco industry,
drug control results still fall short with respect to the ambitions enshrined in the UN conventions. Further steps
towards resolving the drug control equation are required and possible.  Since drug control proceeds essentially by
trial and error, there have been many conceptual advances that have found practical applications and yielded good
results over the years. A number of recent developments offer the prospect of better results.  
A holistic approach
Addressing the drug problem in a broader sustainable development context 
The drug problem has a negative impact on the functioning of societies as a whole.  It can hinder development pro-
grammes and compromise peacemaking and reconstruction efforts in countries torn by civil war. In turn, poverty,
strife and feeble governance are fertile ground for drug production, trafficking and abuse.  Those various dimen-
sions can become so interlocked that getting out of the vicious circle they create can only be accomplished through
a comprehensive approach.  Confined for too long to special programmes handled by specialized agencies, drug con-
trol priorities are now finding their way into the mainstream of the socio-economic agenda.  
Starting at community level, this broader understanding of the socio-economic dimensions of the drug problem
must notably be reflected in a society-wide approach. Public institutions cannot do everything.  Interventions are
far more effective when they are joined by the various actors in civil society (such as families, non-governmental
organizations, and the media) in a common purpose and programme. 
Providing an integrated response to the drugs and crime nexus 
The overlaps between the twin sectors of drugs and crime control have increased and the integration of programmes
is progressing, as exemplified by the recent merger of the two within UNODC. The connections between drug traf-
ficking, organized crime and, to some extent, the financing of terrorism, have been brought to the forefront of inter-
national attention. The recent enrichment of the multilateral system with a new set of ground-breaking instruments
against transnational organized crime,  trafficking in human beings, smuggling of migrants, trafficking in firearms
and corruption is opening the way for potentially significant advances in the fight against drugs and crime.
Addressing the drugs and crime nexus under the new paradigm of human security 
Stemming from the 2000 UN Millennium Summit, the work of the Commission on Human Security is advancing
a new paradigm of security that would complement the fundamental concepts of human development and human
rights.  The notion of 'human security' that encapsulates this new paradigm can provide a much needed conceptual
link between drugs/crime control and sustainable development policies.  
A more synergistic approach
An ongoing regeneration of drug control strategies is expected to improve their efficacy in the coming years. The
1998 UNGASS stated the importance of integrated and balanced approaches to the drug problem.  In 2003, gov-
ernments called for a comprehensive strategy, as well as further development of evidence-based initiatives and of data
collection, analysis and evaluation tools to support them. 
There remain huge terras incognitas in drug-related data and statistics, especially in developing countries.  Also, still
little is known about the structure and dynamics of drug markets at national, regional and global levels. There is a
pressing need to fill that knowledge gap in order to develop more synergistic drug control strategies. The deficiency
of compartmentalized sectorial and geographical approaches must be addressed. 
Illicit drugs are commodities at the centre of lucrative, clandestine and transnational markets.  Albeit illegal, these
markets obey basic supply and demand rules and respond to stimuli and pressures.  Understanding the rules will
help to better conceive the kind of pressures that could break them. Both more efforts to improve drug related data
collection and analysis, as well as vigorous research programme into the way drug markets are structured, operate
and evolve are required.
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A more dynamic approach
Understanding and controlling drug epidemics
Though drugs are commodities, their use diffuses into susceptible segments of the population like infectious dis-
eases. The term 'drug epidemics'  thus offers a useful analogy. The powerful dynamics created by the combination
of the incentives and behavior of a ruthless market with the contagious characteristics of an epidemic explain why
drug use can expand so rapidly and become so difficult to stem. Since young people are particularly vulnerable, it
is important to monitor closely the prevalence, incidence and evolution of illicit drug use among them.  
Analysis of, and responses to, the drug problem have so far been too static. Both tend to treat the phenomenon as
essentially linear. Fine-tuning and sequencing drug control interventions to maximize their effectiveness would
require the development of dynamic, non-linear models of the drug problem.  Understanding how drug epidemics
evolve and how feedback effects can alter their evolution, would help to better balance and time interventions. It
would also help to allocate resources across sectors and over time, significantly improving the cost-effectiveness of
drug control strategies. Research on that topic has started.  Further work is needed to produce and validate models
that would have an operational value.  
Chapter 2: Trends
Opium / Heroin Market
Production
At the global level, illicit opium poppy cultivation declined 6% to 169,000 ha in 2003, equivalent to a potential
heroin production of approximately 480 tons. Opium poppy cultivation is now 40% less than in the early 1990s,
when it was approximately 270,000 ha. However, the distribution of cultivation has changed over the past decade,
with a decline in the low opium yield areas of South-East Asia and an increase in the high opium yield areas of
Afghanistan. In 2003, more than 90% of the  illicit cultivation of opium poppy took place in three countries:
Afghanistan, Myanmar and Laos. 
An increase of cultivation in Afghanistan, combined with a higher opium yield (45 kg/ha) than in South-East Asia
(13 kg/ha), resulted in an overall increase of 5% of global illicit opium production between 2002 and 2003. In 2003,
the 3,600 tons of opium produced in Afghanistan (the second highest opium production in Afghanistan's history),
provided more than three-quarters of the world's illicit opium supply. 
The potential farmgate value of opium production in 2003 at the global level was estimated at about US$1.2 bil-
lion. More than 85% of this amount was made in Afghanistan. The amount of opium poppy cultivation in
Afghanistan in 2004 will continue determining the level of the world's supply of illicit opium and heroin. The results
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of the Afghan farmers' intention survey conducted by UNODC and the Afghan Government in October 2003, the
time of planting for the 2004 opium poppy season, indicated that over two-thirds of the opium farmers interviewed
intended to increase their level of opium poppy cultivation in 2004; only a few stated an intention to decrease.
Trafficking
Global seizures of opiates (heroin, morphine and opium expressed in heroin equivalents) increased by 9% in 2002
after having fallen by 22% in 2001. The increase was a consequence of the doubling of morphine seizures, which
was a reflection of the resumption of large-scale opium poppy cultivation and processing in Afghanistan in 2002.
Heroin seizures, in contrast, declined by 15% as the huge stocks, which were built up in 1999/2000, were gradu-
ally depleted. Some preliminary data for 2003, however, suggest that trafficking in opiates, including heroin,
regained momentum as Afghanistan had another good opium poppy harvest. In line with the fact that the world's
two largest illicit opium production areas are located in Asia, most opiates seizures also take place in Asia (65% of
all opiates seizures in 2002). Europe accounts for 28% and the Americas for 6% of global seizures. Iran, followed
by Pakistan, were the two countries with the largest opiate seizures worldwide in 2002. Iran alone accounted for
25% of global opiate seizures in 2002, Pakistan for 16%. Taking heroin in isolation, Central Asia accounted for
about a third of all seizures made in the countries surrounding Afghanistan. The proportion of Central Asia in heroin
seizures made in countries surrounding Afghanistan was twice as high in 2002 as in 2000, indicating more use of
the Central Asian trafficking route.  Opiate seizures rose by almost 20% in Europe in 2002 and were back to the
levels reported in 2000.  
Abuse
Heroin abuse in the countries of Western Europe continued on a stable to declining trend. The number of drug
related deaths, mostly related to heroin, fell by some 20% between 2000 and 2002. There are also indications that
the injecting of drugs has been stable or decreasing over the last few years in most countries in Western Europe.
Newly diagnosed HIV infections related to injecting drug use (IDU) have experienced a general decline since 2000.
They fell in Western Europe by more than 30% between 2000 and 2002. 
The Russian Federation appears to be Europe's largest heroin market: its total number of drug users is now esti-
mated to be 3 to 4 million people, of which one third are heroin abusers.  The Russian Federation also has one of
the highest IDU related HIV rates in the world, and, until 2001, it was increasing rapidly. In 2002, however, newly
reported cases of IDU related HIV declined strongly in the Russian Federation as well as in a number of other coun-
tries of the former Soviet Union and in Poland, leading to a significant decline in the overall number of  newly diag-
nosed HIV cases (minus 43% in the Russian Federation and minus 36% in the countries of the former Soviet
Union). 
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The pattern of opiate abuse trends in Asia was mixed in 2002. Stable/declining trends were reported from most
countries in  East and South-East Asia, reflecting falling opium production in Myanmar and Laos. Stable or declin-
ing trends were also reported from Pakistan and some of the Central Asian countries, a delayed consequence of
Afghanistan's opium poppy ban of 2001. Central Asia, which suffered for many years from the strongest growth
rates of heroin abuse and  IDU related HIV, saw a marked decline in the number of newly diagnosed HIV cases in
2002. In Pakistan overall heroin abuse was reported to have declined slightly in 2002. In India, overall opiate abuse
was reported to have remained stable in 2002 following years of increase. Thailand shows a continuing downward
trend in opiate abuse since the mid 1990s, though this runs in parallel with an increasing trend in methampheta-
mine use. 
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In contrast to a majority of Asian countries reporting stable or declining abuse trends in 2002,  opiate abuse was
reported to have continued rising in China, the world's most  populous country. The number of registered drug
addicts rose in  2002 and in 2003 to exceed 1 million people,  a 15-fold increase over the 1990-2003 period. The
most significant decline of opiate abuse in recent years was reported from Oceania in 2001.  It lasted well into 2002
and - according to preliminary data - into 2003 as well largely due to the 2001 shortage of heroin in Australia's
domestic market.
Heroin abuse, which increased in the Americas over the last decade, finally stabilized in 2002.  In the USA, general
population surveys revealed a basically stable level in 2002. In  contrast to the situation in North America, a number
of countries in South America, the Caribbean and Central America (Argentina, Colombia, Venezuela, El Salvador,
and the Dominican Republic) reported rising levels of opiate abuse in 2002, reflecting the ongoing production of
opium in the region.
Coca/Cocaine Market
Production
Global coca cultivation continued declining for the fourth straight year in 2003. The total area under coca cultiva-
tion in Colombia, Peru and Bolivia combined declined to 153,800 ha, an 11%  decline from 2002 and a 30%
decline from the peak of coca cultivation in 1999.  As has been the case since 1996, the majority of all coca culti-
vation (56%) took place in Colombia, 29% took place in Peru and 15% took place in Bolivia. In 2003, world poten-
tial cocaine production was 655 tons, down from 800 tons in 2002. It amounted to 155 tons in Peru, 60 tons in
Bolivia and about 440 tons in Colombia,  down from 580 tons in the previous year.
Trafficking
Cocaine seizures remained stable in 2002, and were some 10% less than in 1999, the latest peak year of  global
cocaine production. After having increased dramatically in the 1980s at the time when cocaine production sky-
rocketed, cocaine seizures have been characterized by a stabilization / decline in recent years, reflecting  the pro-
duction trend.    The bulk of cocaine seizures continue to take place in the Americas. In 2002,  55% of all cocaine
seizures took place in South America (including Central America and the Caribbean), 32% in North America and
13% in Europe (of which 99% in Western Europe). The most striking trend in recent years has been the strong
increase in European cocaine seizures, reflecting underlying shifts in trafficking. Although Europe's record seizures
of 2001 were not repeated in 2002, the proportion of cocaine seizures made in Europe (13% of global seizures in
2002) was substantially higher than in 1990 (6%) or in 2000 (8%).
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Abuse
The spread of cocaine use is losing momentum. In North America it appears to have been basically stable. The
annual prevalence of cocaine use in the USA was 2.5% of the population age 12 and above in 2002. Canada also
reported a stabilization of cocaine use in 2002. In Mexico cocaine use remained basically stable over the 1998-2002
period.  In South America in 2002, use stabilized in Bolivia and Peru. Cocaine use continues to rise in Europe,
though at a lower pace than in previous years. Crack cocaine is still concentrated in few locations in Europe, but
there is a risk that, once established in local markets, it could spread across the continent.  Cocaine use remains low
in Asia, but increases were seen in the Near East and in South Asia.
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Cannabis Market
Production
Cannabis herb production has been rising and may have reached some 32,000 tons in 2002. It is globally dispersed,
with 142 countries reporting cannabis plant seizures over the 1992-2002 period. North America seems to be the
world's largest cannabis market, accounting for two-thirds of global cannabis herb seizures over the 2001-2002
period. US authorities report that two-thirds of cannabis herb is domestically produced. In South America,
Colombia and Paraguay are among the main source countries. Cannabis production in Africa is reported from
practically every country. Most countries in Europe also report domestic production of cannabis. The most
frequently cited source country in Europe is Albania which supplies most countries in the Balkan region as well as
Italy. The Netherlands was the second most frequently cited source country in Europe in 2002. If available estimates
from various sources are combined, data show a strong decline of cannabis herb production over the 1989-1992
period,  followed by an increase over the subsequent decade so that global cannabis herb production in 2002 has
again reached levels similar to the late 1980s. In Western Europe, the world's largest cannabis resin market, where
more than two-thirds of all cannabis resin seizures were made in 2002, about 80% of the cannabis resin is estimated
to originate in Morocco. Global cannabis resin production is estimated at about 7,400 tons; of this, about 3,000 tons
are produced in Morocco.  
Trafficking
The two cannabis products, cannabis herb (marijuana) and cannabis resin (hashish) remain the most extensively traf-
ficked drugs worldwide. Practically all the countries of the world are affected by cannabis trafficking.  Seizures of
cannabis exceed those of other drugs in almost all countries. In 2002, a total some of 5,800 tons of cannabis prod-
ucts were seized globally.  This total includes more than 4,700 tons of cannabis herb, more than 1,000 tons of
cannabis resin and more than 1 ton of cannabis oil.  The volume of seized cannabis products was more than 15 times
the volume of cocaine and more than 100 times the amount of heroin seized. The upward trend in cannabis seizures,
which began in the early 1990s, continued in 2002. Cannabis herb seizures remained generally stable, but cannabis
resin seizures increased in 2002, offsetting the decline reported the previous year. Overall cannabis seizures were
almost twice as high in 2002 as a decade earlier. Over the 2001-2002 period, 55% of all cannabis seizures were
reported from the Americas, 20% from Africa, 16% from Europe, 9% from Asia and less than 1% from Oceania.
In 2002 cannabis seizures fell in Oceania and in Africa but increased in Asia, the Americas and in Europe.
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Abuse
Global cannabis consumption continued its steep rise over the 2000-2002 period.  This follows a gradual increase
in the early 1990s (1991-1997) and some stabilization over the 1997-2000 period. In the USA, the level of cannabis
use remained largely stable in 2002 as compared to a year earlier. In Mexico, one of the largest source countries of
cannabis herb, household surveys conducted in 2002 showed a decline in marijuana use, following years of increase
in the 1990s. In contrast to stable trends in North America, cannabis consumption (according to national experts'
perceptions reflected in UNODC's Drug Abuse Trend Index) continued rising in South America, including the
Caribbean and Central America, Western and Eastern Europe, Africa and Asia (where the increase is less pronounced
than in other regions).
Amphetamines-type stimulants market
Production
The global production of methamphetamine and amphetamine is estimated at around 410 tons (range 290 - 516
tons) and ecstasy production is estimated at 113 tons (range 50 - 200 tons) in 2002. Annual production of ATS is
thus larger than heroin but smaller than cocaine.  The main producers of methamphetamine are in South-East Asia
(including Myanmar, China and the Philippines) and North America (USA and Mexico).  The main producers of
amphetamine and ecstasy are in Europe and include the Netherlands (apparently the largest producer), Belgium,
Poland, the Baltic states, the UK and Germany. 
Production of ATS, which has increased globally over the last decade, is dominated by methamphetamine, followed
by ecstasy and amphetamine. About 11,900 clandestine laboratories were dismantled in 2002.  More than 80% of
them produced ATS. This proportion was less than 20% in the early 1990s. Most ATS laboratories that were
dismantled produced methamphetamine (about 95% in 2001 and 2002). 
A record number of methamphetamine laboratories and methamphetamine precursor chemicals were seized in 2002,
most of them in North America. The USA undertook 97% of all reported methamphetamine laboratory seizures in
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2002. The largest number of laboratories dismantled in East and South-East Asia were reported from China (13),
Myanmar (4) and the Philippines (4) in 2002. 
The number of detected amphetamine laboratories has increased again in recent years after falling in the 1990s. Most
amphetamine laboratories were dismantled in Europe.  A shift of production from Western Europe towards Eastern
Europe has been noticed since the mid 1990s.
The number of dismantled clandestine ecstasy laboratories rose almost 3-fold over 1992-2002 period. Most ecstasy
laboratories are still dismantled in Europe, but production is rising in Asia. While the number of dismantled ecstasy
laboratories declined in Europe, and remained more or less stable in North America, it increased strongly in Asia.  
Trafficking 
In 2001 and 2002 ATS seizures declined, mainly due to a fall of methamphetamine seizures in China. The decline
in 2002 amounted to 7% as compared to a year earlier. Over the 1992-2002 period China reported the highest ATS
seizures, followed by Thailand, the USA, the UK and the Netherlands. In 2001 and 2002,  the highest ATS seizures
worldwide were reported from Thailand, followed by China. The increase of ATS seizures over the last decade was
significantly higher than that of heroin or cocaine, despite the fall in 2001 and 2002 described above.  Over the
2001/2002 period, more than 60% of global ATS seizures were methamphetamine and close to 20% were ecstasy
seizures.
Abuse
Use of ATS is rising, but the increase in 2002 was less significant than a year earlier. While large increases in the use
of methamphetamine were reported from China and Singapore in 2002. A number of other countries in East and
South-East Asia reported some stabilization/decline in consumption levels of amphetamine/methamphetamine.
Some of the strongest increases in recent years occured in Thailand where the proportion of people admitted to
treatment for methamphetamine abuse rose from 2.1% in 1995 to 50.5% in 2001. In 2003, however, a crackdown
on the market appears to have led to a fall in methamphetamine abuse.
There has been a stabilization of amphetamines use in the Oceania region and in North America.  Following massive
increases in the consumption of amphetamines (mainly amphetamine) in the 1990s, the overall trend for Western
Europe as a whole was basically stable over the 2000-2002 period. Also, following years of increases, countries of
Eastern Europe reported - for the first time - largely stable levels of amphetamine consumption in 2002. 
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* Seizures reported in kilograms and in units; a unit ('pill') of ecstasy was assumed to contain on average 100 mg of MDMA; a 'unit' of
amphetamine / methamphetamine was assumed to contain 30 mg of mphetamine / methamphetamine. 
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Global ecstasy consumption has increased consistently over the last decade and it appears to have continued rising
in 2002, though at a significantly slower pace than in 2001. The ongoing popularity and consequent spread of
ecstasy use in many developing countries continued. In several of the largest ecstasy markets of Europe and North
America, where massive increases were experienced in the 1990s, consumption stabilized or showed signs decline.
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1. THE WORLD DRUG PROBLEM: A STATUS REPORT
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The multilateral drug control system is a very valuable
piece of political capital, agreed upon through an incre-
mental process spanning a century. Its legal framework
is provided by the three international drug conven-
tionsa. Adherence to the conventions is almost univer-
sal, and most States Members of the United Nations
have ratified them.  The scope of control over drugs has
broadened and deepened over the years, from the regu-
lation of licit production and trade to the goal of inter-
national cooperation against the multi-faceted problem
of illicit drugs.  
As we approach the second century of international
drug control, it is useful to look back in order to see
more clearly forward.  The central principle of the drug
control system was, and still is, to limit the use of those
psychoactive substances that are under international
control to medical and scientific purposes.  Nicotine,
however, was never put under the control regime, even
though it is a strongly psychoactive and addictive sub-
stance, and claims so many lives.  Since the market for
this 'licit' drug is relatively un-regulated, it offers an
instructive comparison with markets for the more care-
fully controlled  'illicit' drugs (such as cannabis, cocaine,
heroin and the ATS).  A good indicator for comparison
is the annual prevalence of drug (licit and illicit) use.
One fifth of the world population, 1.3 billion people,
uses tobacco.  Only 3% of the world population, which
is less than 0.2 billion people, uses illicit drugs.  Tobacco
consumption is thus seven-fold more than illicit drug
use.  Comparisons of mortality are even more telling.
The World Health Organization estimates that some
200,000 people died from drug abuse in the year 2000,
equivalent to 0.4% of all deaths worldwide.  Tobacco,
however, claimed 25 times as many lives (4.9 million),
equivalent to 8.8% of all deaths.  If the measure of dis-
ability-adjusted life years (DALYs) is used, then drug
abuse would have caused the loss of 11.2 million years
of healthy life, but tobacco would have caused the loss
of five times as many years of healthy life (59.1 million).
These are dramatic illustrations of the efficacy of the
multilateral drug control system.  The number of illicit
drug users would doubtless have been larger if illicit
drugs were sold as freely as the licit ones.  
Yet there can also be no doubt that the second half of
the 20th century has witnessed an epidemic of illicit
drug use.  Though neither the numbers, nor the conse-
quent label of an 'epidemic' can be very precise, it is
quite clear that illicit drug use has increased very rapidly
since the middle of the 20th century.  The evolution of
psychoactive substance use over time can be traced and
1.1. The policy landscape
a) The Single Convention on Narcotic Drugs of 1961 (United Nations, Treaty Series, vol. 520, No.7515), the Convention on Psychotropic Substances
of 1971 (Ibid., vol. 1019, No.14956) and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of
1988 (Ibid., vol.1582, No.27627).
Table 1: Extent of tobacco and illicit drug consumption, 2001-2003 (or latest year available)
Tobacco Illicit drugs 
GLOBAL (million people) 1,270 185
In % of global population 20% 3%
In % of global population age 15
and above 29% 4.2%
Sources: for illicit drugs: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates;
estimates for tobacco were calculated from individual country data published by the World Health Organisation. 
described by historical and anthropological enquiry.
This yields fertile results, but is unlikely to be able to
answer questions  - so salient in the contemporary world
- about whether the drug problem is getting better, or
worse, and about whether drug production and con-
sumption are decreasing, or increasing.  Long-term
enquiry is further impeded by the fact, noted above,
that drugs became separated into legal and illegal ones
no more than a century ago.  
Measuring the size of the illicit drug problem today, in
terms of how many drugs are produced, trafficked and
consumed, is not easy but can be done.  Given the illicit
nature of the activity, it may not be a perfectly accurate
estimate, but the current state of knowledge is certainly
sufficient to provide a reasonable orders of magnitude,
as the following chapters of this report demonstrate.
Deriving a long-term trend from such an estimate, how-
ever, requires a comparable estimate for a certain period,
or moment in time, in the past. Even in the best of cir-
cumstances, this is difficult.  The systematic recording
of economic, social and demographic statistics has fol-
lowed industrialization, and seldom preceded it.  It is
thus nowhere more than about three centuries old.  The
creation of the United Nations and the unfolding of its
development agenda in the second half of the 20th cen-
tury obviously created huge improvements, particularly
in establishing globally aggregated economic and demo-
graphic statistics.  Establishing trends for illicit drug
production and consumption is quite another matter,
and has to rely on qualitative assessment derived from
historical and anthropological study.  Quantitative trend
analysis in this area is thus limited by the availability of
historical data, and that usually goes back no more than
three or four decades. 
One of the reasons why an international drug control
system emerged in the 20th century was the opium
problem in China. Long a problem in the country, at
least from the 17th century onwards, opium use
assumed epidemic proportions in the latter half of the
19th century.  Because international drug control began
with a conference, at Shanghai in 1909, to consider
China's opium epidemic, a good deal more is known
about it than about previous epidemics or problems of
psychoactive substance abuse.  Even though the num-
bers are uncertain, it is the first case in which some
quantitative assessments of drug production and con-
sumption are possible. For all the caveats, the numbers
seem to indicate that a hundred years ago, China had
nearly double the number of opium users (25 millionb)
as there are in the world today (15 million, see below).
There was also, depending on the measure used, three
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Fig. 1: Substance abuse related deaths and disability
adjusted life-years (DALYs) lost due to
substance abuse at the global level 
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Fig. 2: Opium production in 1907/1908* and 2003
(excl. poppy straw)
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survey reports 2003/2004.
b) International Opium Commission, Shanghai, China, 1-26 February, 1909; Vol. 1, Report of the Proceedings, p.68. 
to six times as much opium produced in the world a
century agoc.
While the opium epidemic of China can be used as a
marker, it cannot constitute a baseline against which a
subsequent world trend can be measured.  All that can
be said of the first half of the 20th century, therefore, is
that after the Shanghai Conference, there were greater
efforts to limit the use of some psychoactive drugs
(botanical and synthetic) to medical purposes. In the
second half of the century, clearer quantitative assess-
ments become possible.  In the 1950s, China solved its
opium problem.  In the same decade, Japan saw a huge
increase in the abuse of methamphetamine, and brought
it under control.  An upsurge in drug abuse in many
parts of the world, however, began to be perceived in the
1960s.  Whether this was actually an upsurge or merely
new awareness of an older phenomenon is difficult to
establish.  The upsurge was recorded in North America,
then in Europe, and began to spread to developing
countries along the main drug trafficking routes.  In the
United States of America (USA), the peak in drug use
was reached in the late 1970s for cannabis and in the
mid-1980s for cocaine (according to national household
survey data). Drug use then fell until the early 1990s,
rose again slightly in subsequent years, but appears to
have been basically stable since the late 1990s. In the
majority of other countries, by contrast, drug con-
sumption continued rising. This has been the case in
many parts of Asia, Africa, South America and Eastern
Europe. In most of Western Europe drug use increased
as well. Heroin use stabilised in the 1990s and this trend
seems to have continued into the first years of the new
millennium.
Though there is no long-term time-series data on drug
abuse at the global level, a number of indirect indicators
such as treatment for drug abuse, drug-related mortal-
ity, drug consumption/possession related arrests and
drug seizures suggest that more drugs are now being
consumed than a few decades ago. The most readily
available indicator at the global level is seizure data.
Drug seizure data has been collected at the international
level since the times of the League of Nations and cor-
relates positively -when considering longer-term trends
- with drug production and drug consumption. This
data shows increases over the last few decades, reflecting
not only improved enforcement efforts or better report-
ing, but also rising drug problems in many countries of
the world. In 2000-2002, average annual seizures of
cannabis were 17 times higher than average annual
seizures over the 1947-66 periodd; seizures of opiates
(opium, morphine, heroin) were 19 times higher; and
cocaine seizures were as much as 8,700 times higher.
There are no comparable figures for amphetamine-type
stimulants (ATS), which were still legal in most coun-
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c) The figure above does not account for most of the medical morphine produced in the world today, since that is extracted directly from the opium
poppy plant by an industrial process (the "poppy straw method").  About 305 tons of licit medical morphine was produced in 2001/2002 (INCB,
Narcotic Drugs 2002, New York, 2003).  If this is converted back to opium, using an average conversion ratio of 1:10, we get 3050 tons of opium
equivalent.  Adding this to the opium estimate for 2002, we have a total of 8,360 tons, which is still nearly three times smaller than the 30,000 tons
estimated for 1907/1908.
d) The sharp decline in cannabis seizures from the peak in the early 1980s was the result of eradication in South America and slowing demand in the
USA.
Fig. 3: Average annual cannabis seizures (herb, resin
and oil)
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Fig. 4: Average annual seizures of opiates in heroin
equivalents*
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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tries in the 1950s and 1960s.  This changed with the
1971 Convention on Psychotropic Substances. If cur-
rent seizures are compared with average annual seizures
over the 1967-74 period, ATS seizures (excluding
ecstasy) grew 128 times.  
The total number of drug users in the world today is
clearly more than it was two or three decades ago (cur-
rent estimates are detailed below). More countries are
affected by drug abuse, particularly those in which drugs
are produced, or through which the drugs transit. This
trend has been exacerbated by the fact that the tradi-
tional plant-based drugs have been increasingly supple-
mented by synthetic drugs, thus providing a broader
choice for consumers. Synthetic drugs have also reversed
the traditional trafficking pattern of plant-based drugs,
which went from developing countries to developed
ones. The trend towards "globalization" facilitates cross-
country trafficking, and "modernization" has diluted
many traditional systems of regulating drug use.  There
are huge and evolving literatures on the subjects of mod-
ernization and globalization, and they are not detailed
here.  What is important to note, in the present context,
is that the rapidity of social and economic change is
double-edged, because it creates opportunities for rapid
increases in drug abuse and the criminal activity that
supplies illicit drug markets.  This is not a new phe-
nomenon.  There is a dark side of technological
progress, which has often created conditions for drug
abuse to spread.  The most well known examples are the
gin epidemics of the 18th century after the discovery of
the distillation process; the on-going tobacco epidemic
after the mechanization of cigarette production and the
invention of the safety match in the 19th century; and
the morphine/heroin epidemics of the late 19th century
after advances in chemistry made it possible to extract
or refine the pure drugs from opium, and the invention
of the hypodermic syringe made it possible to inject the
pure drug directly into the bloodstream.
One further example, because of its great contemporary
relevance, may better illustrate the problem.  Urbaniza-
tion is often used as an indicator for modernization and
development.  It is also closely associated with drug
abuse.  This is not to say that drug abuse is an exclu-
sively urban phenomenon, because it is not.  The rural
incidence, however, seems either to be associated with
developed regions of the world, or with traditional pat-
terns of consumption (such as coca-chewing or opium-
smoking) in less developed regions.  It would thus seem
reasonable to argue that rapid rates of urbanization
create conditions in which drug abuse may spread more
rapidly.  In the second half of the 20th century, the drug
abuse epidemic being discussed here has unfolded in
parallel with a dramatic growth of urbanization.
According to the latest United Nations estimatese, about
3 billion people, or 48% of humanity, now live in urban
settlements.  This proportion was only 29% in 1950.  In
2007, the urban population is projected to surpass the
50% mark.  For the first time in human history, there
will be more urban than rural dwellers.  Between 2000
and 2030, the world's urban population will grow at
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Fig. 5: Average annual cocaine seizures 
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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Fig. 6: Average annual ATS seizures (excl. ecstasy) 
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e) United Nations, World Urbanization Prospects: The 2003 Revision, Data Tables and Highlights (ESA/P/WP.190, New York, 2004).
double the average annual rate of the total world popu-
lation.  At this rate of growth, the world's urban popu-
lation will double in 38 years, or in about half the
average lifetime of a person.  Arresting the growth of
drug abuse, therefore, will be that much harder to
achieve.  
In these kinds of enabling conditions, some of which
were noted above, it is remarkable that the diffusion of
the drug epidemic to the general population has been
contained.  Less than 5% of the youth and adult popu-
lation - the annual prevalence rate of drug use today - is
certainly evidence of containment, particularly when
compared with the annual prevalence rate of some 30%
for tobacco.  There are, however, three important
caveats.  First, there is no clear baseline, as explained
above, with which to compare this 5% diffusion.  Sec-
ondly, though the large majority of the population
(95%) remains untouched by illicit drug use, some very
susceptible segments of that population, particularly
youth, have been seriously affected by it.  Thirdly, while
it can be argued that a diffusion of the epidemic in the
general population has been contained, it cannot be
argued that the epidemic has been stopped, or eradi-
cated.  The overarching objective of the drug control
conventions - restricting the use of psychoactive sub-
stances under international control to medical and sci-
entific use - has not yet been achieved.  
The overwhelming majority of countries and their gov-
ernments, however, remain convinced that this is still a
reachable goal.  So, also, does public opinion in the vast
majority of countries.  Current levels of illicit drug use,
together with the health consequences and criminal
activities associated with it, have consistently been
deemed unacceptable by both policy makers and public
opinion.  This is why the multilateral drug control
system still enjoys almost universal adherence.   The very
fact of such an intensive and extensive level of consen-
sus provides a crucial sense of perspective for evaluating
the paradoxical actions of a small number of very vocal
actors to break ranks and challenge the spirit of multi-
lateralism.
The majority of governments, precisely because they
still regard the drug conventions as relevant, have made
continuous efforts to achieve better results in bringing
the drug problem under control.   It was in recognition
of this equality - in suffering the consequences of drug
abuse and in accepting responsibility for combating it -
that the international community came together, ten
years after the signing of the 1988 Convention, to re-
examine the global drug problem. The twentieth Gen-
eral Assembly Special Session on Drugs (UNGASS)
devoted to 'Countering the World Drug Problem
Together' that took place in New York from 8-10 June
1998 was called, in the Secretary General's words, to
deal with the 'tragic reality' of the proliferation of drugs
over the previous thirty years, 'an example of the previ-
ously unimaginable becoming reality very quickly'.  
The Political Declaration adopted at UNGASS com-
mitted signatories to intensifying their efforts to resolve
the drug problem with full respect for human rights and
sovereignty and in a spirit of trust and cooperation.
States agreed to establish the year 2003 as a target date
for the introduction of new or enhanced demand reduc-
tion strategies and programmes in collaboration with
public health, social welfare and law enforcement
authorities and to achieve significant, measurable results
by the year 2008.  Within the same time frame, they
agreed to develop strategies to eliminate or significantly
reduce the illicit cultivation of the coca bush, the
cannabis plant and the opium poppy. 
Other key documents adopted at the Special Session
include the Declaration on the Guiding Principles of
Drug Demand Reduction and Measures to Enhance
International Cooperation to Counter the World Drug
Problem, the latter being subdivided into five areas for
particular attention: the illicit manufacture of amphet-
amine-type stimulants (ATS) and their precursors; the
control of precursors; judicial cooperation; money laun-
dering, and international cooperation to eradicate illicit
cultivation and to promote alternative development.    
The innovative shifts in policy emphasis that resulted
from UNGASS can be summarized as follows:
• A parity of approach between demand and supply
policies;
• The setting of fixed goals and target dates for each
sector of drug control; 
• The focus on improving and standardizing
methodologies for the collection and analysis of
drug-related data;  
• The cross-disciplinary and 'holistic' approach to
the drug problem; and 
• A greater burden sharing of drug control efforts by
means of multilateral partnerships a) with the pri-
vate sector and b) with other agencies in the UN
system.
In many respects, policy developments at regional and
national levels have taken their cue from the UNGASS
call to action, particularly with regard to developing
instruments for estimating the incidence, prevalence
and consequences of illicit drug use and for interpreting
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production, trafficking and seizure patterns; determined
efforts are underway to make more accurate estimates of
the costs to society of drug abuse. Thanks to UNGASS,
the capacity to evaluate drug policies and programmes
is gradually being incorporated into all national drug
strategies.
A mid-term review of progress towards meeting the
goals set at UNGASS was conducted last year.  Over 70
government ministers and representatives from 124
countries participated in the Ministerial Segment of the
46th session of the Commission on Narcotic Drugs held
in Vienna on 16 and 17 April 2003.  The results, not
presented here but detailed in reports to the Commis-
sionf, showed encouraging progress, but noted that the
UNGASS goals were still distantg.  The Ministerial seg-
ment concluded with a Joint Ministerial Statement and
further measures to implement the action plans ema-
nating from UNGASSh.  Ministers reaffirmed their
commitment to the outcome of UNGASS and to the
principle that action against the world drug problem
was a common and shared responsibility requiring an
integrated and balanced approach.   It was recognized
that progress in meeting the goals set had been consid-
erable but uneven, although the increased efforts and
achievements of many States had shown positive results.
Government representatives reaffirmed that interna-
tional cooperation and the mainstreaming of drug con-
trol efforts were indispensable in attaining the universal
aspirations of international peace and security, eco-
nomic and social progress, a better quality of life and
improved health in a world free of illicit drugs.  
1.2 THE DYNAMICS OF WORLD
DRUG MARKETS 
1.2.1 What is the current level of drug use in
the world?
The total number of drug users in the world is now esti-
mated at some 185 million people, equivalent to 3% of
the global population, or 4.7% of the population aged
15 to 64.  The new estimates confirm that cannabis is
the most widely used substance (close to 150 million
people), followed by the ATS (about 30 million people
for the amphetamines, primarily methamphetamine
and amphetamine, and 8 million for ecstasy).  Slightly
more than 13 million people use cocaine, and 15 mil-
lion use opiates (heroin, morphine, opium, synthetic
opiates), including some 9 million who take heroin.    
These estimates are based on data for the period 2001-
2003, or the latest year available. Overall, the new esti-
mates are slightly higher than those reported in the
previous World Drug Report (2000), which reflected
the drug use situation in the late 1990s. Changes in the
two sets of estimates must be interpreted with caution,
however, because they not only reflect actual changes in
the number of drug users but, to an unknown and prob-
ably large extent, changes in data collection and report-
ing methods as well. With these caveats in mind, a
simple comparison of the two sets of estimates shows a
strong increase for ecstasy and amphetamines, and a
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f ) Second biennial report on the implementation of the outcome of the twentieth special session of the General Assembly, devoted to countering the
world drug problem together.  Report of the Executive Director.  E/CN.7/2003/2, Vienna, 17 February 2003.
g) Encouraging progress towards still distant goals. Progress report by the Executive Director to the Mid-term Review of UNGASS. UNODC/ED/2,
Vienna, 8 April 2003.  
h) Joint Ministerial Statement and further measures to implement the action plans emanating from the twentieth special session of the General
Assembly.  E/2003/28/Rev.1.  E/CN.7/2003/19/Rev.1.
Amphetamines Ecstasy
in % of global 
population
3.0% 2.3% 0.5% 0.1% 0.2% 0.2% 0.2%
9.2
* Annual prevalence is a measure of the number/percentage of people who have consumed an illicit drug at least once 
in the 12 month-period preceding the assessment.
0.2% 0.3% 0.4% 0.2%
in % of global 
population age 15-64
4.7% 3.7% 0.7%
Cocaine Opiates
of which 
heroin
(million people) 185 146.2 29.6 8.3 13.3 15.2
All illicit 
drugs 
Cannabis
Amphetamine-type stimulants
Table 2: Extent of drug use (annual prevalence*) estimates 2001-2003
more moderate one for cannabis (which probably
under-estimates the actual trend), as well as for opiates
(mainly reflecting higher estimates for the use of syn-
thetic opiates in some countries). Estimates of heroin
use remain largely unchanged, as increases in Central
Asia and Eastern Europe were offset by strong declines
in Australia and more moderate ones in some Asian
countries. The number of cocaine users is now margin-
ally lower than it was in 2000. The difference, however,
does not necessarily reflect a real trend as cocaine use
continued to rise in several countries of Latin America
and Europe, while remaining stable in others over the
last few years. 
The impact on health…
One way of assessing the negative health impact of illicit
drug use is to utilize the notion of 'problem drugs'.
Though there are different definitions of 'problem
drugs'i, they all seem to be based on the criterion of
treatment demand for addiction.  The definition of a
'problem drug' used in the present report is the extent
to which abuse leads to treatment demand for a partic-
ular drug. The term, therefore, does not necessarily
relate to the size of the population consuming it.
Cannabis, for example, is the most consumed illicit
drug worldwide; it is not, however, the main problem
drug for which people seek treatment. 
…is most serious for the opiates, particularly in Asia
and Europe, but there is significant treatment demand
for methamphetamine in East and South-East Asia,
cocaine in the Americas and cannabis in Africa 
Based on that definition, opiates are the most serious
problem drug in the world, as they are responsible for
most treatment demand: 67% in Asia, 61% in Europe
and 47% in Oceania. In much of South East Asia, how-
ever, methamphetamine emerged as the main problem
drug over the last decade. In the Americas, cocaine is
still the main problem drug, accounting for 60% of
treatment demand in South America and around 29%
in North Americaj.   In the USA, however, the number
of people admitted to treatment institutions for heroin
abuse has begun to exceed the number of people admit-
ted for cocaine abuse in recent years (1999 to 2002). In
Africa, cannabis consistently comes first, accounting for
65% of treatment demand. 
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Fig. 7: Estimates of annual prevalence of drug use at the global level in the late 1990s and in 2001-2003
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Poly-drug abuse is rising
Most of the data presented here covers the 1998-2002
period.  Compared to previous calculations, covering
the 1995-97 period, and presented in Global Illicit
Drug Trends 2003, there has been a general decline in
the importance of opiates in Europe and in Asia. In the
Americas, the relative importance of cocaine has
declined. In general, poly-drug abuse seems to be
increasing.  
1.2.2.  How is the drug problem evolving? 
Difficulties of measurement
Is global drug abuse increasing? Is the problem getting
better or worse? How is it changing? Epidemiological
surveys would be the most appropriate tools for answer-
ing such questions.  Unfortunately, relatively few coun-
tries have effective drug abuse monitoring systems. Data
on drug use prevalence is therefore not comprehensive
and robust enough to establish the type of global time-
series required to document answers to such questions.
Other indicators, however, can help to shed some light
on the evolution of the problem.
National experts' perceptions
Governments report annually on trends in drug abuse
among the general population.  The information is pro-
vided for each of the main drug types on a five-point
scale (large increase, some increase, no great change,
some decrease, large decrease). For the majority of coun-
tries, where abuse-monitoring systems are lacking, the
responses are primarily the perceptions of national drug
control agencies about the evolution of the drug prob-
lem. Results must thus be treated with some caution.
Despite these caveats, such reports provide valuable
insights into the growth patterns of drug abuse. At the
global level, they represent the most comprehensive data
set of expert opinion on the evolution of drug abuse,
provided in a consistent manner over more than a
decadek.
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Map 1: Main problem drugs (as reflected in treatment demand), 1998-2002 (or latest year available)
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k) The analysis on drug abuse trends for the year 2002 is based on the replies of 95 countries and territories. Over the last decade, 151 countries and
territories reported drug abuse trends to UNODC, which underlines the fact that drug abuse is a truly global phenomenon. 
Source: UNODC, Annual Reports Questionnaire Data/DELTA and National Government Reports.
The spread of drug abuse may be losing momentum…
As a whole, drug abuse continues to spread at the global
level, but the trend may be loosing momentum. There
is, however, a notable exception.  The consumption of
cannabis herb, the most commonly used illicit drug in
the world, appears to be spreading at an accelerated
pace. During the last decade, the highest increases, after
cannabis, were for the ATS (mainly ecstasy), followed by
cocaine and the opiates. 
Throughout the last decade, more countries reported
increases than decreases in drug abuse, indicating that
drug consumption continues to spread in geographical
terms. This does not necessarily mean that the total
number of drug users is rising, because increases in
smaller countries could be offset by declines in a few
larger countries. The spread of drug abuse, however, appears to be losing momentum. In 2000, 53% of all
drug abuse trends reported by governments showed an
increase; this proportion fell to 46% in 2001 and 45%
in 2002. In parallel, the percentage of reports indicating
declining levels of abuse was on the rise: from 21% in
2000, to 23% in 2001 and to 26% in 2002. 
The spread of drug abuse in 2002, as in previous years,
was accounted for primarily by cannabis, followed by
ATS, cocaine and opiates and, to a lesser extent, benzo-
diazepines. Only 4% of the responding governments
perceived a decline in cannabis herb consumption in
2002, against more than 50% perceiving an increase.
Four out of ten countries reported an increase in the use
of ATS (ecstasy, followed by amphetamine and metham-
phetamine), cocaine-type substances and opiates
(heroin, followed by opium and morphine).
Reports of increases continued to outnumber reports of
declines for 2002. Nonetheless, a significant number of
countries did see falling levels of opiate use (25% of the
countries reporting), of ATS use (19%) and of cocaine
use (13%). For LSD, other hallucinogens,
methaqualone, morphine and barbiturates, the number
of countries reporting increases was more or less the
same as those reporting declines.  
…except for cannabis herb, which is still accelerating
A comparison of the net results (number of countries
reporting increases minus number of countries report-
ing declines) for 2001 and 2002, suggests that the over-
all spread of drug use at the global level continued, but
lost some momentum in 2002. The only exceptions
were cannabis herb and, to a lesser extent, the benzodi-
azepines, which both spread faster in 2002 than a year
earlier.   
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Fig. 8: Global drug abuse trends in 2000 
(based on information from 96 countries) 
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Fig. 9: Global drug abuse trends in 2001 
(based on information from 96 countries) 
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Fig. 10: Global drug abuse trends in 2002 
(based on information from 95 countries) 
large 
decrease
9%
large 
increase
14%
no great 
change
29%
some 
increase
31%
some 
decrease
17%
Source: UNODC, Annual Reports Questionnaire Data.
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Fig. 11: Global substance abuse trends of selected drugs in 2001 and 2002  (based on information from 96
countries in 2001 and 95 in 2002)
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The global consumption trend for heroin (stable to declining) and cocaine (stable) can be illustrated by the net
number of countries reporting increases less those reporting decreases.  A drug abuse index, derived from national
expert perceptions (see Methodology section), is still under construction for globally aggregated heroin and cocaine
trends.  It can, however, be used to illustrate cannabis and ATS trends, which seem to be moving upward.  
Fig. 13: Heroin use trend, 1992 - 2002 
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Fig. 14: Cocaine use trends, 1993 - 2002 
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Fig. 15: Global Cannabis consumption trend: based
on national experts' perceptions, 
1992 - 2002
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Fig. 16: Global ATS consumption trend: based on
national experts' perceptions, 1992 - 2002
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Source: UNODC, Annual Reports Questionnaire Data.
Sseizures are an indirect indicator of the evolution of
the global drug problem
Another source of information on the evolution of the
world drug problem is the seizures of illicit drugs by
national law enforcement agencies.  Seizure data have
the significant advantage of a relatively systematic and
comprehensive recording and reporting by govern-
ments. Consistent world time-series are therefore easier
to build than in the case of abuse data. Although law
enforcement efforts might influence the level of seizures
in individual countries, independently from the actual
level and evolution of the drug problem there, the evo-
lution of seizures has generally been in line with trends
in drug production and consumption where such data
is available. For periods of several years and over large
geographical areas, seizure data can therefore be used as
a reasonably good indicator of underlying changes in
illicit drug trafficking patterns and, by extension but
with some caution, as an indirect indicator of the extent
and evolution of the drug problem as a whole.  The
seizure data can be viewed from three different angles:
the number of seizures, the weight, or quantities of
drugs seized and the number of doses, or units of drugs
seized.
The total number of seizures has increased consistently
since the early 1990s, but there were signs of stabiliza-
tion or decline in 2002
The aggregate level of trafficking, as reflected in the
number of seizure cases reported, appears to have stabi-
lized/declined in 2002 following a period of strong
increases in the 1990s. The increase over the 1990-2000
period (from 0.3 to 1.3 million cases, or 15% p.a.) was
a reflection of actual increases in trafficking as well as of
improvements in reporting. In 1990, 55 countries and
territories reported drug seizure cases to UNODC; by
2002, reporting had increased to 114 countries and ter-
ritories.  In 2001 the number of seizure cases peaked at
almost 1.4 million. For 2002 the number declined, by
16%, to 1.1 million, but was still higher than in any
year of the 1990s. The actual number of seizure cases at
the global level is probably higher than 1.1 million
because more governments report drug seizures in
weight terms (176 countries & territories in
2001/2002) than in terms of the number of cases (131
over the same period).  
Changing patterns since the early 1990s 
In 2002, cannabis accounted for 55% of all seizures
cases, followed by the amphetamine-type stimulants
(24%, including ecstasy), opiates (12%) and cocaine-
related substances (7%). The evolution of seizure cases
since the early 1990s points to the following changes in
trafficking patterns: 
• A decline in the relative importance of cannabis:
this reflects the emergence of other substances for
recreational drug use in many parts of the world
as well as the development of cannabis production
closer to consumer markets, which limits the pos-
sibility of making a seizure.  Since 2002, however,
the share of cannabis has stabilized. 
• The rapid emergence of ATS: the proportion of
ATS in global seizures cases more than tripled over
the last decade, clearly demonstrating the rising
importance of ATS production, trafficking and
abuse. No significant change, however, occurred
between 2001 and 2002. 
• An increase of opiates: the proportion of opiates in
total seizure cases increased between 1990 and
1999, reflecting inter alia the expansion of opium
production in Afghanistan.  As production in that
country fell in 2000 and 2001, the proportion of
opiates in global seizure cases also fell. There seems
to be a one-year time lag between the production
and the subsequent seizure of opiates. Consistent
with this, the massive decline of Afghanistan's
opium production in 2001 had its main impact
on seizure cases in 2002. This downward trend is,
however, unlikely to continue. Given rising levels
of opium production in Afghanistan in 2002,
2003 and probably in 2004 as well, it can be
expected that opiate seizure trends will be
reversed. 
• An increase, followed by stabilization, of cocaine:
the proportion of cocaine in global seizure cases
rose in the 1990s, in line with the expansion of
coca cultivation in Colombia over that period.
More recently, seizure cases have stabilized, reflect-
ing declines of coca production in Colombia.   
In terms of quantities, cannabis seizures are the largest.
Based on information provided by 165 countries and
territories in 2000, 161 in 2001 and 152 in 2002,
cannabis products (herb and resin) represent the largest
quantities of illicit drugs seized, followed by coca-type
substances (coca leaf and cocaine), opiates, stimulants
(amphetamine and methamphetamine), and ecstasy.
This ranking has not changed in recent years, though
the relative importance of ATS has increased over the
last decade. Ranking the different drug categories on the
basis of weight seized, however, has limited utility.
Cannabis herb or coca leaf, for instance, are much
bulkier products than heroin or ecstasy. It is nonetheless
useful, for the purposes of trend analysis, to monitor the
evolution of quantities seized from year to year.  
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Quantities seized remained largely stable from 2001 to
2002, except for ecstasy, which increased  
The quantities of drugs seized remained largely stable in
2002, as compared to a year earlier, with the exception
of ecstasy.  Seizures increased slightly for cannabis herb
(3%), were largely stable for cocaine, and declined for
amphetamines (-16%, following years of massive
increases in the 1990s), as well as for heroin (-10%) and
opium (-10%).  When compared to 2000, the overall
decline in opium seizures is more impressive (-55%).
This probably reflects an increase in the processing of
opiates within Afghanistan.  By contrast, ecstasy seizures
increased by 26% from 2000 to 2002, and by 37% from
2001 to 2002. Cannabis resin seizures also showed a
strong increase in 2002 (+22% on a year earlier); how-
ever the increase was only 3% as compared to the year
2000.
Quantities increased over 1992-2002, particularly for
ecstasy, depressants and amphetamines 
Over a 10-year period, ecstasy, depressants and amphet-
amines show the strongest increases. During that time,
the quantities of ecstasy seized increased annually by an
average of 27%, depressants by 20% (mainly benzodi-
azepines) and amphetamines by 19%. Cannabis herb
seizures rose by 7.4% p.a., heroin by 7% p.a., cannabis
resin by 5% p.a. and cocaine by 2.5% p.a. In contrast,
seizures of LSD (reported in units) declined by almost
20% p.a. over the same period, establishing a trend of
reduced production, trafficking and abuse of this sub-
stance over the last decade.    
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Fig. 17:  Proportion of seizure cases according to drug category, 1990 - 2002
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Fig. 18: Global cannabis seizures (in weight
equivalents) 2000-2002
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Fig. 19: Global seizures (in weight equivalents) 
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Fig. 20: Average annual change in seizures 1992-2002
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Fig. 21: Trends in world seizures, 1992 -2002 (in metric tons)
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Seizures in terms of consumption units/doses…
Since the ratio of weight-to-psychoactive effect varies
greatly from one drug to another, the indicator of the
weight of seizures assumes more utility if it is converted
into a typical unit of consumption, or the dose taken by
drug users to experience a 'high'l.  Expressing drug
seizures in typical units/doses enables a more meaning-
ful comparison of the quantities of different drugs
seized.  Since typical doses tend to vary across regions
and user groups, however, such comparisons should
only be interpreted as indications of overall patterns
rather than as precise estimates.
…show strong increases through the 1990s, but signs of
stabilization in 2001/2002
Some 26 billion drug units were seized in 2002. This is
about the same level as in the previous two years, up
from about 14 billion units in 1985 and in 1990. Based
on these calculations, overall seizures increased by 6.6%
p.a. from 1990 to 2000 and were basically stable over
the 2000-2002 period. In 2002, 68% of all seizures (in
unit equivalents) were of cannabis, 14% each were of
opiates and cocaine type substances, and only 3% ATS.
The low proportion of ATS in that distribution (3%
versus 24% of the total number of seizures) reflects the
fact that ATS trafficking is largely intra-regional, with
production taking place close to consumers. The short-
ened trafficking chain thus limits the possibility of inter-
cepting shipments because they seldom cross borders.
As a result, seizures tend to be numerous but small when
compared with other drugs (coca products, for instance,
represent 14% of the units seized, but only 7% of the
number of seizures). 
Since 1985, unit seizures show…
Analysis of the changing proportions of the different
drug groups since 1985 shows the following picture:  
A decline, and then a rebound of cannabis: the propor-
tion of cannabis in global seizures declined from 90% in
1985 to 57% in 1996, but has since resumed an upward
trend, reaching 68% in 2002. This reflects increasing
cannabis production and consumption in recent years.
• An increase, then decline of cocaine: the propor-
tion of cocaine in global seizures rose from 4% in
1985 to 21% in 1990, as global coca production
rose rapidly. It then declined to 14% of global
seizures in 2002, reflecting the recent reduction in
cocaine production.
• A general increase of opiates: the proportion of
opiates in global seizures rose from 4% in 1985 to
24% by 1996. It fell to 14% by 2002 as opium
production in Afghanistan contracted in 2000 and
2001. Given the resumption of opium poppy cul-
tivation in that country in 2002, a further increase
in 2003 and indications of an even further
increase in 2004, opiate seizures can be expected
to go up.    
• An increase, and then a decline of ATS: the pro-
portion of ATS grew from about 1-2% of global
seizures to 6% in 2000 (mainly reflecting a major
crack-down on domestic ATS production by
China). In subsequent years, the share of ATS in
global seizures declined, to 3% in 2002.    
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Fig. 22: Global seizures in unit equivalents, 
1985 - 2002 
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l) For the purpose of this calculation, the following typical consumption units/doses (at street purity) were assumed: cannabis herb, 0.5 grams; cannabis
resin, 0.135 grams; cocaine and ecstasy, 0.1 grams; heroin and amphetamines, 0.03 grams; LSD, 0.00005 grams (50 micrograms).
The intensity of trafficking is highest in the Americas,
followed by Europe, both in absolute…  
Seizures expressed in drug units can also give some indi-
cation of the 'trafficking intensity' and/or the efficacy of
law enforcement in various regions. The strongest 'traf-
ficking intensity' by far is recorded for the Americas,
which accounted for 40% of global seizures in 2002,
followed by Europe (29%), Asia (21%) and Africa
(9%).  Seizures in the Oceania region accounted for less
than 1% of the world's total. 
…and population-weighted terms
The figures given above do not take population differ-
ences into account. A calculation of seizures in unit
equivalents on a per capita basis provides a somewhat
different picture. The largest seizures are still found in
the Americas (12 units per inhabitant in 2002)m and in
Europe (10 units), but Africa comes next (3 units),
below the global average of 4 units, followed by Ocea-
nia (3 units). Given the large population in Asia, per
capita seizures in this region are relatively small (2 units
per inhabitant).  However, in the countries around
Afghanistan (Pakistan, Iran, Central Asia) per capita
seizures of 13 units in 2002 were even higher than in the
Americas or in Europe.
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Fig. 23: Proportion drug categories in seizures in unit equivalents, 1985 - 2002
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Fig. 24: Regional breakdown of drug seizures in unit
equivalents,  1985-2002
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m) They are particularly high in North America: 16.9 units per inhabitant. In South America (incl. Central America and the Caribbean) seizures
amounted to 7.4 units per inhabitant and were thus still almost twice as high as the global average (4.2 units per capita).
Fig. 25: Per capita seizures of drugs in unit
equivalents in 2002 
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Over 1985-2002, unit seizures decreased, in relative
terms, in the Americas and increased in Europe  
Seizures increased in all regions over the 1985-2002
period. The most noticeable shifts - in relative terms -
were the reduced importance of seizures in the Ameri-
cas (from 58% of global seizures in 1985 to 40% in
2002) and the increase in Europe (from 7% in 1985 to
29% in 2002).  The patterns for the other regions are
less clear because they fluctuated strongly from year to
year.  
The short-term trend patterns observed from 2001 to
2002, however, are not in line with the long-term ones.
Seizures increased in the Americas (from 37% to 40%
of global seizures, or +12% in absolute terms), mainly
due to increased enforcement efforts in South America.
Seizures in Asia rose by 18% in 2002 (from 19% to
21% of global seizures), mainly due to increases
reported from South-West Asia. European seizures
declined by 7%, and African ones by 19%, from 12%
to 9% of global seizures. The decline in Africa was
caused by lower seizures reported from East and South-
ern Africa.  By contrast, seizures increased in West and
North Africa.    
In regional terms, unit seizures show ... 
The regional distribution of seizures in unit equivalents
shows a distinct pattern: 
• In most regions cannabis is by far the most widely
seized substance. 
• In Africa, cannabis accounted for 99% of seizures
expressed in unit equivalents in 2002, clearly
highlighting its continuing importance in the
region; the relatively low proportion of cannabis
in total seizures in Oceania seems to be primarily
a consequence of differences in enforcement pri-
orities (as compared to other regions);   
• Seizures of cocaine-type substances are high in the
Americas (31% of the seizures in the Americas in
2002, i.e. more than twice the global average).
This is consistent with the role of South America
as the source of cocaine and of North America as
the main consumer market for it;  
• Seizures of opiates are high in Asia (43% of all
Asian seizures in 2002, i.e. three times the global
average), as can be expected from the presence of
the main opium production centers in this region.
Seizures of opiates - in proportional terms - are
almost twice as high in Europe (9% of European
seizures) as in the Americas (5% of American
seizures); 
• Seizures of ATS, in proportional terms, are high-
est in Oceania, accounting for about half of all
seizures in 2002. In Asia, ATS account for 9% of
all seizures. If only East- and South-East Asia are
considered, ATS account for about half of all
seizures. In absolute terms, ATS seizures are higher
in Asia than in any other region. 
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Fig. 26: Proportion of drug seizures in different regions based on seizures in unit equivalents, 1985-2002
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The global production trend is stable for opium, declin-
ing for coca, and seems to be increasing for cannabis and
the ATS
The global illicit production of opium (from which
heroin is processed) has remained stable, at around
4,000 to 5,000 metric tons, since the early 1990s, but
has become increasingly concentrated in Afghanistan.
Coca cultivation (cocaine is extracted from the leaves of
the coca bush) was stable during most of the 1990s, but
has been steadily decreasing since 1999 (minus 30%
from 1999 to 2003).  There is unfortunately not enough
data to establish a precise global illicit production trend
for cannabis, which appears to be increasing.  Cannabis
is now reportedly cultivated in more than 140 countries
throughout the world.  The situation is somewhat sim-
ilar for ATS, although the spectacular progression in the
number of seizures of illegal laboratories since the mid-
1990s (from less than 1000 in 1995 to about 10,000 in
2002) is in line with the trends reported for ATS con-
sumption.
Fairly robust data series are available to monitor the
global evolution of illicit cocaine and opiate production
over time.  This is unfortunately not the case for ATS
and even less so for cannabis.  For those two drug cate-
gories, the consumption and especially seizure data pre-
sented above, and detailed in subsequent chapters of this
report, still offer the best sources of information avail-
able.
For the opiates, monitoring systems based on annual
surveys of illicit opium poppy cultivation in source
countries indicate that world illicit production has basi-
cally remained stable since the early 1990s, at around
4,000 to 5,000 metric tons per year.   This period, how-
ever, has been characterized by a major shift of produc-
tion from South-East to South-West Asia, with an
increasing concentration in Afghanistan.  It is also
marked by the emergence of opium production in
Colombia, albeit at much lower levels than in Asia.
For cocaine, the cultivation of the raw material (the leaf
of the coca bush) is concentrated in three countries of
the Andean region.  During the 1990s, coca cultivation
and potential cocaine production remained more or less
stable, but increasingly shifted from Peru and Bolivia to
Colombia.  From 1999 to 2003, however, coca cultiva-
tion declined by 46% in Colombia, and by 30% in the
three countries taken together. As a result, the potential
availability of cocaine on world markets has been
reduced significantly and is now at the lowest level since
the late 1980s.
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Fig. 27: Regional breakdown of seizures in unit
equivalents
Source: UNODC, Annual Reports Questionnaire Data/ DELTA.
Fig. 28: Global opium poppy cultivation, 1990 - 2003
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Fig. 29: Global coca bush cultivation, 1990 - 2003 (ha)
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Opiate market at the crossroads in Afghanistan
Considering trends in cultivation, production and con-
sumption, the global heroin market was largely stable in
2002, but there are indications of a slight expansion in
2003 and a larger one is forecast for 2004. As opium
poppy cultivation is increasingly concentrated in
Afghanistan, which has been producing three-quarters
of the world's illicit opium in recent years, the fate of
the world heroin market will largely depend on what
happens in that country.
Last year, UNODC reported that although production
had generally stabilized over the 1998-2002 period,
major shifts were at work. This analysis has been borne
out for 2003. One example of a continuing market
trend is the consolidation and contraction of cultiva-
tion. More than 90% of global opium production takes
place in Afghanistan, Myanmar and Laos, with
Afghanistan now assuming the vast majority of this
share.  In 2003, Myanmar and Laos experienced strong
declines in cultivation, minus 24% and minus 14%
respectively.  Both countries have been implementing
resolute opium elimination programmes in recent years
and already achieved a cumulative reduction of 60% of
the area under cultivation since 1996. The trend is
expected to continue in 2004 and, if sustained over the
next few years, would virtually take South East Asia off
the global illicit opium production map.  The rapid pace
of elimination is, however, putting tremendous eco-
nomic pressure on farmers, often from ethnic minori-
ties, who have relied for so long on opium production
as a means of survival.  There is evidence in the eastern
Shan states of Myanmar, that some of those populations
are now facing a serious humanitarian crisis.  As Myan-
mar and Laos are assuming their responsibilities in
reaching the goals agreed upon by the international
community at the UNGASS, it is of paramount impor-
tance that the donor community fully takes its share of
the burden as well and provides relief and development
assistance to a population that belongs to the poorest of
the poor.  Myanmar and Laos ranked 131st and 135th,
respectively, out of 175 countries, on the 2003 Human
Development Indexn; and the ethnic minorities who
live in the remote opium producing areas have a stan-
dard of living that is even below that of the general pop-
ulation.
Afghanistan, in contrast, experienced an 8% increase in
total area under opium poppy cultivation in 2003.  This
increase was offset by the reduction in South East Asia
and, globally, illicit opium cultivation declined by 6%.
Perhaps more relevant, however, are the shifts in pro-
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Fig. 30: Detections of clandestine ATS laboratories at the global level, 1990-2002
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1.2.3.  The outlook for world drug markets 
n) UNDP, Human Development Report 2003, New York, 2003.
duction. These continue and could redefine the charac-
teristics of the supply side of the heroin market in the
future. In particular the variation in opium yield
between cultivation sites continues to influence produc-
tion trends. Therefore, despite the absolute decrease in
cultivation, increasing cultivation in Afghanistan, com-
bined with the higher yield per hectare (typically three
to four times higher than in South East Asia) has lead to
a 5% rise in global illicit opium production in 2003.
Especially with cultivation in Afghanistan forecast to
rise in 2004 , this trend is expected to continue and
global opium/heroin production to expand. 
The extent to which these supply trends have defined
the market, especially in Western and Eastern Europe,
Central Asia, and the Russian Federation, has been
made apparent by the disastrous social and health con-
sequences they bring with them. This could jeopardize
the sustainability of the stabilization of heroin abuse
recorded in 2002, a late consequence of the opium pro-
duction ban in Afghanistan in 2001.  There are even
signs that in 2002, newly reported cases of Intravenous
Drug Use (IDU) related HIV declined strongly in
Europe's largest heroin market, the Russian Federation
(minus 43%). However, in some countries, including
the Russian Federation, stabilization has occurred at
very high levels. As these are, by now, established heroin
consumer markets, it could mean that if supply
increases this year and next year (when the 2004
Afghanistan opium production reaches the market), as
forecast, increased availability could raise demand. 
Unlike in South East Asia, the opium production prob-
lem in Afghanistan is deeply intertwined with the over-
all political and socio-economic situation of the country
.  As a consequence, it cannot be solved separately and
needs to be tackled as an integral part of the stabiliza-
tion and reconstruction agenda.  Because of
Afghanistan's overwhelming role in the supply of illicit
opiates, rapid progress (over a few years) in eliminating
opium production there could well dry up the world
heroin market.  Timing is crucial, however, because a
gradual approach to elimination would only enable the
market to adapt, as it has often done in the past, and
production to shift to other areas.  The Afghan govern-
ment has adopted a national drug control strategy that
calls for 75% reduction of opium production within
five years.  The main obstacles currently hindering its
implementation appear to be the poor security situation
in the provinces and the involvement of local warlords
and, in some cases, of provincial authorities, in the drug
business.
Progress on the control of cocaine supply offset by geo-
graphical spread of consumption 
While the markets are inherently different, some of the
same characteristics of consolidation and stabilization,
which have been recently observed in the global heroin
market, are also present in the global cocaine market. 
The general stabilization and decline in coca cultivation
and cocaine production has been sustained for the fifth
year in a row. There is no indication that this trend is
likely to be reversed. Vigilant supply reduction efforts
continue in Colombia, Peru and Bolivia. While there
have been some set backs, these efforts are likely to be
sufficient to sustain overall declines in cultivation and
production.  The overall area under cultivation fell to
154,000 ha in 2003.  Both cultivation and production
remain heavily concentrated in Colombia, where 56%
of coca bush cultivation and 67% of cocaine production
took place in 2003. 
Last year, UNODC reported that Bolivia and Peru were
having difficulties in consolidating the declines in their
countries. Although the downtrend was sustained in
Colombia, its pace slowed from minus 30% in 2002 to
minus 16% in 2003. Setbacks included shifts in the
localities under cultivation in the individual countries.
In Bolivia, for instance, cultivation in the area of the
Yungas of La Paz grew 17%, to represent 71% of the
total coca cultivation of the country, and in Colombia
cultivation in Narino and Meta increased 17% and 38%
respectively.
The last peak in cocaine production was in 1999. Since
that time, global cocaine seizures have stabilized and
gradually declined in line with production. Unfortu-
nately, the cocaine market has been able to establish
itself in new geographical locations. Although the bulk
of seizures still take place in the Americas, they have
declined steadily along a general trend since 1991, while
seizures (and consumption) in Western Europe have
increased along a slightly steeper general trend over the
same period.  In North America and Western Europe,
seizures for 2002 fell by about a fifth, parallel to a dra-
matic and encouraging rise in seizures in the three
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o) UNODC, Afghanistan, Farmers' Intentions Survey 2003/2004, Vienna, February 2004.
p) UNODC, The Opium Economy in Afghanistan, An International Problem, New York, 2003.
source countries. Seizures in Colombia exceeded those
in the USA in 2002 and were the largest worldwide. 
It is the long-term dispersion of the cocaine market,
however, that appears to have more relevance for policy
makers. The cocaine market has been characterized by a
high degree of adaptability.  Over the last ten years the
criminal organizations that run the market have been
disbanded, but have re-formed. They are now run in a
completely different manner than they were ten years
ago. Despite the potential disruption caused by this, the
declines in production, and the completely changed
composition of production, which has led Bolivia to
become an almost negligible producer and Peru to pro-
duce only a fifth of global supply, new markets are still
being established today.  
While there are indications that the expansion of
cocaine consumption is losing some of the momentum
it had in the 1990s, and while traditional markets such
as the USA and Mexico are stabilizing, new markets
continue to emerge.  According to UNODC's Drug
Abuse Trend Index, cocaine use has increased dramati-
cally in Southern America, Central America and the
Caribbean since 1995.  Abuse levels are high and
increasing in Brazil and Colombia. There are exceptions
to this trend in Bolivia and Peru. 
Europe, one of the fastest growing cocaine markets over
the last decade, has shown signs of stabilization, notably
in the UK and Germany in 2003.  Growth since 2000
in other European countries, including Spain, France,
the Benelux countries, Italy, Switzerland, Austria and
the Balkans, however, indicates that the European
cocaine market remains buoyant. Another indication of
this is the continued emergence of crack cocaine in sev-
eral European locations. Notorious for its association
with high levels of violence and crime and the destruc-
tive effect it has had on North American urban com-
munities, crack cocaine is also known to be persistent
once it gets a foothold in a local market. This trend
should be monitored closely. Albeit still at low levels,
significant growth in cocaine consumption has taken
place in the Near East and South Asia, including in
India, the world's second most populous country. Most
of this expansion has only taken place in the past three
years, providing further indication that the cocaine
market continues to disperse geographically. 
The coca market has caused many serious social prob-
lems for all countries in the Andean region. The minute
0.075% of Colombia's national territory which were
under coca cultivation in 2003, for example, belies the
devastating effect this trade has had on the country.
Colombia faces a myriad of social and economic prob-
lems. Some of which are related to the illicit drug trade
and some are not. On May 10, 2004, Jan Egeland, the
United Nations Under Secretary General for Humani-
tarian Affairs stated "Colombia is by far the biggest
humanitarian catastrophe of the Western hemisphere".
(UN Press Briefing 10/5/04.)  According to the Colom-
bia coca survey for 2003, over the past 5 years over 1.5
million people are thought to have fled to escape rural
violence. The country has the third largest internally
displaced population crisis in the world. The level of
homicides and kidnappings is extremely high. 
Internal displacement is one of the most damaging
things which can happen from a humanitarian point of
view. This level of disenfranchisement leaves the person
with no community, no security, often no shelter, food,
water, sanitation, healthcare and education. It is one of
the most dangerous situations a human being can be in,
especially in high conflict areas.  While most of Colom-
bia's internally displaced persons end up in the sprawl-
ing barrios and shanty towns around large cities, others
end up engaged in illicit production activities, putting
them at even further risk and perpetuating the displace-
ment cycle. All coca growing areas in Colombia show a
high level of forced displacement. 
The Andean region, Colombia in particular, have suf-
fered greatly as a result of cocaine production. Conse-
quently, over the last years, governments in each country
have been making concerted efforts to reduce the culti-
vation of coca and production of cocaine.  After three
years of declines the international community can be
confident that actions at the national level are having
beneficial effects. 
Cannabis: a thriving market
Dispersion is a defining characteristic of the world
cannabis market. Cannabis is the most widely pro-
duced, trafficked and consumed illicit drug in the
world. The market in which the drug is produced,
traded and consumed is pervasive and persistent, per-
haps because of the vast number of places in which the
drug is produced and the high levels of availability
which this has created. 
If cannabis plant seizures are used as an indicator, as
many as 142 countries produced cannabis between
1992 and 2002. The bulk of the trafficking of cannabis
herb takes place in North America, with Mexico and the
USA respectively accounting for 34% and 23% of
global seizures.  These two countries are followed by
Nigeria, Brazil and South Africa.  
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The production of cannabis resin is concentrated in 40
countries. Three of these, Morocco, Pakistan and
Afghanistan, are main producers. Consumption is con-
centrated, and increasing, in Western Europe.  Two
thirds of all cannabis resin were seized there and some
80% of that apparently originated in Morocco. In 2003,
UNODC and the Government of Morocco conducted
the country's first comprehensive cannabis survey. The
survey revealed a potential cannabis resin production of
3,080 metric tons. 
As noted in previous sections of this chapter, the global
market for cannabis continues to thrive.  Consumption
is rising in South America, and the market continues to
expand in both Western and Eastern Europe, as well as
in Africa. In the United Kingdom, Europe's largest
cannabis market, use has stabilized over the last three
years, but at extremely high levels: among the general
population it is now twice as high as it was in the early
1990s. Even in Asia, where increases in cannabis use are
less pronounced, the two most populous countries,
China and India, have reported large increases. How-
ever, use has remained generally stable in the USA, the
world's largest cannabis market in economic terms.
This trend was largely paralleled in Ontario, the most
populous province of Canada, and in Mexico.   
Mixed signals from ATS markets
Although the market for ATS is expanding and buoyant,
there are some signs that the rate of increase is not quite
as rapid as it was over the last ten years.  The ATS
market is fragmented and geographically distinct. It is
essentially composed of a number of chemically related
synthetic drugs, three of which - amphetamine,
methamphetamine and ecstasy - dominate certain
regions.  Also, unlike the plant-based drugs, ATS are
produced with chemicals that are common and often
readily available, in easily concealed laboratories.
Because these laboratories tend to be small and portable
(sometimes even referred to as 'kitchen laboratories'),
interdiction is easily eluded through moving or aban-
donment. Manufacture frequently takes place close to
the consumers and less high-risk international traffick-
ing is required.  These characteristics, which will con-
tinue to define the market in the future, are extremely
important because of the adaptability they give to pro-
ducers and distributors. Consumers, also, have demon-
strated flexibility - especially regarding ecstasy.  This has
led to a situation where the three main geographical
regions of ATS consumption are expanding and partly
merging.  Finally, it is possible that the proximity of the
production sources to the main markets could mean
that there is a more direct link between declines in avail-
ability and declines in consumption. 
Internationally, law enforcement agencies have become
aware that it is these production characteristics which
led, at least in part, to the market's phenomenal growth
over the past ten years. They therefore concentrate on
dismantling laboratories and interdicting precursor
chemicals. There has been a clear upward trend in their
ability to do this and, in 2002, more than 9,300 clan-
destine methamphetamine laboratories were disman-
tled, a 14% increase over the previous year. Most of
these were dismantled in the USA.  In several countries
of Western Europe, enforcement efforts were also inten-
sified, including the Netherlands, the main source of
ecstasy and amphetamine in Europe.  Ecstasy produc-
tion is also beginning to appear in South-East Asia,
along with large-scale production of methamphetamine.   
Of all the ATS, methamphetamine has the most nega-
tive health and social consequences.  It is prevalent in
North America and East and South-East Asia, which is
its largest market. Methamphetamine abuse continues
to rise in the region, especially in China, Singapore,
Myanmar and the Republic of Korea.  China's market,
which is relatively recent, has been characterized by an
extremely steep increase since 1997.  There are indica-
tions that this is due to the introduction of ecstasy in
that year and its possibly overtaking methamphetamine
in the recent period. Thailand, which has one of the
highest methamphetamine prevalence rates in the
world, experienced a decline in consumption in 2003,
and a stabilization/decline is thought to have occurred
in Japan. There have also been some positive signs in
Europe: amphetamine consumption seems to be stabi-
lizing, with continuing declines reported from the UK
and Ireland.  After years of steep increases, ampheta-
mine use stabilized for the first time in Eastern Europe
in 2002.  A resurgence of methamphetamine and
amphetamine markets, however, cannot be excluded.
The flexible production structure and negative health
consequences of the drugs therefore make it imperative
that control and prevention efforts are intensified. 
The global market for ecstasy continues to expand,
although at a much slower pace than in previous years.
The evolution of this market is a cause for serious con-
cern.  While there are signs of stabilization or contrac-
tion in some of the more established markets of Western
Europe and North America, and a loss of momentum in
the increases reported from Oceania (which seems to
have the highest levels of ecstasy use worldwide) the
market is expanding to several developing regions where
public resources for prevention and control are scarce.
Apart from the example of China, which was cited
above, the ecstasy market seems to be expanding into
other parts of Asia, South America and Southern Africa. 
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1.3  INJECTING DRUG USE AND HIV/AIDS
Global estimates, provided by UNAIDS and WHO, indicate that by the end of 2003 between 34 and 46 million
people were living with HIV/AIDS. Between 4.2 and 5.8 million people were infected in 2003 alone.  In the same
year, between 2.5 and 3.5 million people died of AIDS. While the bulk of new infections are due to unsafe sexual
behaviour, the use of contaminated injection equipment among injecting drug users continues to fuel the pandemic,
particularly in Eastern Europe, Central, South and South-East Asia and Latin America. 
Map 2: Estimates on the size of the IDU populations available in 130 countries and territories (1998 - 2003)
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1.3.1 Extent and characteristics of HIV/AIDS
epidemics among injecting drug users
According to a review of the Reference Group on the
Prevention and Care of HIV/AIDS Among Injecting
Drug Users in 2003, information on the size of the
injecting drug users population is available for 130
countries and territories, and data on the association of
HIV infection with injecting drug use for 78. The group
estimated that there are approximately 13 million
injecting drug users worldwide, of which 8.8 million are
in Eastern Europe, Central, South and South-East Asia,
1.4 million in North America, and 1 million in Latin
America.
HIV/AIDS epidemics among injecting drug users are
characterised by significant regional and in-country
variations, but prevalence figures for HIV/AIDS among
injecting drug users easily reach more than 50% and in
some cases up to 90% of the injecting drug use popula-
tion in a very short period of time, often less than six
months. Examples for such epidemic explosions include
various cities in North America, some countries of the
former Soviet Union, and countries and localities in
South and South-East Asia. Experience also shows that
if resolute action is not taken quickly, prevalence
remains at very high levels for a long time.
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Fig. 31: Outbreaks of HIV/AIDS epidemics among injecting drug users, selected cities
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Fig. 32: HIV/AIDS prevalence among injecting drug users in Manipur (India) and Bangkok (Thailand) 1988-1997
Sources:  U.S. Census Bureau, Population Division, International Programs Center, Health Studies Branch, May 2003, and Weniger BG,
Limpakarnjanarat K, Ungchisak K, Thanprasertsuk S, Choopanya K, Vanichseni S, Uneklabh T, Thongcharoen P, Wasi C. The epidemiology
of HIV infection and AIDS in Thailand, AIDS 1991; 5(suppl 2): S71-S85
Source: Ball, AL, Rana S, Dehene, KL, HIV Prevention among Injecting Drug Users: Responses in Developing and Transitional Countries,
Public Health Reports 113, Supplement 1, 170-181, 1998; and Stimson GV, Adelekan M, Rhodes T, The diffusion of drug injection in
developing countries, Paper presented at the Sixth International Conference on the Reduction of Drug Related Harm, Florence, Italy, 1995
The recently evolving HIV/AIDS epidemics in coun-
tries of the former Soviet Union are of particular con-
cern.  Though heroin is the most frequently injected
drug, a significant number of users also inject the so-
called 'home produced' drugs, including 'jeff' and 'vint'
(ephedrine-based stimulants extracted from cough
syrups or tablets), and 'hanka' (a liquid derivative of
opium poppy).  The sharing of injection equipment,
particularly needles and syringes, is widespread with
many injecting drug users also reporting practices
whereby a drug solution is squirted from a donor
syringe into another, either by removing the plunger
('back loading') or needle ('front loading') from the
receiving syringe.   Drug users often share filters and
rinse water, and draw up their drug solution from a
common pot.
Various explanations have been offered for the
HIV/AIDS epidemic in these countries. The most fre-
quently cited ones concern the collapse of institutions,
particularly for health and drug control, which followed
the break-up of the Soviet Union.  This, combined with
expanding production in Afghanistan, created a huge
influx and increased availability of drugs. Drug treat-
ment and health care facilities could not cope with the
rapidly increasing number of injecting drug users and
the health and social consequences of drug use. One of
the most disturbing dimensions of the epidemic is the
fact that young people below the age of 24 constitute
the majority in the drug injecting population and are
those mostly affected by HIV/AIDSq.
Serious HIV/AIDS epidemics among injecting drug
users have also been observed in countries of South,
South-East and East Asia. Many of these countries have
a tradition of opium smoking for health reasons (to ease
the symptoms of lung and bowel diseases). With chang-
ing illicit drug market patterns, however, many users
switched from smoking opium to injecting heroin,
thereby significantly increasing the risk of blood-borne
infections.  Except for Cambodia, all HIV/AIDS epi-
demics in that region started in injecting drug use pop-
ulations in the late 1980s and early 1990s, and later
moved into the general population.  Injecting drug use
still remains the most frequent route of HIV transmis-
sion in these countries and continues to fuel the epi-
demicsr.
In countries of Latin America, cocaine is the most fre-
quently injected drug.  Cocaine users inject more fre-
quently than opiate users, thereby increasing
significantly the risk of HIV transmission. As in other
countries, drug consumption behaviour depends on ille-
gal drug market patterns, and particularly in Latin
American countries crack cocaine, which is not injected,
sometimes replaces cocaine use. Evidence suggests that
the use of crack is strongly associated with high-risk
sexual behaviour, thus contributing to the spread of
HIVs.
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Fig. 33: Registered HIV infections per million in
countries of former USSR, cumulative
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q) Tim Rhodes, Catherine Lowndes, Ali Judd, Larissa A. Mikhailova, Anya Sarang, Andrey Rylkov, Mikhail Tichonov, Kim Lewis, Nina Ulyanova,
Tatiana Alpatova, Victor Karavashkin, Mikhail Khutorskoy, Matthew Hickman, John V. Parry and Adrian Renton: Explosive spread and high
prevalence of HIV infection among injecting drug users in Togliatti City, Russia; AIDS 2002, 16:F25-F31
r) Reid,G and Costigan, G. Revisiting The Hidden Epidemic; A situation assessment of drug use in Asia in the context of HIV/AIDS. The Centre for Harm
Reduction, Australia, January 2002; The World Bank, Social Monitor Thailand, Building on Success, Confronting the future, Bangkok, November
2000
s) Rossi D, Goltzman P, Cymerman P, Touze G, Weissenbacher M.Human immunodeficiency virus/acquiredImmunodeficiency syndrome prevention in
injection drug users and their partners and children: lessons learned in Latin America--the Argentinean case. Clin Infect Dis. 2003 Dec 15;37 Suppl
5:S362-5;Touze G. Obstacles to the development of prevention and public health policies in Argentina. Clin Infect Dis. 2003 Dec 15;37 Suppl
5:S372-5; Calleja JM, Walker N, Cuchi P, Lazzari S, Ghys PD, Zacarias F. Status of the HIV/AIDS epidemic and methods to monitor it in the Latin
America and Caribbean region. AIDS. 2002 Dec;16 Suppl 3:S3-12.
The rise in HIV infections among injecting drug users
in the Middle East and North Africa is also a cause for
concern. In some countries, more than half of all known
HIV infections are among injecting drug users. Prison
settings seem to be particularly high-risk environments:
HIV prevalence among injecting drug users in 10 pris-
ons in Iran has reached as high as 63 per cent. It has
been estimated that Iran could be home to as many as
200,000 injecting drug userst.
1.3.2 HIV transmission among injecting drug
users
The shared use of syringes and needles has been associ-
ated with HIV transmission among injecting drug users
since the beginning of the HIV/AIDS pandemic in the
1980s. Commonly referred to as "syringe or needle
sharing," this represents a situation in which two or
more drug users sequentially use the same injecting
equipment to inject a dose of liquefied drugs, such as
heroin, other opiates, cocaine or amphetamines. Factors
that lead to needle and syringe sharing include borrow-
ing and lending, selling, buying and renting, or even
picking up a syringe discarded by a previous user. Shar-
ing of needles and syringes is often a consequence of a
lack of perceived risk for HIV infection, group norms
and rituals, inaccessibility of clean injecting equipment,
and / or the inability to carry injecting equipment due
to familial, social or legal environments. 
In situations where injecting drug users prepare and use
drugs together, a variety of additional avenues for HIV
transmission exist. For example, injecting drug users
often share items while preparing the drug for con-
sumption, including cookers, water cups, filters, spoons
and swabs, ampoules and other containers used for drug
preparation, storage and transport, among others.
Within the networks of drug consumers, use of drugs is
rarely an individual act and the sharing of drugs is an
important and frequent communal activity, associated
with economic and social incentives. One situation,
strongly associated with HIV infection, is the use of so
called "shooting galleries", particularly when renting
injection equipment at these venues is included.
Another context is the use of professional injectors,
where those selling the drugs also do the injecting, using
the same syringe and needle for many clients.
There are indications that individual risk behaviour is
influenced by the context in which drugs are purchased
and used, including drug paraphernalia laws, which
govern the accessibility and availability of clean inject-
ing equipment, drug policing and law enforcement
practices, gender, ethnic and health inequalities, and
general public policies oriented to health and drug use
more broadly. 
There is evidence that individual injecting risk behav-
iour and HIV infection among injecting drug users is
associated with the length of the drug taking careeru,
injecting frequencyv, the types of drug usedw, unstable
living conditionsx, imprisonmenty as well as the avail-
ability of clean injection equipmentz.   The length of the
injecting career is positively associated with the likeli-
hood of being infected with HIV.  Some studiesaa sug-
gest, however, that younger, less experienced injectors
are at an increased risk for HIV infection, because they
seem more likely to engage in risk behaviours, while
their older, more experienced counterparts may be more
competent in managing risk situations. 
HIV is not only transmitted through the sharing of
injection equipment among injecting drug users, but
also through sexual transmission to partners. High-risk
sexual behaviour, i.e., having sex without using a
condom, is often linked with drug use. Female drug
users who are also sex workers and do not use condoms
regularly are particularly at risk of acquiring and trans-
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t) UNAIDS, WHO. AIDS Epidemic Update, December 2003.                                                                            
u) Estebanez P, Russell NK, et al. Determinants of HIV prevalence amongst female IDU in Madrid. Euro J Epidemiol 2001;17(6):573-580.
v) Bruneau J, Lamothe F, et al. Sex-specific determinants of HIV infection among injection drug users in Montreal. Canadian Med Assoc J
2001:164(6):767-73; Strathdee SA, Galai N, Safaiean M, Celentano DD, Vlahov D, Johnson L, Nelson KE. Sex differences in risk factors for HIV
seroconversion among injection drug users: a 10-year perspective. Arch Int Med 2001;161:1281-1288. 
w) Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco.
JAMA 1989;261:561-565.
x) Patrick DM, Strathdee SA, et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int
J STD AIDS 1997:8(7):437-45.
y) Muller R, Stark K, Guggenmoos-Holzmann I et al. Imprisonment: a risk factor for HIV infection counteracting education and prevention
programmes for intravenous drug users. AIDS 1995;9:183-90. 
z) Grund J-PC, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, Des Jarlais DC. Drug sharing among injecting drug users: patterns, social context,
and implications for transmission of blood-borne pathogens. Soc Sci Med 1996;42(5):691-703.  
aa) For example, Fennema JSA, van Ameijden EJC, van den Hoek A, et al. Young and recent-onset injecting drug users are at higher risk for HIV.
Addiction 1997;92:1457-1465.  
mitting HIV. In several countries, such as the United
States, Spain and Italy, sexual transmission of HIV from
injecting drug users to non-drug injecting sexual part-
ners has long been the dominant pattern of heterosex-
ual transmission.
One of the reasons why HIV spreads from injecting
drug users to other populations is the fact that a con-
siderable number of drug users enter into sex work to
finance their drug dependence. In fact, among drug
users, sex work is often seen as an alternative to crimi-
nal behaviour to obtain cash or drugs. It has often been
observed that sex workers inject stimulants to be able to
cope with the stress of their professionab. Hard data on
the problem are scant, but the little available informa-
tion indicates that there are significant numbers of drug
injecting sex workers and sex working injecting drug
usersac in Eastern and Western Europe, Central Asia,
South and South-East Asia and the Americas. For exam-
ple, a study of street sex workers in an Eastern European
country indicated that 24.6% of them were also inject-
ing drug users. Another study examining female inject-
ing drug users in North America found that 70% of
them also exchanged sex for money or drugsad. In the
same study, 56% of male injectors had also exchanged
sex for money or drugsae.
A study carried out in Dhaka, Bangladesh indicates that
in a sample of male sex workers, 11% had injected
drugs. Among male injecting drug users in the same city
who had injected for two years or less, 16 % had
exchanged sex for cash or drugs . 
Another reason for the diffusion of the virus from
injecting drug users to the general population is the fact
that injecting drug users are frequently incarcerated.
The sharing of injecting equipment and sexual inter-
course, mostly between men, is widespread in prison
settings of most countries of the world, and the likeli-
hood of being infected with HIV is very high. As a con-
sequence, HIV infection rates in prison settings are
generally higher than the national averageaf. After the
prisoner’s release, the virus is spread via sexual transmis-
sion to sexual partners, and via needle sharing to other
injecting drug users. There are approximately 10 million
people imprisoned across the world at any given time.
This is a shifting population, with large numbers of
people entering prisons and/or being released.  A total
figure of about 30 million prisoners worldwide annually
is therefore not far fetched.  These prison populations
constitute a significant risk factor for the diffusion of
HIV. 
1.3.3 Measures to respond
Twenty years of research in various aspects of
HIV/AIDS among injecting drug users and the experi-
ence from numerous programmes and projects indicate
that HIV/AIDS epidemics among injecting drug users
can be prevented, stabilized and even reversed. One
important lesson learned is that effective responses have
to be based on sound assessment of the drug use and
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Fig. 34: Mixing patters of different subpopulations,
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ab) Alegria M, Vera M, Freeman DH et al. HIV infection, risk behaviors, and depressive symptoms among Puerto Rican sex workers. Am J Public
Health 1994;84:2000-2
ac) Chaplinskas S & Mårdh P. Characteristics of Vilnius prostitutes. Int J STD & AIDS, 2001, 12:176-180.
ad) Rothenberg R, Long D, Sterk C, Pach A, Potterat J, Muth S, Baldwin J, Trotter R. The Atlanta Urban Networks Study: a blueprint for endemic
transmission. AIDS 2000;14:2191-2200.
ae) Government of Bangladesh. Report on the Second Expanded HIV Surveillance, 1999-2000, Bangladesh, Dhaka, GoB/UNAIDS, 2000.
af ) Jürgens, R, HIV/AIDS prevention for drug dependent persons within the criminal justice system, Presentation at the Commission on Narcotic
Drugs Ministerial Segment: Ancillary Meeting on HIV/AIDS and Drug Abuse, Vienna 2003
HIV situation, and the socio-cultural and political con-
text. Policies governing HIV/AIDS prevention have to
adopt pragmatic approaches taking into account that
drug dependence is a chronically relapsing condition
and therefore provide for addressing high-risk behav-
iour.  
There is some evidence to suggest that the availability
and regular use of clean injecting equipment can pre-
vent, halt and perhaps even reverse HIV/AIDS epi-
demics among injecting drug users. Examples include
cities such as Sydney, Glasgow and Toronto. In Brazil,
extensive outreach to injecting drug users reduced the
percentage of injecting drug users in newly detected
HIV infections from a high of 25.5% in 1991 to 12.1%
in the year 2000. If clean injecting equipment becomes
scarce, as happened for example in Edinburgh in the
early 1980s (see the figure on selected cities above), a
serious HIV/AIDS epidemic could be provokedag.
Effective programmes could typically include a wide
variety of measures ranging from drug dependence
treatment, including substitution treatment, outreach to
injecting drug users to provide them with information
on safer sex and injecting practices, clean needles and
syringes, and condoms, voluntary counselling and test-
ing, treatment of sexually transmitted infections, and
interventions for special populations-at-risk such as
prisoners and sex workers who inject drugs. Such pro-
phylactic measures are desirable, but, as the Interna-
tional Narcotics Control Board has noted, should not
promote and/or facilitate drug abusah.
Both scientific evidence and the experience with such
programmes would seem to indicate that such a pack-
age would be effective in reducing the risk of HIV trans-
mission among injecting drug users and the risk of HIV
diffusion from drug users to the general population.
Over the past two decades effective programmes have
moved through a significant paradigm shift, away from
waiting for drug users to enter institutional services, to
offering services to drug users where they are: in their
communities and where they use drugs.  
1.4. CONCEPTUAL ADVANCES IN 
DRUG CONTROL 
The preceding sections of this chapter have presented
the terms of the difficult equation that must be solved
by the international community. On one side, clear
policy objectives and a long established consensus on
the need to address the drug problem through a multi-
lateral approach has generated one of the most devel-
oped systems of international cooperation ever created
in the realm of social policy.  Decades of experience
accumulated by drug control agencies at national,
regional and global levels have helped to progressively
identify virtually every possible dimension of the drug
problem and to evolve an array of corresponding inter-
ventions. Drug control programmes now span many
domains of traditional public policy, from justice and
police, to economics and finance, and to education and
health. On the other side of the equation, despite the
favourable comparison with the public health disaster
created by the largely uncontrolled tobacco industry, it
is undeniable that results have so far not been commen-
surate with the ambitions enshrined in the UN drug
conventions and consistently reaffirmed by policy
makers and public opinion thereafter. 
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Fig. 35: Percentage of injecting drug users among
newly detected HIV infections in Brazil
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Source: UNODC, Country Office Brazil. 
ag) Brettle RP. Epidemic of AIDS related virus infection among intravenous drug abusers. BMJ 1986;292:1671.
ah) Report of the International Narcotics Control Board for 2003, p.36.   New York, March 2004
Since the entry into force of the 1961 convention, drug
abuse and the criminal ventures that feed it have spread
and grown to levels that have kept the problem high on
the list of public anxieties.  The perception, often
voiced, that battle after battle is being lost in the "war
on drugs" is certainly a consequence of that situation.
The performance of the control system is not com-
monly judged on the basis of what it might have suc-
cessfully averted - an epidemic on the scale of nicotine
addiction -  but rather on what it has so far failed to cor-
rect - the persistence and geographical spread of illicit
drug production, trafficking and abuse and of their
often dramatic consequences.  Since the elimination of
the problem, as opposed to its mere containment, was
always stated as the overarching goal of the drug control
system, it is only fair that it be judged on that basis. 
Are the objectives of the international drug control
system too ambitious?   There are fortunately few people
who question the basic philosophy that underlies the
universally shared commitment of adult generations to
protect their younger ones from the tragedy of addiction
to dangerous psychoactive substances.  The cynical
notion that a certain proportion of each generation
could acceptably be lost to drug addiction violates the
most basic of human ethics. A society free of the drugs
that have been declared unsafe by public health experts
remains a morally laudable and politically legitimate
objective. 
More serious, however, have been the criticisms of the
efficacy of the methods used to reach that objective.  In
some cases, those methods have even been accused of
exacerbating the problem, or some of its adverse conse-
quences.  The fact that some of these critiques have been
made by drug control experts and practitioners them-
selves bears testimony to the readiness of the drug con-
trol community to question its own methods of work.
More importantly, it shows that drug control proceeds
essentially by trial and error.  As mistakes are made, and
as lessons are learned, new or improved approaches need
to be conceived and implemented.  
Illicit crop control programmes offer a good illustration
of such empirical and pragmatic approaches.  Pioneered
to a large extent by the United Nations, the concept of
'alternative development' was developed when the lim-
itations of programmes that relied merely on eradica-
tion became apparent.  After an initial phase of simple
crop substitution (replacing the drug crop with a licit
one) that proved too narrow, it was expanded to encom-
pass a range of sophisticated socio-economic develop-
ment measures that included food security, off-farm
income generation, education, primary health care, road
construction, micro-credit schemes, etc.  Improvements
were made incrementally over the years, and eventually
came to integrate such notions as bottom-up planning
and community empowerment.  There are countless
other examples of such conceptual advances that found
practical applications in other sectors of drug control
and yielded good results.  It is not the objective of this
report, however, to list these advances and document
their achievements.  It is neither the objective of this
report to present the dissenting views that have been
voiced by the anti-prohibitionist lobby and debated
extensively for over a decade. The debates have not
changed very much, and UNODC covered them in a
previous issue of this reportai.
One of the objectives of this report is, rather, to propose
some new steps towards resolving the drug control equa-
tion described above.  They are informed by a number
of recent developments that have either not yet been
fully translated into practice, or are still at the concep-
tual stage.  They conform to the overarching objectives
of the international drug control system, as well as offer
the prospect of better results.  They are suggested below
under three categories: a holistic approach; which must
become more synergistic; as well as more dynamic.  The
terms may be familiar, but the approach is not simply a
'more-of-the-same' variety. 
1.4.1. A holistic approach
Addressing the drug problem in a broader sustainable
development context 
Because of its far-reaching socio-economic dimensions,
the drug problem has a negative impact on the func-
tioning of societies as a whole.  In particular, it can sig-
nificantly hinder development programmes in poor
nations and compromise peacemaking and reconstruc-
tion efforts in countries torn by civil war. In turn, situ-
ations of poverty, strife and feeble governance are fertile
ground for drug production, trafficking and abuse.
Those various dimensions can become so interlocked
that getting out of the vicious circle they create can only
be done through a comprehensive approach. Although
53
1. The world drug problems: A status report
ai) UNDCP, World Drug Report, New York, 1997.
this aspect of the drug problem has long been perceived,
and documented in a growing body of literatureaj, it is
only recently that it started to trigger an attitudinal
change among policy makers.  Confined for too long to
special programmes handled by specialized agencies,
drug control priorities are now finding their way into
the mainstream of the socio-economic agenda.  
Starting at community level, this broader understanding
of the socio-economic dimensions of the drug problem
must notably be reflected in a society-wide approach.
Public institutions cannot do everything.  Interventions
are far more effective when the state and the economy
are joined by the various actors in civil society (such as
families, non-governmental organizations, and the
media) in a common purpose and programme.  
At the international level, interactions and joint ven-
tures between drug control organizations, development
agencies and financial institutions are developing.  In
2002, UNODC identified the need to "place drugs and
crime issues in the context of sustainable development"
as one of its six mid-term operational guidelinesak.
Providing an integrated response to the drugs and crime
nexus 
It is only logical that this more holistic perception of the
drug problem be vigorously applied to the twin sectors
of drugs and crime control.  The overlaps between the
two have become so vastal that promoting their integra-
tion should not be difficult.    Yet historical and institu-
tional reasons, among others, have, in fact, long limited
the degree of integration.  For instance, the progressive
integration of the drug control and crime prevention
programmes within a common UN Office only started
in 1997.  The merger of the two within one internal
structure was formally approved in March 2004am.
Dramatic world events in recent years have certainly
contributed to bringing the connections between drug
trafficking, organized crime and, to some extent, the
financing of terrorism, to the forefront of international
attention. The recent enrichment of the multilateral
system with a new set of ground-breaking instruments
against transnational organized crime, trafficking in
human beings, smuggling of migrants, trafficking in
firearms and corruptionan is opening the way for poten-
tially dramatic advances in the fight against drugs and
crime.
Addressing the drugs and crime nexus under the new
paradigm of human security 
Stemming from the 2000 UN Millennium Summit, the
seminal work of the Commission on Human Security is
advancing a new paradigm of security that will comple-
ment the fundamental concepts of human development
and human rightsao.  The notion of 'human security'
that encapsulates this new paradigm has the potential to
provide a much needed conceptual link between drugs
and crime control policies, on the one hand, and sus-
tainable development policies, on the other hand.  The
final report of the Commission, released in 2003,
stresses the need to address international crime, illegal
trade in arms, drugs, natural resources and people as
part of a holistic human security agenda.
"Human security focuses on the protection of people,
not borders and territories.  The added value of human
security is its focus on a broader range of violent threats
facing people, including war and internal conflict, but
also communal conflict and serious criminality.  It also
broadens understanding of the causes of violent conflict
by emphasizing the links with poverty, the inequalities
among communities and the impact of sudden down-
turns and risks. To protect and empower people in con-
flict, a broad range of interconnected policies is required
[…]"ap.
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aj) See for instance: Barnett R. Rubin, The Political Economy of War and Peace in Afghanistan, [http://institute-for-afghan-
studies.org/ECONOMY/political_economy_of_war_peace.htm], June 1999; World Bank, P. Collier and A. Hoeffler, The Economics of Civil War,
Crime and Violence, [http://econ.worldbank.org/files/12205_greedgrievance_23oct.pdf ], October 2001; UNODC, The Opium Economy in
Afghanistan, An International Problem, New York, 2003;  INCB, Report 2002, chapter 1, New York, 2003. 
ak) Commitment to Good Governance.  Progress Report on Management Reform by the Executive Director (April 2002 - April 2003).
UNODC/ED/1, 8 April 2003. 
al) Report of the International Narcotics Control Board for 2003, Chapter 1, New York, March 2004
am) United Nations Secretariat, Secretary General's Bulletin, ST/SGB/2004/6, March 2004.
an) United Nations Convention against Transnational Organized Crime (General Assembly Resolution 55/25, annex I). The Convention entered into
force on 29 September 2003, along with its Protocol to Prevent, Suppress and Punish Trafficking in Persons, Especially Women and Children
(General Assembly Resolution 55/25, annex II).  The Protocol against the Smuggling of Migrants by Land, Air and Sea (General Assembly
Resolution 55/25, annex III) entered into force on 28 January 2004.  The Protocol against the Illicit Manufacturing of and Trafficking in Firearms,
Their Parts and Components and Ammunition has not yet entered into force.  The United Nations Convention Against Corruption was adopted
by the General Assembly by Resolution 58/4 of 31 October 2003.
ao) Commission on Human Security, Human Security Now, New York, 2003.
ap) Ibid, p. 33.
1.4.2. A more synergetic approach
While much is awaited from the mainstreaming of the
drug control agenda within broader conceptual and
political frameworks, an ongoing regeneration of drug
control strategies per se is also expected to improve their
efficacy in the coming years. 
The United Nations General Assembly Special Session
on Drugs in its June 1998 Political Declaration clearly
stated the importance of implementing an integrated
and balanced approach as part of a reinvigorated strat-
egy that included time-bound and measurable targets, as
well as a set of action plans.  Meeting in early 2003 to
review the status of implementation of the actions plans,
governments identified the need for "a comprehensive
strategy that combines alternative development […]
eradication, interdiction, law enforcement, prevention,
treatment and rehabilitation as well as educationaq."
They also called for the further development of evi-
dence-based approaches and of data collection, analysis
and evaluation tools to support themar.
While these statements might sound familiar, they do,
in fact, highlight one of the most difficult intellectual
challenges that the drug control community must now
face. As pointed out in other sections of this report,
there remain huge terras incognitas in drug-related data
and statistics.  There is also surprisingly little that is
known about the structure and dynamics of drug mar-
kets at national, regional and global levels. There is a
pressing need to fill that knowledge gap. This is not just
for the greater good of science but because, unless a far
more synergetic approach is adopted to conceive drug
control strategies and to implement the vast array of
interventions they encompass, there is a real fear that
governments will, year after year, have to repeat the dis-
tressing statement that "drug abuse remains at an unac-
ceptably high levelas."
The example of Afghanistan is illustrative. The size of
the drug production and trafficking problem has
reached massive proportions in that country. Its tremen-
dous national and international consequences have
moved it to the top of the national and international
political agenda. Two years ago, the devastation of the
country by decades of civil war left policy makers with
a drug control apparatus that amounted to a blank sheet
of paper. The firm and courageous position of the new
regime on that issue was matched by the readiness of the
donor community to provide expertise, technical assis-
tance and financial resources.  A national drug control
strategy was soon developed.  It contained all the classic
elements of a sound drug control programme (legisla-
tion, law enforcement, alternative development,
demand reduction, monitoring, etc.).  Yet, leaving aside
the fundamental question of security and governance,
drug control experts have been facing formidable diffi-
culties in translating the strategy into effective interven-
tions tailored to the situation at hand. In the light of
what was noted above, one possible explanation could
be that (a) planned interventions have remained essen-
tially compartmentalized into the traditional sectors,
without a prescription to dose, integrate and sequence
their implementation; and (b) that the strategy has not
been conceived on the scale of the transnational market,
of which Afghanistan is only a segment.  To this day,
despite the fact that the inter-linked elements of the
international Afghan heroin market span an entire con-
tinent, there is no multilateral operational strategy to
tackle them all in a coordinated and synergetic manner. 
A number of analysts have pointed out the need to
remedy the deficiency of approaches that are too  secto-
rially and geographically compartmentalized. Changing
this requires that more efforts be made to improve drug
related data collection and analysis.  It also requires deci-
sion makers to support a vigorous research programme
on the way drug markets are structured, operate and
evolve.  
Illicit drugs are commodities. Produced, transformed,
transported, distributed, purchased and consumed, they
are at the centre of lucrative clandestine, and to a very
large extent, transnational markets.  Albeit illegal, these
markets, like any other market, obey a number of basic
supply and demand rules and respond to internal and
external stimuli and pressures.  Understanding the rules
will help to better conceive the kind of pressures that
could break these marketsat.
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aq) Joint Ministerial Statement and further measures to implement the action plans emanating from the twentieth special session of the General
Assembly, 16 April 2003.  E/2003/28/Rev.1.  E/CN.7/2003/19/Rev.1, p.2.  
ar) Ibid., p.4.  
as) Ibid.
at) R. Anthony and A. Fries, "Farmgate-to-Street Model of Narcotics Trafficking", in proceedings of the Expert Group on Technical Challenges to the
Drug Community, UNODC and US ONDCP, Vienna, 2003. A revised version of this paper will be published in a forthcoming issue of United
Nations, Bulletin on Narcotics; The RAND Drug Policy Research Center has also been working on models of various dimensions of the drug problem
[http://www.rand.org/multi/dprc/projects/model.html].  An ongoing project (P. Reuter and V. Greenfield, "Examining the consequences of reducing
Afghanistan's heroin production") focuses on the development of a simulation model of the global trade in Afghan heroin. 
1.4.3. A more dynamic approach
Though drugs are commodities, their abuse diffuses
into susceptible segments of the population like an
infectious disease. The term 'drug epidemics' thus offers
a useful analogy. The powerful dynamics created by the
combination of the incentives and behavior of a ruthless
market with the contagion characteristics of an epi-
demic explain why drug abuse can expand so rapidly
and become so difficult to stem. Since young people are
particularly vulnerable, it is important to monitor
closely the prevalence, incidence and evolution of illicit
drug use among themau.
Analysis of, and responses to, the drug problem have so
far been too static and treated the phenomenon as essen-
tially linear. Fine-tuning and sequencing drug control
interventions to maximize their effectiveness would
require the development of dynamic, non-linear models
of the drug problemav.  Understanding how drug epi-
demics start, spread, reach a plateau and then decline,
and how feedback effects can alter their evolution,
would help to decide at which moment of the process
what type of intervention, or mix of interventions, are
most likely to be effective.  It would also provide guide-
lines on how to allocate resources among the various
sectorial interventions at any given time.  For instance,
a certain type of intervention (say, law enforcement)
might be more effective than another one (say, preven-
tion or treatment) at certain stages of the epidemic, and
less at others.  Since drug control budgets are finite,
shifting the share of resources among the different cate-
gories over time could significantly increase the cost-
effectiveness of drug control strategies.
Research on, and interest in, the development of more
dynamic models of the drug problem have increased in
the last decade or so - essentially in North America and
Europe. A few years ago, the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA)
launched a research project on the use of modelling in
drug epidemiologyaw and the European Commission
supported the establishment of a European Network to
promote research on mathematical and statistical mod-
elsax. UNODC and the Technical University of Vienna
organized a symposium on the subject in 2000ay.  As
part of an increasing knowledge-based approach to drug
control policy, these efforts should be further encour-
aged and expanded with a view to produce and validate
models that would assist policy makers in launching
innovative and cost-effective drug control programmes.
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au) School surveys offer valuable sources of information in that respect. In recent years, a limited number of countries have also been promoting the use
of random drug testing among pupils, as part of their drug abuse prevention policies in schools.
av) J.P. Caulkins, "The dynamic character of drug problems", United Nations, Bulletin on Narcotics, Vol. LIII, Nos. 1 and 2, 2001, New York, 2001.
aw) EMCDDA, Modelling drug use: methods to quantify and understand hidden processes, in EMCDDA Scientific Monographs, Lisbon, April 2001.
ax) EMCDDA, European Network to Develop Policy Relevant Models and Socio-Economic Analysis of Drug Use, Consequences and Interventions,
Final Report, Lisbon, January 2002.
ay) UNDCP, Dynamic drug policy: Understanding and controlling drug epidemics, in Bulletin on Narcotics, Vol. LIII, Nos. 1 and 2, 2001, New York,
2001.
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In 2003, opium poppy cultivation fell slightly…
At the global level, illicit opium poppy cultivation
amounted to an estimated 169,000 ha in 2003, a six per
cent decline compared to 2002. Opium poppy cultiva-
tion is now 40% less than it was in the early nineties,
when it stood at approximately 270,000 ha. However,
the distribution of cultivation has changed over the past
decade, with a decline in the low opium yield areas of
south-eastern Asia and an increase in the high opium
yield areas of Afghanistan.
In 2003, more than 90% of the  illicit cultivation of
opium poppy still took place in three countries:
Afghanistan, Myanmar and Laos. Compared to 2002,
there was an overall decline of 9% in opium poppy cul-
tivation in these countries due to decreases in Myanmar
(-24%) and Laos (- 14%). The declines were attributed
to the Governments’ efforts to reduce opium poppy cul-
tivation, notably through raising farmers’ awareness of
the illicit status of the crop, promoting alternative liveli-
hood and conducting eradication, on a voluntary basis,
in Laos. In contrast, between 2002 and 2003, opium
poppy cultivation increased again in Afghanistan (+8%)
to reach 80,000 ha.
… but opium production increased 
The increase in cultivation in Afghanistan, combined
with the higher opium yield (45 kg/ha) than in South-
East Asia (13 kg/ha), resulted in an overall increase of
5% of global illicit opium production between 2002
and 2003. In 2003, the 3,600 metric tons of opium pro-
duced in Afghanistan, the second highest opium pro-
duction estimate in Afghanistan’s history, provided more
than three-quarters of the illicit opium supply of the
world.
Since 1995, opium poppy cultivation in Pakistan had
remained below 1,000 ha,  even averaging a low as 250
ha from 1999 to 2001. In 2003, however, the Govern-
ment of Pakistan reported a total of 2,500 ha of opium
poppy cultivation, following the eradication of 4,200
ha. The increase might be due to several factors, includ-
ing high opium prices and farmers hoping to replicate
the apparent prosperity reported among neighbouring
Afghan opium farmers.
While heroin originating from South-West Asia pre-
dominantly supplies neighbouring countries, Central
Asia and Europe, the heroin market in the United States
is mainly supplied by opium harvested in Colombia and
Mexico. Although eradication of opium fields took
place in both countries, the annual trend (2002-2003)
of the net amount of opium poppy harvested is unde-
termined. The particular conditions of the growth of
opium poppy in these two countries – unsystematic
crop calendar, inaccessible areas, plus significant cloud
cover in Colombia – make the monitoring of the crop
very difficult. Consequently, the establishment of robust
estimates for this part of the world continues to be chal-
lenging.
Unlike coca cultivation, which is limited to a few coun-
tries in the Andean region, opium poppy is grown in
many parts of the world. Low levels of illicit cultivation
exist in many regions and countries such as Viet Nam,
Russia, Ukraine, Central Asia, Caucasus region, Egypt,
Peru and Thailand. The latter, an important centre of
illicit opium poppy cultivation in the sixties, has
become a negligible source of opium in recent years,
declining even further in 2003. 
Although the figure should be taken with caution due
to the paucity of data, the potential farmgate value of
opium production in 2003 at the global level is esti-
mated at about US$1.2 billion. More than 85% of this
sum was made in Afghanistan. 
2.1. Opium / Heroin market
2.1.1. Production
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Heroin prices increase slightly…
Heroin prices, expressed in US-dollars, have shown
some minor increases in the USA and in Western
Europe since 2002. Paradoxically, the slight increase in
heroin prices ran parallel to an increase in heroin supply.
In Europe the increase in prices in US dollar terms
masked a decrease in prices in Euro terms following the
strengthening of the Euro against the dollar. More
oddly, both in the USA and Europe, heroin purity
seemed to be on the rise in 2003 though data for this
year, especially for Europe, remains incomplete. Should
the increase in heroin purity be confirmed, it would
mean that the heroin market reacted to the increase in
heroin supply by marketing a higher quality, more
potent type of heroin at slightly higher prices.
Outlook for 2004: further increase to be expected…
The amount of opium poppy cultivation in Afghanistan
in 2004 will continue determining the level of the
world’s supply of illicit opium and heroin. The results of
the Afghan farmers’ intention survey conducted by
UNODC and the Afghan Government in October
2003, at the time of planting for the 2004 opium poppy
season, indicated that 69% of the opium farmers inter-
viewed intended to increase their level of opium poppy
cultivation in 2004. Only 4% stated an intention to
decrease. The latest evidence received from Afghanistan
in February 2004, and anecdotal evidence from UN
mission to poppy growing areas received in March and
April 2004, seems to confirm that the farmers did actu-
ally plant poppy on a large scale in 2004, to an extent
which  would exceed cultivation levels in 2003. 
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1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
CULTIVATION(1) IN HECTARES
SOUTH-WEST ASIA
  Afghanistan 41,300 50,800 49,300 58,300 71,470 53,759 56,824 58,416 63,674 90,583   82,171 7,606 74,100 80,000
  Pakistan 7,488 7,962 9,493 7,329 5,759 5,091 873 874 950 284 260 213 622 2,500
  Subtotal 48,788 58,762 58,793 65,629 77,229 58,850 57,697 59,290 64,624 90,867 82,431 7,819 74,722 82,500
SOUTH-EAST ASIA
  Lao PDR 30,580 29,625 19,190 26,040 18,520 19,650 21,601 24,082 26,837 22,543 19,052 17,255 14,000 12,000
  Myanmar 150,100 160,000 153,700 165,800 146,600 154,070 163,000 155,150 130,300 89,500 108,700 105,000 81,400 62,200
  Thailand (2) 1,782 3,727 3,016 998 478 168 368 352 716 702 890 820 750
  Viet Nam (2) 18,000 17,000 12,199 4,268 3,066 1,880 1,743 340 442 442
  Subtotal 200,462 210,352 188,105 197,106 168,664 175,768 186,712 179,924 158,295 113,187 128,642 123,075 96,150 74,200
LATIN AMERICA
  Colombia (3) 1,160 6,578 5,008 15,091 5,226 4,916 6,584 7,350 6,500 6,500 4,300 4,100 4,100
  Mexico (4) 5,450 3,765 3,310 3,960 5,795 5,050 5,100 4,000 5,500 3,600 1,900 4,400 2,700 4,800
  Subtotal 5,450 4,925 9,888 8,968 20,886 10,276 10,016 10,584 12,850 10,100 8,400 8,700 6,800 8,900
OTHER
  Combined (5) 8,054 7,521 2,900 5,704 5,700 5,025 3,190 2,050 2,050 2,050 2,479 2,500 2,500 3,000
GRAND TOTAL 262,754 281,560 259,686 277,407 272,479 249,919 257,615 251,848 237,819 216,204 221,952 142,094 180,172 168,600
POTENTIAL PRODUCTION IN METRIC TONS
SOUTH-WEST ASIA
  Afghanistan 1,570     1,980     1,970     2,330     3,416     2,335     2,248     2,804     2,693     4,565     3,276     185        3,400     3,600     
  Pakistan 150        160        181        161        128        112        24          24          26          9            8            5            5            52          
  Subtotal 1,720 2,140 2,151 2,491 3,544 2,447 2,272 2,828 2,719 4,574 3,284 190 3,405 3,652
SOUTH-EAST ASIA
  Lao PDR 202        196        127        169        120        128        140        147        124        124        167        134        112        120        
  Myanmar 1,621     1,728     1,660     1,791     1,583     1,664     1,760     1,676     1,303     895        1,087     1,097     828        810        
  Thailand (2) 20          23          14          17          3            2            5            4            8            8            6            6            9            
  Viet Nam (2) 90          85          61          21          15          9            9            2            2            2            
  Subtotal 1,933     2,032     1,862     1,998     1,721     1,803     1,914     1,829     1,437     1,029     1,260     1,237     949        930        
LATIN AMERICA
  Colombia (3) 16          90          68          205        71          67          90          100        88          88          58          50          50          
  Mexico 62          41          40          49          60          53          54          46          60          43          21          71          47          84          
  Subtotal 62          57          130        117        265        124        121        136        160        131        109        129        97          134        
OTHER
  Combined (5) 45          45          -         4            90          78          48          30          30          30          38          40 40 50
GRAND TOTAL 3,760      4,274      4,143      4,610      5,620      4,452      4,355      4,823      4,346      5,764      4,691      1,596      4,491      4,765      
Potential HEROIN 376         427         414         461         562         445         436         482         435         576         469         160         449         477         
OPIUM
HEROIN
(1) Potentially harvestable, after eradication.
(2) Due to low levels of production, cultivation and production for Viet Nam as of  2000 and for Thailand as of 2003 were included in the category
“Other countries”.
(3) According to the Government of Colombia, cultivation covered 7,350 ha and 6,500 ha and production amounted to 73 mt and 65 mt in 1998 and
1999 respectively. 
(4) Sources: As its survey system is under development, the Govt of Mexico indicates it can neither provide cultivation estimates nor endorse those
published by UNODC which are derived from US Government surveys.
(5) Includes countries such as Russia, Ukraine, Central Asia, Caucasus region, Egypt, Peru, Viet Nam (as of 2000) and Thailand (as of 2003)
OPIUM
Table 1. GLOBAL ILLICIT CULTIVATION OF OPIUM POPPY AND PRODUCTION 
OF OPIUM, 1990-2003
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Fig. 1: GLOBAL OPIUM POPPY CULTIVATION 1990-2003 (ha)
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Fig. 2: GLOBAL OPIUM PRODUCTION 1990-2003 (metric tons)
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AFGHANISTAN - OPIUM POPPY CULTIVATION, 1990-2003 (ha) AFGHANISTAN - OPIUM PRODUCTION, 1990-2003 (metric tons)
MYANMAR - OPIUM POPPY CULTIVATION, 1990-2003 (ha) MYANMAR - OPIUM PRODUCTION, 1990-2003 (metric tons)
  LAO PDR - OPIUM POPPY CULTIVATION, 1990-2003 (ha) LAO PDR - OPIUM PRODUCTION, 1990-2003 (metric tons)
REST OF THE WORLD - OPIUM POPPY CULT., 1990-2003 (ha) REST OF THE WORLD - OPIUM PRODUCTION, 1990-2003 (metric tons)
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Fig. 3. 
Annual opium poppy cultivation and opium production in main producing countries, 1990 - 2003
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2. Trends Opium / Heroin market
Fig. 4: Opium Poppy Cultivation 
Fig. 5: Opium Yields in Afghanistan and Myanmar (kg / ha)
Fig. 6: Opium Production
2002
Myanmar
(828 mt)
Rest of the 
World
(263 mt)
Afghanistan
(3,400 mt)
76%
18%
6%
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Rest of the 
World
(24,700 ha)
Myanmar
(81,400 ha)
Afghanistan
(74,100 ha)
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Rest of the 
World
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Differences in opium yield between Afghanistan and Myanmar are due to differences in opium poppy varieties
and growing conditions. Variations of yields from year to year in the same country are mostly caused by changes
in weather conditions and/or, as in the case of Afghanistan in 2001, by a shift in the relative distribution of
cultivation from irrigated to rain-fed land.
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Farmgate price Production
US$ per kg metric tons
Myanmar 130                       810                            105
Afghanistan 283                       3,600                         1,019
Lao, PDR 160                       (1) 120                            19
Colombia 194                       50                              10
Mexico 194                       (2) 84                              16
Other (4) 251                       (3) 102                            25
Total opium 4,765 1,195
(4) Includes Pakistan.
Potential value
(million of US$)
(2) Farmgate price not available: value based on price in Colombia
(3) Average price based on the total value and production from the five countries listed above.
(1) Based on 2002 opium prices. 2003 opium prices will be available in June 2004
71 105
1,019
Afghanistan
MyanmarOthers
Table 2. Potential farmgate value of opium, 2003
Fig. 7: Potential farmgate value of opium, 2003 (million of US$)
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Fig. 8: USA: heroin retail and wholesale prices, 
1990-2003 (US$/gram)
Fig. 9: EUROPE: heroin retail and wholesale
prices, 1990-2003 (US$/gram)
* premilinary data for 2003.
Note: Retail and wholesale prices are not directly comparable because purity levels differ.
Table 3. Reported opium poppy eradication, in ha, 1993 - 2003
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Fig. 10: Wholesale heroin prices in Europe and the USA, 1990-2003 (US$/gm, at street purity)
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Afghanistan 400      121      21,430
Colombia 9,400   5,314   5,074   7,412   7,333   3,077   8,434   9,279   2,583   3,371   2,994
Lao PDR 4,134
Mexico 13,015 10,959 15,389 14,671 17,732 17,449 15,461 15,717 15,350 19,157 n.a.
Myanmar 160      1,041   3,310   1,938   3,093   3,172   9,824   1,643   9,317   7,469   638
Pakistan 856      463      867      654      2,194   1,197   1,704   1,484   n.a. 4,185
Thailand 1,706   1,313   580      886      1,053   716      808      757      832      507      767
Vietnam 672      477      1,142   340      439      426      n.a.
0
100
200
300
400
U
S$
/g
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Retail Wholesale
Retail  396 377 351 341 253 236 200 173 183 151 135 114  90  130
Wholesale 229 210 197 186 177 176 166 148 141 118 87 62 52 80
90 91 92 93 94 95 96 97 98 99 00 01 02 03
1990-2003 (US$/gram)
0
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U
S$
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Retail Wholesale
Retail  244  202  192  136  147  144  138  107  106  96  68  61  64  68 
Wholesale 132 92 101 70 70 63 56 45 41 38 30 27 29 32
90 91 92 93 94 95 96 97 98 99 00 01 02 03
* preliminary data for 2003
*
*
After a decline in 2001, seizures increased again in
2002…
Global seizures of opiates (heroin, morphine and
opium, expressed in heroin equivalentsa) increased by
9% in 2002 after having fallen by 22% in 2001. The
increase was a consequence of the doubling of morphine
seizures, reflecting the resumption of large-scale opium
poppy cultivation and processing in Afghanistan in
2002. Heroin seizures, in contrast, declined by 10%,
probably because the large stocks built up from the
bumper harvests of 1999 and 2000 were beginning to
deplete.  Preliminary data for 2003 suggest, however,
that heroin trafficking regained momentum with
another large opium poppy harvest in Afghanistan.
… remaining concentrated in Asia, particularly South-
West Asia… 
In 2002, 65% of all opiate seizures were made in Asia,
28% in Europe and 6% in the Americas.  Most of the
world's opiates are seized in Asia, because it contains the
two largest production areas.  South-West Asia is the
larger of the two.  Afghanistan's neighbours, Iran and
Pakistan, thus had the largest opiate seizures in 2002,
with Iran accounting for 25% and Pakistan for 16% of
the world total.  South-West Asia as a whole accounted
for 43% of global opiate seizures in 2002. If the coun-
tries of Central Asia are added, 49% of global seizures
took place in these sub-regions.  
Opiate seizures in South-West Asia rose by 18% in
2002, reflecting the resumption of large-scale opium
poppy cultivation -- primarily in Southern and Eastern
Afghanistanb. Opiate seizures in Central Asia remained
stable in 2002.  However, as compared to the year 2000
(the year prior to the poppy ban in Afghanistan), opiate
seizures were 24% higher in Central Asia and 36%
lower in South-West Asia. This suggests that the previ-
ous trafficking patterns were not fully re-established in
2002. In other words, traffickers who had switched to
the Central Asia route did not switch back to the tradi-
tional route through Pakistan or Iran.  
If heroin is considered by itself, Central Asia accounted
for about a third of all seizures made in the countries
surrounding Afghanistan. This proportion was twice as
high in 2002 as in 2000, indicating greater use of the
Central Asian trafficking route in recent years. There is
also evidence that much of the opiates smuggled
through Central Asia are in the form of heroin while
more of the exports through Pakistan and Iran are still
in the form of opium and morphine. This is consistent
with reports of several dozen clandestine heroin labora-
tories in Afghanistan, concentrated in the eastern and
north-eastern parts of the country, often close to the
border. In South-West Asia heroin constitutes about a
third of the opiates seized; in Central Asia the propor-
tion was as high as 94% in 2002. In Tajikistan, which
accounted for 78% of all the heroin seized in Central
Asia in 2002, heroin seizures rose by 80% in the first 10
months of 2003.
… and to a lesser degree in South-East Asia…
The second Asian production area is South-East Asia,
where 14% of the world's opiates were seized in 2002.
This proportion declined, however, by 23% in 2002,
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2.1.2. Trafficking
0
20,000
40,000
60,000
80,000
100,000
80 82 84 86 88 90 92 94 96 98 00 02
ki
lo
gr
am
s
Heroin Morphine Opium
Fig. 11: Seizures of opiates (in heroin equivalents),
1980-2002
Source: UNODC, Annual Reports questionnaire Data/DELTA.
a) For the purposes of this calculation it is assumed that 10 kg opium are equivalent to 1kg morphine or 1 kg of heroin. 
b) The Taliban ban on opium cultivation in 2001 was very effective in the south and east of Afghanistan.  It did not apply to large sections of the main
opium producing districts of Northern Afghanistan because they were outside Taliban control.   As a consequence, the 2002 increases in opium
production were - for obvious reasons - higher in the south and east than in the north. 
reflecting the ongoing reduction of opium production
in Myanmar and the Lao PDR. (Opium production in
the Golden Triangle also fell by 23% in 2002). Opiate
seizures in South-East Asiac were 29% of the opiate
seizures in Central and South-West Asia in 2002. Simi-
larly, opium production estimates for South-East Asia
for 2002 were equivalent to about 28% of those for
South-West Asia. The interception rates (see below) in
these sub-regions are therefore similar: 11% in Central
& South-West Asia and 12.5% in South-East Asia in
2002.
Reports of dismantled heroin laboratories over the
2000-2002 period were received from Myanmar, Hong
Kong SAR of China, India and Malaysia. Some seizures
of heroin in Taiwan Province of China (2002) and Aus-
tralia (2003), which did not have the same profiles as
heroin from South-East Asia or South-West Asia, raised
concerns that there may be some heroin manufacture in
the Democratic People's Republic of Korea (North
Korea).    
… as well as in Europe 
Europe accounted for 28% of global opiate seizures in
2002. Some 90% of the opiates destined for European
markets are estimated to come from Afghanistan. The
bulk of the large and rapidly growing C.I.S. market is
supplied by opiates transiting the Central Asian coun-
tries. Most of the heroin destined for West Europe still
seems to move along the Balkan route. Turkey remains
a principal transshipment location. 
Thus far, significant proportions of opiates coming
through Central Asia have only been reported for some
of the Nordic countries, notably Finland. St. Petersburg
and the Baltic countries seem to be important trans-
shipment points for these activities. Minor quantities
are trafficked via Russia and Belarus to Poland for ship-
ment to Germany. A small proportion of the heroin
found on the German market is shipped directly from
Central Asia to Germany. 
Opiate seizures rose by almost 20% in Europe in 2002
and were back to the levels reported in 2000.  The
increase was essentially due to a strong increase of mor-
phine seizures in Turkey, which reported the third
largest opiate seizures worldwide in 2002.  The Turkish
authorities continued to dismantle heroin laboratories,
particularly in eastern parts of the country.  Much of the
heroin wholesale trade in Western Europe is still
reported to be controlled by Turkish/Kurdish groups,
though in recent years Albanian groups (originating in
Kosovo, in the F.Y.R. of Macedonia and in Albania)
appear to have obtained significant market share in a
number of countries.  In the northern parts of England,
the heroin business seems to be controlled by groups of
Asian origin, and supplied directly from Pakistan. In the
southern parts of the UK, the heroin wholesale trade
continues to be controlled by mainly Turkish groups.
The retail sale of heroin in Europe, in contrast, is rarely
controlled by Turkish groups.         
Excluding data from Turkey, opiate seizures in Europe
fell by 10% in 2002 and were 16% lower than in the
year 2000. Heroin seizures fell by 16% in 2002.  If the
decline in seizures had been a result of reduced enforce-
ment, supply would have increased and heroin prices
would have fallen. This was not the case. Heroin prices
remained stable in 2002, suggesting that the lower
seizures were a result of less trafficking.   Since there
appears to be a time lag of 6 to 18 months between pro-
duction of the opium and arrival of the heroin on the
European market, much of this decline in 2002 is likely
to have been a consequence of the strong reduction of
opium production in Afghanistan in 2001. 
The resumption of poppy cultivation in Afghanistan in
2002, a large harvest in 2003, and indications of further
expansion in 2004, all make it likely that the trafficking
towards Europe will increase again. Germany, for
instance, already reported an increase in heroin seizures
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c)  including China. 
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Source: UNODC, Annual Reports questionnaire Data/DELTA.
Fig. 12: Seizures of opiates (in heroin equivalents),
1980-2002
of 42% over the first two quarters of 2003 as compared
to a year earlier. Similarly, heroin seizures in Turkey rose
by more than 70% over the first three quarters of 2003
as compared to a year earlier.  
There are no indications that prices reacted in any sig-
nificant way to rising seizures in 2003. Heroin whole-
sale prices, expressed in US dollars, remained largely
stable in Western Europe in 2003, though they fell in
Euro-terms. Indications of rising seizures and
stable/declining prices suggest that the trafficking of
opiates to Western Europe is likely to have increased
again in 2003 and a further rise can be expected for
2004 as well.   
Opiate seizures in the Americas are smaller than in
Europe but are growing rapidly 
Less opiate trafficking takes place in the Americas than
in Europe.  Seizures in the Americas accounted for 6%
of global opiate seizures in 2002.  For most of the 1980s
and the 1990s, seizure trends in Europe and the Amer-
icas paralleld each other with American heroin seizures
amounting to about a fifth of the European ones.  In
recent years, however, the trends have diverged. In
2002, American seizures rose to about a third of Euro-
pean seizures.  In contrast to Europe, where heroin
seizures fell by 27% between 2000 and 2002, they
increased in the Americas by 30% in 2001 and 20% in
2002. Between 2000 and 2002, heroin seizures in
North America rose by more than 50%, and in South
Americad by more than 60%.  Increasing seizures prob-
ably reflected both better enforcement because the
volume of trafficking seems to have increased.  This
would be consistent with reports that heroin use has
increased in the USA since the mid-1990se.
US authorities estimated that close to 60% of the heroin
they seized originated in Colombia and 30% in Mexico
in 2002. (Colombia and Mexico were also the only
countries in the Americas reporting the dismantling of
clandestine heroin laboratories in recent years). For the
first time, US authorities mentioned Venezuela as a
potential source country for heroin.  Authorities in
Venezuela, however, still consider that it is a transit
country with all the heroin originating in Colombia.
The Mexican authorities estimated that 80% of the
heroin in their market was of domestic origin and the
remaining 20% originated in Colombia and various
Asian countries. Heroin imports into Canada are mainly
from South-East Asia (via China) though imports from
South-West Asia (via Europe) and from South America
(via the USA) were reported as well. 
After a strong decline in 2001, opiate seizures resumed
growth in Oceania in 2002
The largest market for opiates in Oceania is Australia.
Towards the end of 2000, Australia in cooperation with
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Source: UNODC, Annual Reports questionnaire Data/DELTA.
d) South America including Central America and the Caribbean.                                                                   
e) From 1995 to 2002, the prevalence of lifetime use of heroin  rate among youths aged 12 to 17 increased from 0.1 to 0.4 percent; among young
adults aged 18 to 25 the rate rose from 0.8 to 1.6 percent. (Substance Abuse and Mental Health Services ,  Results from the 2002 National Survey on
Drug Use and Health: National Findings,  Rockville, MD, 2003).
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Fig. 14: Heroin seizures in the Americas and 
in Europe, 1985-2002
Source: UNODC, Annual Reports questionnaire Data/DELTA.
a number of South-East Asian countries, dismantled
several key trafficking networks that supplied the mar-
kets of Oceania. As a result, the supply of opiates was
substantially reduced in 2001. While trafficking
resumed and supply grew again in 2002, heroin avail-
ability did not return to pre-December 2000 levels. As
a result of the continued supply squeeze, the street-level
purity of heroin stayed low, prices remained high
(though they are starting to decrease again) and abuse
levels remained relatively low.  
Most of the heroin used in Oceania comes from the
Golden Triangle. The key transshipment points for
heroin destined for the Australian market were Hong
Kong SAR of China, Vietnam and Malaysia in 2002. In
2003, the Australian authorities intercepted a major
shipment of heroin involving North Korean traffickers.
The amount of heroin seized in this shipment was
equivalent to more than a quarter of all the heroin seized
in Australia in 2002.     
Opiate seizures remained limited in Africa
Seizures of opiates in Africa accounted for 0.3% of
global seizures in 2002.  These small amounts are not
necessarily an indication of low trafficking levels, they
are more probably a result of limited resources for law
enforcement. In sub-regional terms, 40% of opiates in
Africa were seized in West Africa, and a third was seized
in East Africa.   Most of the heroin was reported to have
originated in Afghanistan/Pakistan, and to a lesser
extent in South-East Asia. Pakistan, India and the
United Arab Emirates are often used for the transship-
ment of South-West Asian heroin and Thailand for
South-East Asian heroin. In several African countries,
90% or more of the heroin seized was destined for re-
export to Europe and the USA. 
The global interception rate of opiates increased to 19%
in 2002
In 2002, global production of illegal opiates was esti-
mated to be 449 mt (expressed in heroin equivalents).
Of this total, 83.7 mt of opiates were seized. The global
interception rate of opiates was thus 19% of all illegally
produced opiates. This is the third highest level ever
recorded. (Higher interception rates were reported for
the years 2000 and 2001). The interception rate was
almost twice as high in 2002 as in the 1980s or the first
half of the 1990s, suggesting an improvement in global
law enforcement over the last two decades.  
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OPIATES INTERCEPTED - AFRICA - 1992-2002
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Fig. 19: Global seizures of opium, 1992 - 2002
Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Metric tons 53 85 145 247 174 195 178 239 213 107 97
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Fig. 20: Global seizures of heroin and morphine, 1992 - 2002
Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Metric tons* 35 56 42 44 40 54 56 61 77 66 74
 *metric ton equivalents. 1 kilogram of morphine is assumed to be 1 kilogram of heroin. 
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The opiates, notably heroin, continue to be the main
problem drugs in the world.  Two thirds of treatment
demand in Asia, Europe and Oceania, which account
for three quarters of the world's total population, is
related to the abuse of opiates. Even in the USA, where
cocaine was traditionally the main problem drug, more
people were admitted for heroin abuse treatment (28%
of all treatment demand excluding alcohol) than for
cocaine abuse (23%) in  2001. 
Opiate use (including heroin) over the 2000-2001
period affected some 15 million people or 0.4% of the
population age 15-64. More than 9 million people are
estimated to abuse heroin, slightly more than 0.2% of
the population age 15-64. 
More than half of the world's opiate users are found in
Asia (7.8 million), primarily in the countries
surrounding Afghanistan and Myanmar. The highest
prevalence rates have been reported from Iran,
Kyrgyzstan and the Lao PDR. India has the largest
number of opiate users, though prevalence rates there
are lower than in neighbouring Pakistan or Myanmar. A
national household survey conducted in India in 2001
found that 0.7% of the male population age 12-60
consumed opiates, equivalent to about 0.4% of the total
population age 15-64. More than half of all opiate use is
heroin use; most of the rest is accounted for by opium
consumption.
The total number of opiate users in Europe amounts to
some 4 million people. This  accounts for a quarter of
the global total (0.8% of the population age 15-64).
Two thirds of Europe's opiate users are found in Eastern
Europe, partially due to very high levels of opiate use in
the Russian Federation. IDU related HIV data and
independently conducted school surveys also seem to
confirm thisf. The highest levels of opiate use in Western
Europe are found in Luxembourg, Portugal, the UK,
Italy and Switzerland (ranging from 0.6%-1% of the
population age 15-64). 
Some of the difference between Western and Eastern
Europe in the overall prevalence rates of the general
population may be also due to differences in the
methods for making national estimates. The West
European estimates are largely based on the concept of
"problem" drug users. These are arrived at through
various estimation techniques: different multiplier
methods, capture-re/capture methods, multivariate
indicators, etc. The estimate for the Russian Federation
is derived from the number of registered drug users, the
proportion of opiate users and a multiplier derived from
local studies. The majority of opiate users in the Russian
Federation (and in some other C.I.S. countries)
consume a brew of poppy straw (known as 'kompot')
which is injected. If this is excluded and only heroin
abuse is considered, the result would reveal about the
same number of heroin users in Eastern Europe as in
Western Europe. Heroin abuse has been on the rise in
Eastern Europe over the last decade (except for 2002)
while it remained stable or showed declining levels in
most West European countries.
Opiate use levels in Oceania, prior to 2001, used to be
significantly above the global average. However, a
heroin shortage in Australia in 2001, in combination
with  readily available treatment capacity, helped to
reduce heroin abuse significantly, and it remained at the
lower levels in 2002 as well. Overall levels of heroin
abuse are thus approaching the global average. 
In the Americas about 2½ million people use opiates
(about 1/6th of global opiate use), including 1.4 million
people abusing heroin. There is a concentration in
North America where 60% of all opiate use or close to
90% of all heroin abuse in the Americas occurs. The
USA (0.6% of the population age 15-65) is, by far, the
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2.1.3. Abuse
2.2.3.1. Extent
f ) The weighted average (by the size of the youth population) of lifetime prevalence of heroin use among 15-16 year olds in West Europe (ESPAD
survey data and other surveys for Germany, Spain, and the Benelux countries) was 1.7%, less than half the average rate found in Eastern Europe
(3.8%). (UNODC, Global Illicit Drug Trends 2002).
largest heroin market in the Americas. The rather high
levels of opiate use reported from South America are
mainly due to the large-scale use of synthetic opiates
reported from Brazil (diverted from the licit market
where they are used as analgesics). If only heroin abuse
is considered, South America seems to have the lowest
levels of abuse worldwide, though there are indications
that heroin abuse is rising.  Estimates for countries in
Africa suggest that opiate use is still below the global
average. It is basically linked to abuse of heroin in those
urban areas which serve as transshipment locations for
international trafficking activities. Opium use is not
widespread. 
Importance of opiate use compared to other drugs 
As part of the Annual Reports Questionnaire (ARQ),
countries are asked to rank drugs according to
prevalence.  This ranking can provide key information
about the patterns of drug abuse, particularly in
countries which have not yet undertaken any in-depth
epidemiological surveys. The question is based on the
assumption that experts in the field are likely to have a
good idea about the main drugs of abuse in their
country even if no epidemiological study has been
undertaken in the country concerned.  
According to the results of this exercise, opiates are of
significant importance in Asia and large parts of Eastern
Europe, ranking 1st or 2nd  as compared to other drugs.
It should be noted though that a number of countries in
these regions ranked both cannabis and opiates as the
most prevalent drug. Moreover, a number of countries
of the former Soviet Union and in Asia  have drug-
registry systems; opiate users are more likely to enter
such registries than cannabis users. 
Despite some methodological deficiencies, Map No.8
shows very clearly that opiate use is primarily a problem
in Asia and in Eastern Europe, confirming the patterns
derived from prevalence estimates. By contrast, in
Western Europe, in several of the new EU countries,  in
North and Central America, in Oceania and parts of
Eastern, Southern and Western Africa,  heroin is the
4th to 6th most prevalent substance of abuse. One
exception is the UK which has one of the highest heroin
prevalence rates in Western Europe; still, heroin, in
terms of prevalence, ranks only 7th  among the
substances most widely abused in that country. 
A low relative importance of heroin abuse was also
reported from countries in South America. This seems
to confirm that heroin abuse is not widespread in that
region.  
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Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
Number of  people in % of  population Number of  people in % of  population
(in million)  age 15-64 (in million)     age 15 - 64
EUROPE 4.0 0.75 2.75 0.51
- West Europe 1.3 0.41 1.27 0.41
- East Europe 2.7 1.18 1.48
OCEANIA 0.1 0.5 0.06 0.3
AMERICAS 2.5 0.45 1.42 0.26
- North America 1.5 0.54 1.24 0.45
- South America 1 0.37 0.18 0.07
ASIA 7.8 0.32 4.13 0.17
AFRICA 0.8 0.17 0.8 0.17
GLOBAL 15.2 0.38 9.16 0.23
Opiates of which heroin
            Opiate abuse above global average
            Opiate abuse close to global average
            Opiate abuse below global average
Table 4:     Annual prevalence estimates of opiates use: 2001-2003
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Map 8: Use of opiates (including heroin) 2001 - 2003 (or latest year available)
> 1% of  population
0.3 - 0.5% of  population
0.1 - 0.3% of  population
0.5 - 1%  of  population
Main cultivation areas
Level of abuse (Annual prevalence)
< 0.1%  of  population
Data not available
(1993)
2
1
Ranking
(1 = most prevalent drug)
7 or more
4 - 6
3
1998
2000
No data provided
2000
Map 9: Ranking of opiates in order of prevalence in 2002
Sources: UNODC Annual Reports Questionnaires data, SAMSHA US National Household Survey on Drug Abuse, Iranian Ministry of Health,
Rapid Assessement Study and UNODC ARQ,Council of Europe, ESPAD.  
82
World Drug Report 2004 Volume I. Analysis
GLOBAL
Stabilization of heroin abuse in 2002 
At the global level, there are still more countries report-
ing increases than declines in the use of opiates (heroin,
morphine and opium).  Nonetheless, progress has been
made in recent years. If the difference between the
number of countries reporting increases in heroin abuse
and those reporting stable or declining trends is calcu-
lated, the resulting balance is now clearly in favour of
countries reporting stable or declining levels of abuse.
This is in sharp contrast to the situation throughout
most of the 1990s when the number of countries report-
ing increases was far higher than those reporting
decreases. The results in 2002 were thus the most
encouraging over the last decade.  
A comparison between the trend reports for the year
2000 and subsequent years shows that the number of
countries reporting 'large increases' declined markedly,
while the number of countries  reporting  decreasing
levels of heroin abuse  were on the rise. While in 2000,
23% of all responding countries reported a 'large
increase' of heroin abuse, this proportion fell to 9% in
2001 and 2002, suggesting that the heroin epidemic lost
momentum in 2001 (the year in which global opium
production fell by 65%) and did not recover in 2002.
In parallel, the number of countries reporting declining
levels of  heroin abuse rose  from 17% in 2000 to 23%
in 2001 and to 26% in 2002 . 
Unfortunately, these positive trends may not continue
over the next few years as global production of  opium
- on the strength of expanding production in
Afghanistan - is increasing.    
2.2.3.2. Trends 
(10)
(5)
0
5
10
15
20
92 93 94 95 96 97 98 99 00 01 02
(n
et
-)
 n
u
m
b
er
 o
f 
co
u
n
tr
ie
s 
Fig. 21: Heroin abuse trend, 1992 - 2002 
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Source: UNODC, Annual Reports questionnaire Data/DELTA.
stable
21%
some 
increase
39%
large 
increase
23%
some 
decrease
15%
large 
decrease
2%
stable
29%
some 
increase
39%
large 
increase
9%some 
decrease
16%
large 
decrease
7%
stable
30%
some 
increase
35%
large 
increase
9%
some 
decrease
22%
large 
decrease
4%
Fig. 22: Heroin abuse trends in 2000
(n = 47 countries)
Fig. 23: Heroin abuse trends in 2001 
(n = 70 countries)
Fig. 24: Heroin abuse trends in 2002
(n = 69 countries)
Source: UNODC, Annual Reports questionnaire Data/DELTA.
Source: UNODC, Annual Reports questionnaire Data/DELTA.
Source: UNODC, Annual Reports questionnaire Data/DELTA.
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EUROPE
Stable/declining trends of heroin abuse in Western
Europe 
Heroin abuse reported to UNDOC from the countries
of West Europe continued on a stable to declining
trend. These trends are confirmed by a number of sta-
tistical data, including household surveys, proportion of
populations in treatment for heroin abuse,  age of pop-
ulations in treatment, the prevalence of HIV/AIDS
among drug addicts,  the amount of first time offenders
in drug law violations and drug related deaths.  Most of
these indicators showed a deterioration in the 1980s.
They stabilized, or showed even falling levels of abuse in
several West European countries in recent years. These
trends became even more pronounced in 2001 and
2002. Thus, out of 16 reporting countries only two
countries saw an increase in the use of opiates in 2002.
Ten reported a stable trend and four experienced a
decline.
Using the trend information collected from Member
States over a number of years, a new analytical tool,
called Weighted Analysis on Drug Abuse Trends (more
simply referred to as Drug Abuse Trend Index)  was
designed by UNODCg to allow for a slightly more
sophisticated analysis of regional trends in drug abuse.
The Index takes into account the degree of change in
drug abuse levels, as reported by member states, and the
different population size of the countries. Each degree
of trend estimation, reported by Member States,  was
given a numerical value ranging from -2 to +2 (with -2
representing a large decrease; -1 some decrease; 0 no
great change; +1 some increase; and +2 a large increase).
The results of individual countries were then weighted
by the country's size in terms of population, i.e. esti-
mates for a drug type (in this case heroin) were multi-
plied by the proportion of the population (age 15-64)
of the country in its particular regionh.  The national
estimates were added to represent annual sub-regional
trend estimates. Based on this a cumulative trend figure
for the respective sub-region was calculated. The result-
ing Drug Abuse Trend Indexi for Western Europe
showed only some minor increases in the use of heroin
in the second half of the 1990s, followed by some
decline over the 2000-2002 periodj.   The overall trend
over the last decade was relatively stable.  
The pattern revealed in this index is confirmed by other
indicators. Drug related deaths, which in the European
context are mainly related to abuse of opiates, increased
only slightly during the 1990s but declined - according
to preliminary calculations - by almost 20% between
2000 and  2002 in Western Europe and are now back
to levels last seen in the early 1990s. Strongly declining
g) The Weighted Analysis on Drug Abuse Trends was first used for UNODC's Report to the Commission on Narcotic Drugs,  World Situation with
Regard to Drug Abuse, 15-22 March 2004. 
h) For more information on the construction of the index, see chapter on methodolgy. 
i) The advantage of such an analysis is that differences (in the degree of the changes) are reflected in the final results. In addition, the population size
affected by the estimated trend is taken into account. This gives more weight to the results reported from larger countries which - in absolute terms
- are likely to have a higher addict population than smaller countries. This weighting procedure reduces the likelihood, but does not completely
prevent, the calculation of  misleading results. A country with a low prevalence in drug abuse is still given the same weight as a country with a high
prevalence rate and a similar population (though  in reality its impact on the overall trend would  be smaller). Otherwise, the same limitations, as
discussed earlier, apply to the Drug Abuse Trend Index. The information remains based on expert opinions of government officials which may or
may not adequately reflect actual trends.  UNODC is also aware that some of the underlying assumptions do not necessarily hold true. For instance,
it cannot be guaranteed that the differences between various reported degrees of drug abuse trends (e.g. between "some increase" and "large increase")
are interpreted in the same way in different countries.   Irrespective of these caveats, the overall results - wherever comparisons with other indicators
could be made - were found to be basically in line with these indicators. 
j) If all countries in a year  reported  'some increase'   the index would have to rise by 1. If half of the countries, in terms of population, reported '
some increase'  and the rest reported a stable trend, the increase of the index would amount to 0.5 in a specific year. The largest increase in  Western
Europe for heroin in any specific year over the last decade amounted to 0.5 (in 1992); the largest increase over the last five years was 0.2 in 1999
(the year of Afghanistan's bumper harvest); in 2000 and 2001 the index showed a decline  (-0.2 in 2002).    
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Fig. 25: Heroin consumption trend in Western Europe:
based on national experts’perceptions, 1991 -
2002
Source: UNODC, Annual Reports questionnaire Data/DELTA.
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numbers of drug related deaths were reported, inter alia
from Italy, the UK, Germany, Spain, Switzerland, Aus-
tria and France. Although all  European countries have
undertaken efforts to reduce drug related mortality rates
over the last decade, the general decline over the 2000-
2002 period appears to have been largely the result of
lower levels of supply leading to less high purity heroin
on the market, thereby reducing the risk of overdose.
Unfortunately, this positive trend is unlikely to continue
over the next few years as large-scale opium production
has resumed in Afghanistan and a further rise in
Afghanistan's opium output is expected for 2004.    
"Problem drug use"  appears to have increased slightly
in Western Europe after the mid-1990s. Though prob-
lem drug use in Western Europe is primarily related to
abuse of opiates,  the increase was not related to heroin
abuse, but to poly-drug use (including use of cocaine,
notably crack-cocaine, and use of amphetamines).
Prevalence estimates of  'problem drug use' (mostly opi-
ates), range between 0.2% and 1% (on average around
0.4%) among members of the general population aged
15-64k in Western Europe. Heroin abuse levels identi-
fied through household surveys are significantly smaller,
(in most cases between 0.1% and 0.2% of  the general
population), and have been generally stable or falling.   
There are also indications that injecting of drugs has
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Fig. 26: Drug related deaths in Western Europe, 2000 - 2002
Source: EMCDDA, UNODC, Annual Reports questionnaire Data/DELTA.
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Fig. 27: Acute drug related death in the EU-15, 
1985 - 2002
k) European Monitoring Centre for Drugs and Drug Addiction, Annual Report 2003: the State of the Drugs Problem in the European Union and
Norway (Lisbon, 2003).
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been stable or decreasing over the last few years in most
countries in Western Europe.  Newly diagnosed HIV
infections related to injecting drug use (IDU) have
experienced a general decline since 2000. They fell in
Western Europe by more than 30% between 2000 and
2002. The strongest declines were reported by Portugal
(-53%),  Finland (-53%), Ireland (-29%), Greece (-
26%) and Germany (-25%). Further confirming this
picture there has been a drop in the attribution of new
HIV infections to IDU.  While in 2000 28% of all new
HIV infections had been related to injecting drug use,
the proportion fell to 11% by  2002 and to  8% over
the first two quarters of 2003. Various interventions,
targeted at injecting drug users, appear to have con-
tributed to reducing these levels.  Reflecting HIV infec-
tions contracted in previous years, the number of  newly
diagnosed IDU related AIDS cases (2700 in 2002) still
accounted for 28% of all newly registered AIDS cases in
Western Europe. The largest numbers of IDU related
AIDS cases, registered in 2002, were reported by Portu-
gal (38 per million inhabitants), followed by Spain (30),
Italy (11), Switzerland (7) and France (4). In other West
European countries this figure was around 1 or less. 
Heroin abuse trends in Eastern Europe have been going
upwards, except in 2002 
Heroin abuse in Eastern Europe has grown strongly over
the last decade. This is clearly reflected in UNODC's
Drug Abuse Trend Index. 2002 was the only year when
some (temporary) stabilization at high levels could be
observed. Poland, Slovakia and Croatia all reported
some decline of heroin abuse in 2002; Ukraine, Bul-
garia,  Hungary and the Czech Republic saw abuse levels
stabilize. Reports from the Russian Federation also
point to some stabilization of heroin abuse at high levels
following years of massive increases. Increases in heroin
abuse, in contrast, were reported by Belarus, Latvia and
Romania. Strong increases were reported by Albania,
apparently reflecting Albania's increasing role as an
important transhipment  location (and thus spill-overs
on to the local market) for heroin being shipped from
Turkey via Bulgaria, FYR of Macedonia and Albania to
Italy. 
The best reflection of the underlying trend pattern of
the Drug Abuse Trend index for Eastern Europe is
found in Russian registry data of drug addicts. Their
number doubled between 1995 and 1991 and quadru-
pled over the 1995-2000 period. Following another
strong increase in 2001,  it remained almost unchanged
in 2002, before rising again in 2003 as large shipments
of Afghan heroin flooded the Russian market. This
affected prices and made heroin more accessible to Russ-
ian society. After having increased slightly from an aver-
age of $38 per gram 2001 to $42 per gram in 2002,
heroin prices fell to an average of  $25 per gram in 2003
(ranging from $12 next to the border with Kazakhstan
to $45 next to the border with Finland). 
Based on data from various sources, the Russian Feder-
ation appears to be Europe's largest heroin market. The
total number of drug users in the Russian Federation is
now estimated by the Russian authorities to amount to
some 3 to 4 million people (though, in the absence of
nationwide epidemiological surveys, there are uncer-
tainities regarding these figures).  Amongst this popula-
tion some 2 million (2.1% of the population age 15-64)
Fig. 28: Injecting drug use related (newly diagnosed)
HIV infections in Western Europe* per million
inhabitants
in Western Europe  
per million inhabitants
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Italy, Luxembourg, Netherlands, Portugal, Sweden, UK, 
Iceland, Malta, Norway, Switzerland.
Source: EuroHIV Surveillance in Europe, Mid-Year Report 2003.
Fig. 29: Heroin consumption trend in Eastern Europe:
based on national experts' perceptions, 
1991 - 2002 
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Source: UNODC, Annual Reports Questionnaire Data. 
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are estimated to consume opiates, including about 1
million abusing heroin (range 400,000-1,200,000). The
largest heroin markets in Western Europe - UK
(260,000),  Italy (260,000), Germany (170,000),
France ( 165,000), Spain (145,000) are - in absolute
numbers - significantly smaller. 
The Russian Federation also has one of the highest
injecting drug use (IDU) related HIV rates in the world,
and - until 2001 - it had been increasing rapidly. In
2002, however, newly reported cases of IDU related
HIV declined strongly in the Russian Federation as well
as in a number of other countries of the former Soviet
Union (Kazakhstan, Tajikistan, Kyrgyzstan, Moldova,
Azerbaijan, Georgia, Moldova,  Estonia and Latvia) and
in Poland, leading to a significant decline in the overall
number of  newly diagnosed HIV cases (-43% in the
Russian Federation and -36% in the countries of the
former Soviet Union). While in 2000 65% of all new
HIV cases in the countries of the former Soviet Union
were IDU related, the proportion fell to 41% in 2002.
Nonetheless, the reported numbers of IDU related HIV
infections are still very high by European standards.
Similarly, whereas in Germany or the UK the number
of newly identified IDU related HIV infections was 2
persons per million inhabitants in 2002, the correspon-
ding ratios were 129 in the Russian Federation, 94 in
Ukraine, 58 in Belarus and 33 in Moldova. The levels
in the Baltic countries were even higher: 103 in Lithua-
nia, 164 in Latvia and 516 in Estonia.    
ASIA
Trend towards stabilization of opiate use in 2002…
The pattern of trends in opiates use in Asia in 2002 was
mixed. Stable/declining trends were reported from most
countries in  East and South-East Asia reflecting falling
levels of opium production in Myanmar and Laos.
Stable or declining trends were also reported from Pak-
istan and some of the Central Asian countries, a delayed
Fig. 31: Russian Federation: Number of registered
drug addicts per 100,000 inhabitants, 
1991 - 2003
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Fig. 30: Newly diagnosed HIV and IDU-related HIV cases in Russia and other countries of the former Soviet
Union
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consequence of Afghanistan's opium poppy ban of
2001. The number of countries showing stable or
declining levels of opiate use in Asia thus outweighed
those reporting rising levels of opiate use. This trend
became even more pronounced in 2002. (In 2003, how-
ever, Afghanistan, as well as most of the countries sur-
rounding Afghanistan, started reporting again rising
levels of abuse.)     
...in Central Asia…
Central Asia, which suffered for many years from the
strongest growth rates of heroin abuse and  HIV related
to injecting drug use (IDU), saw a marked decline in the
number of newly diagnosed HIV cases in 2002, which
fell by more than 20%. While, in 2001, 87% of all new
HIV cases were related to injecting drug use,  the pro-
portion fell to 68% in 2002. This decline helped to sta-
bilise the overall number of new HIV cases in this
subregion.     
… in South-West Asia… 
In Pakistan overall heroin abuse was reported to have
declined slightly in 2002, while use of hashish, benzo-
diazepines and solvents increased. At the same time,
however, authorities reported a strong increase in injec-
tion of heroin, a trend also seen in previous years. There
was also an increase in demand for heroin treatment in
2002, notably for injecting heroin users. 
… in South Asia… 
In India, overall opiate use was reported to have
remained stable in 2002 following years of increase,
notably over the 1997-2000 period, as documented in a
Rapid Assessment Study, sponsored by  the Indian Gov-
ernment and UNODCl.   In terms of treatment
demand, the authorities reported a stabilization for
treatment involving heroin and even some decline for
treatment of opium addiction in 2002. Though still
limited,  the injecting of opiates is continuing to
increase.  A national household survey conducted in
India in 2002, found that 0.7% of the male population,
age 12-60, were 'current users' (at least once in the last
month) of opiates, including 0.4% of the male popula-
tion abusing opium, 0.2% heroin and 0.1% other opi-
ates. Other studies showed that around 90% of all drugs
in India are consumed by males. India has thus with
around 2.8 million people (males and females), the
largest absolute number of opiate users worldwide,
although prevalence rates there are smaller than in Pak-
istan, Iran,  Myanmar or Laos. States with high levels of
opiate use are mainly in the north west, close to
Afghanistan, and the north east, close to Myanmar. 
… and in South-East Asia… 
In East and South East Asia the main 'growth sector'
was not opiates but methamphetamine. Poor opium
harvests in South East Asia, notably Myanmar, appar-
ently played a role in this respect. This is clearly reflected
in data from Thailand, which shows a continuing down-
ward trend in opiate use since the mid 1990s running
alongside an increasing trend in methamphetamine use.
While, in 1995,  95% of all people in treatment had
used opiates, by 2001 this proportion had fallen to
Fig. 32: Unweighted opiate abuse trends in Asia 
No. of countries reporting increasing less those
reporting stable/declining levels of abuse
Source: UNODC, Annual Reports Questionnaire Data. 
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Fig. 33: Central Asia: newly diagnosed HIV cases, 
1995-2002
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37%. Declines in opiate use in 2002 were reported from
Myanmar, Indonesia, Singapore, Brunei Darussalam
and the Lao PDR.
As part of the periodic LAO/UNODC opium poppy
surveys in the Lao PDR - the world's third largest
opium producing country - data on opium use is also
collected in the northern provinces where opium pro-
duction takes place. These surveys showed that after a
strong increase over the 1992-98 period, the prevalence
of opium use has fallen again in recent years parallel to
falling opium production. Opium production in the
Lao PDR declined by 20% in 2001, and the number of
opiate users fell by 8% in 2001 as compared to a year
earlier. In 2002 opium production fell by 16% and the
number of opiate users declined by 9%. This pattern
was also repeated in 2003 when both opium production
and opium use declinedm.
The link between opium production and consumption
was confirmed in a more in-depth analysis of the preva-
lence rates in Northern Laos. Villages with opium pro-
duction had, on average, a prevalence rate 27% higher
than non-producing villages in the same region (based
on 2000 data).  While negligible opium use was
reported from the southern provinces, where no poppy
is grown, overall prevalence of opium use in the poppy
growing regions of Northern Laos was 4% of the popu-
lation age 15-64 in 2002, and was thus higher than in
any other country of the world.   
… but continues to grow in China… 
In contrast to a majority of Asian countries reporting
stable or declining abuse trends in 2002,  opiate abuse
was reported to have continued rising in China, the
world's most  populous country. The number of regis-
tered drug addicts rose in  2002 and in 2003 to exceed
1 million people,  a 15-fold increase over the 1990-2003
period. The bulk of the opiates destined for the Chinese
Fig. 34: Thailand: Proportion of addicts using opiates
over the last 30 days prior to entering
treatment (Number of patients in 2001: 39,931)
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Fig. 35: Lao PDR: Prevalence of opiate use in 11
northern provinces
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m) Opium production fell by 14% in the Lao PDR in 2003.  However, due to differences in survey methodology and some missing districts in 2003,
the abuse figures for 2003 are not directly comparable with those reported in previous years. Nonetheless, data are sufficiently robust to indicate
that a further decline took place in 2003 as well. (UNODC, Laos Opium Survey 2003, June 2003).
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Fig. 36:People's Republic of China: Number of
registered drug addicts (70% for heroin in
2003)
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market come from Myanmar (more than 80%). Chi-
nese authorities estimate that some 80% of the opiates
produced in the Golden Triangle are exported to China.
In addition, the Golden Crescent is emerging as a threat
to China. Opiates produced in Afghanistan are consid-
ered to be increasingly shipped to China via Central
Asia. This may also explain why opiate abuse in China
continued to spread despite the fact that opium pro-
duction in South-East Asia was declining. The number
of heroin addicts has been rising, although at a slower
pace than the overall increase in the number of regis-
tered drug addicts. While in 1997/98  20% of the drug
addicts were registered for opium abuse and 80% for
heroin abuse, the latter proportion declined to 70% by
2003, reflecting the fact that the number of people reg-
istered for other drugs, notably ATS, showed a stronger
increase. Despite the strong increase in drug abuse,
including opiate abuse over the last decade, the number
of opiate addicts in proportional terms - around 0.1%
of the general population age 15-64 - is still low com-
pared to other countries and compared to the situation
in China at the beginning of the 20th century (even if
one takes into account the possibility that the total
number of opiate abusers could exceed those officially
registered). 
… preventing the Drug Abuse Trend Index for Asia from
falling
The reported increase from China also meant that
UNODC's overall Drug Abuse Trend Index for Asia,
weighted by the countries' population, did not fall in
2002, despite the large number of countries showing
stable or declining levels of abuse. The rise of the Asian
Drug Abuse Trend Index was stronger than in Western
Europe but less significant than in Eastern Europe.     
OCEANIA
Opiate abuse in Australia has not recovered from the
low in 2001   
The most significant decline of opiate abuse in recent
years was reported from the Oceania region in 2001.  It
lasted well into 2002 and - according to preliminary
data - into 2003 as well. The shortage of heroin in Aus-
tralia's domestic market was largely the result of suc-
cessful law enforcement operations in late 2000 which,
in co-operation with the authorities of other coun-
tries/territories, notably Hong Kong SAR of China,
Myanmar and Thailand, dismantled the major heroin
trafficking rings that had been supplying the Australian
market (Sydney) with heroin from South-East Asia.
This supply shortage was reflected in Australia's new
Drug Use Monitoring (DUMA) system which tests
offenders by means of urine analysis within 48 hours
after arrest at a police station. Other indicators corrob-
orated DUMA's findings. Data from the national
household survey showed a decline of annual prevalence
from 0.8% of the population (age 14 and above) in
1998 to 0.2% in 2001. Overall heroin-related overdoses
fell by around 66% in 2001 and by a further 6% in
2002 to the lowest level since the late 1980s. There were
some minor substitution effects with regard to cocaine
and amphetamines, but most addicts turned to treat-
ment, notably substitution treatment.  Initial fears that
a heroin shortage could lead more crime, did not mate-
rialize. Following a short-term increase, overall crime
rates moved downwards rather than upwards. 
Fig. 37: Opiates consumption trend in Asia: based on
national experts' perceptions 
Sources: UNODC, Annual Reports Questionnaire Data, Field Office
reports. 
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Fig. 38: Australia: Heroin abuse annual prevalence  
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AFRICA
Heroin abuse increased in Africa in 2002 
Heroin abuse has increased in Africa over the last
decade. Following some decline in 2001, abuse was
reported to have increased again in 2002. Levels of
abuse still seem to be rather low in Africa compared to
other regions, mostly due to high prices by local pur-
chasing power standards. Most of the increases in 2002
were reported from countries in Eastern and Southern
Africa.  Increases in Western Africa were reported by
Côte d'Ivoire and Togo and in Northern Africa by
Morocco.
Of all African countries, South Africa collects data on
drug abuse in the most systematic way. Data collection
is undertaken through SACENDU - South African
Community  Epidemiology Network on Drug Use.
Data, based on the primary drug of abuse in treatment
admissions, confirm that a strong increase in heroin
abuse has taken place in the country since the mid
1990s.  Following some signs of levelling off in recent
years, a renewed  upward trend  in treatment demand
for heroin abuse was observed in the first two quarters
of 2003.  In the first half of 2003, more than 7% of all
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Fig. 40: Crime trends in New South-Wales, Australia,
July 1999-Dec. 2002
Source: Source: NSW Bureau of Crime Statistics and Research,
NSW Recorded Crime Statistics.
Fig. 41: Heroin consumption trend in Africa (based on
national experts' perceptions) 
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Fig. 42: South Africa: Proportion of people in
treatment for heroin abuse (1996-2003)
Source:  South African Community Epidemiology Network on
Drug Use (SACENDU). 
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treatment (including alcohol) in Cape Town and in the
Johannesburg/Pretoria region (Gauteng) the largest
heroin markets of the country - was related to heroin
abuse. For South Africa as a whole the corresponding
ratio stood at 5.5% in the first half of 2003. 
A similar kind of information system is currently being
built among the countries of the Soutern African Dev-
elopment Community (SADC Epidemiology Network
on Drug Use - SENDU), assisted by UNODC. Results
from this monitoring system show that higher propor-
tions of people in treatment for heroin abuse than in
South Africa are found in Mauritius (56% in 2002) and
in Mozambique (15% in 2002). In both countries the
proportion of people treated for heroin abuse declined
in 2003 (to 52% in Mauritius and to 11% in Mozam-
bique over the first two quarters of 2003). For other
SADC countries no significant levels of heroin abuse
were reported from  treatment services. Reports from
the East Africa Drug Information System (EADIS)
identified the emergence of heroin abuse, albeit at low
levels, in Uganda, Kenya and Tanzania in recent years.   
AMERICAS
Signs of stabilization in 2002 
Heroin abuse increased in the Americas over the last
decade in 2002.  The overall increase over the last
decade, as reflected in the Drug Abuse Trend Index  was,
but showed signs of stablization, however significantly
less than in Eastern Europe or Asia.  
Stable/declining levels reported from North America 
Heroin abuse was reported to have remained more or
less stable in North America in 2002. In the USA, the
largest heroin market in the Americas, general popula-
tion surveys revealed a basically stable level in 2002.
Overall heroin abuse, including chronic heroin abuse, is
estimated to affect around 1 million people (0.6% of
the population age 12-65).  Following strong increases
in the 1990s the trend among US high school students
Fig. 44: Heroin consumption trend in the Americas 
based on national experts' perceptions 
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is now falling again. In 2003, the lowest level of heroin
abuse among students since 1994 was reported. Heroin
related treatment demand continues rising (2.8% in
2002), though at lower rate than over the 1992-2002
period (average annual growth of 5.4%)).
Heroin continues rising in Southern America
In  contrast to the situation in North America, a
number of countries in South America, the Caribbean
and Central America (Argentina, Colombia, Venezuela,
El Salvador, and the Dominican Republic) have
reported rising levels of opiate use in 2002, reflecting
the ongoing production of opium in the region (notably
in Colombia and, to a lesser extent, in Peru and in
Venezuela).  Despite this, overall levels of opiate use
remain low in South America, with the exception of a
few countries (Brazil, Venezuela and Argentina). A
household survey conducted in late 2001 in Brazil
revealed a relatively high annual prevalence rate for
opiate use of 0.6% among the general population (age
12-65 in cities with more than 200,000 inhabitants).
However, it concerned mainly synthetic opioids,
diverted from licit channels. Heroin abuse remained low
(lifetime prevalence rate of 0.1%; annual prevalence <
0.05%). Annual prevalence of opiate use in Argentina
(1999) amounted to 0.14% and lifetime prevalence to
0.5% of the general population (age 16-64). A study
conducted in the metropolitan district of Venezuela in
2002 revealed a lifetime prevalence of 0.8% among the
population age 8-40, equivalent to a rate of  0.7%
among the population aged 15-64. 
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2.2.1. Production
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
CULTIVATION(1) OF COCA BUSH IN HECTARES
Bolivia (2) 50,300 47,900 45,300 47,200 48,100 48,600 48,100 45,800 38,000 21,800 14,600 19,900 24,400 23,600
Colombia (3) 40,100 37,500 37,100 39,700 44,700 50,900 67,200 79,400 101,800 160,100 163,300 144,800 102,000 86,000
Peru (4) 121,300 120,800 129,100 108,800 108,600 115,300 94,400 68,800 51,000 38,700 43,400 46,200 46,700 44,200
Total 211,700 206,200 211,500 195,700 201,400 214,800 209,700 194,000 190,800 220,600 221,300 210,900 173,100 153,800
POTENTIAL PRODUCTION OF DRY COCA LEAF IN METRIC TONS
Bolivia 77,000 78,000 80,300 84,400 89,800 85,000 75,100 70,100 52,900 22,800 13,400 20,200 19,800 17,100
Colombia 45,300 45,000 44,900 45,300 67,500 80,900 108,900 129,500 165,900 261,000 266,200 236,000 222,100 168,000
Peru 196,900 222,700 223,900 155,500 165,300 183,600 174,700 130,600 95,600 69,200 46,200 49,300 52,500 50,790
Total  319,200 345,700 349,100 285,200 322,600 349,500 358,700 330,200 314,400 353,000 325,800 305,500 294,400 235,890
POTENTIAL(5) MANUFACTURE OF COCAINE IN METRIC TONS
Bolivia 189 220 225 240 255 240 215 200 150 70 43 60 60 60
Colombia 92 88 91 119 201 230 300 350 435 680 695 617 580 440
Peru 492 525 550 410 435 460 435 325 240 175 141 150 160 155
Total 774 833 866 769 891 930 950 875 825 925 879 827 800 655
Table 5. GLOBAL ILLICIT CULTIVATION OF COCA BUSH AND PRODUCTION 
OF COCA LEAF AND COCAINE, 1990-2003
(1) Potentially harvestable, after eradication.
(2) Source: CICAD and US Department of State, International narcotics Control Strategy Report. 
(3) Estimates for 1999 and subsequent years come from the national monitoring system established by the Colombian government with the support of
UNODC.  Due to the change of methodology, figures for 1999 and after cannot be directly compared with data from previous years.
(4) Since 2000 the results are those of the illicit crop monitoring system established with the support of UNODC
(5) Potential manufacture of cocaine is the amount of cocaine that can be made from coca leaf produced in the country concerned. It does not take into
account importation of coca base from other countries.
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Global cultivation of coca has reached its lowest level
since 1985… 
Global coca cultivation continued declining for the
third straight year in 2003. The total area under coca
cultivation in Colombia, Peru and Bolivia combined
declined to 153,800 ha, an 11%  decline from 2003 and
a 30% decline from the peak of coca cultivation in
1999.  As has been the case since 1996, the majority of
all coca cultivation (56%) took place in Colombia, 29%
took place in Peru and 15% took place in Bolivia.   
The largest decrease in coca cultivation took place in
Colombia, where coca cultivation declined 16% from
102,000 ha in 2002 to 86,000 ha in 2003.  This repre-
sents Colombia’s third consecutive year of decreasing
cultivation, and brings the country back to cultivation
levels not seen since 1997.  Cultivation in Peru
decreased 5.4% to 44,200 ha in 2003.  In Bolivia
UNODC and the Bolivian Government completed the
first national coca survey of the country (previous sur-
veys of Bolivia had only covered Yungas of La Paz) with
national estimates compiled from US Government and
Bolivian sources. The results of the first national survey
revealed that 23,600 ha were under coca bush cultiva-
tion, including the12,000 ha permitted by Bolivian Law
Number 1008. 
Although coca cultivation in 2003 for Bolivia was only
about half of the levels reported from other sources in
the mid-1990s, there are worrying signs that coca culti-
vation is on the increase. In the Yungas of La Paz which
accounted for 71% of total coca cultivation in the coun-
try, coca cultivation increased by 18% as compared to
2002.
In Peru the most important decreases in cultivation took
place in the areas of Central Huallaga, where coca culti-
vation has virtually disappeared, as well as in Aguaytia
(-53%). In Alto Huallaga, where 31% of coca is culti-
vated, cultivation declined a significant 11%.  The gov-
ernment estimates that approximately 50,000
households are involved in coca cultivation in Peru. 
UNODC’s Peru Coca Survey for 2003 attributed the
decrease in cultivation to four factors: programmed
eradication implemented by the Control and Reduction
of Coca Leaf in the Upper Huallaga Office (CORAH)
(7,022 ha), the National Commission for Development
and Life without Drugs’ (DEVIDA) voluntary eradica-
tion programme, which includes compensation for
farmers (4,290 ha), the abandonment of coca fields by
farmers without compensation (possibly to avoid forced
eradication) and alternative development programmes.
In Colombia, the most significant reductions in coca
cultivation between 2002 and 2003 were found in the
departments of Guaviare (-11,218 ha or 41% decrease),
Putumayo (-61,666 ha or 45% decrease) and Norte de
Santander (-4,471 ha or 44% decrease), while coca cul-
tivation increased in two departments: Nariño (17,628
ha or 17% compared to 2002) and Meta (12,695 ha or
38% compared to 2002). In 2003, the major coca grow-
ing departments were, in decreasing order of impor-
tance, Nariño, Guaviare and Meta. Together they
accounted for 54% of the total coca cultivation. The
same three departments accounted for 61% of the aerial
eradication efforts.  
In Colombia, eradication was the primary reason for the
decline in cultivation in 2003. Other factors included
abandonment of fields and voluntary eradication. The
armed conflict, as well as fuelling coca production in
some parts of the country, completely impeded it in
others. Moreover, in 2003, there was a slight recovery in
Colombia’s agricultural sector, which led to an increase
in the prices of some key farm products. This also con-
tributed to the decrease in coca cultivation by reducing
incentives for coca cultivation.
Sustained eradication efforts in all three countries were
amongst the vital factors which perpetuated the down-
ward trend of cultivation. In 2003 the Government of
Bolivia reported the eradication of 10,100 ha of coca
fields, mainly in the Chapare region, sustaining a level
of eradication which has occurred since 1998.  The
Peruvian Government reported the eradication of
11,312 ha of coca fields, the second highest level in 20
years. Of this total, 7,002 ha were eradicated by
CORAH and 4,290 ha were voluntarily eradicated
through programmes promoted by DEVIDA.  In
Colombia,  the decrease in coca cultivation in Arauca,
Guaviare, Putumayo and Norte de Santander could be
attributed to a large extent to the aerial eradication cam-
paigns that have intensified considerably since 2002 in
these four departments. Putumayo alone accounted for
76 % of the national eradication records.  In total, about
136,828 ha were eradicated in Colombia 2003, which
is the highest level of eradication yet.
Reducing the world’s potential manufacture of cocaine
to its lowest level since 1989…
The potential production of cocaine reached 655 metric
tons in 2003, down from 800 metric tons in 2002.
Potential cocaine production in Peru amounted to 155
metric tons in 2003, and to 60 metric tons in Bolivia.
In 2003 the global share of cocaine production was
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slightly redistributed between the three countries with
Colombia’s share of cocaine production falling from
75% to 67%. Peru’s share amounted to 24%, and
Bolivia’s to 9% of cocaine production. 
In Peru, the research carried out by Peru’s Tropical Crop
Institute in 2003 supports reports that farmers are
improving coca yields on existing plots instead of
increasing the surface of their cultivation.   Between
2001 and 2003 the average yield of coca crops in the
Upper Huallaga rose from 500 kg/ha/year to
800/kg/ha/year (four harvests per year).  At the country
level, the gross potential farm-gate value of the dry coca
leaf production harvested in 2003 amounted to US$112
million. Considering that 50,000 households cultivate
coca in Peru, discounting maintenance costs, the net
income per household derived from the sale of coca leaf
is around US$1,344 per year. 
In Bolivia, where the law allows for coca production for
traditional use, the total coca leaf production amounted
to 28,300 metric tons, of which 17,100 metric tons
were estimated to have been available for cocaine pro-
duction.  The total gross potential farmgate value of
coca leaf production in Bolivia in 2003 is estimated to
be US$153million, equivalent to 2% of the country’s
GDP or 13.4% of the value added of the (licit) agricul-
tural sector.  The gross income from coca leaf produc-
tion amounted to US$500 per capita (coca growers and
non-growers) in the coca producing regions in 2003.
The overall (licit) GDP per capita in Bolivia was around
US$880 in 2003. 3.8% of the country’s total popula-
tion live in the coca producing regions.
UNODC has not yet conducted a scientific and com-
prehensive study on coca leaf and cocaine productivity
in Colombia, but information gathered from other
sources, enabled the estimation of the potential cocaine
production in Colombia at about 440 metric tons.
Using the average price for coca base of US$793/kg in
2003, and assuming a one to one conversion rate
between cocaine and coca base, the total farmgate value
of the 440 metric tons of coca base produced in Colom-
bia in 2003 would amount to about US$ 350 million.
However, there is some sign of shifting cultivation pat-
terns and improved techniques…
UNODC’s surveys consistently reveal signs that farmers
are improving and adapting their cultivation tech-
niques, both to increase yield and to hide crops.  In
Bolivia, for example, fertilizers and pesticides have been
widely used for coca cultivation in the Yungas of La Paz,
but it is only in 2003 that the irrigation of coca fields
has become common. 
The interpretation of satellite images in Bolivia revealed
that most of the new coca fields were established to the
detriment of the primary forest. Farmers are also inter-
spersing their coca crop with other licit crops, such as
rice, cassava,  pineapple and citrus trees. Farmers time
the addition of the coca crop to the licit crop carefully,
when the licit crop is at about half of its maturity. While
this technique is neither new nor complex, it may be
growing more common as a method of avoiding eradi-
cation. This, for example, is done in Chapare in Bolivia
where most of the eradication takes place.
In Peru, there has been some shifting in cultivation,
with Apurimac Ene replacing Alto Huallaga as the area
with the largest area under coca cultivation. Although
cultivation is declining in Alto Huallaga, it remains
high. UNODC’s alternative development programmes
in the region estimate that 80% of farmers income in
the area of Mozon in Alto Huallaga comes from coca
cultivation. In Mozon, coca cultivation is concentrated
in the steep slopes of the mountains, while licit crops
tend to be cultivated in the more productive soils of the
lower valleys.  The insecurity and violence brought
about by organizations of coca farmers in Mozon were
constant in 2003, especially in the higher areas where
the coca cultivation is concentrated.  Mozon accounts
for 71% of the cultivation in the Alto Huallaga area, in
the other areas agriculture is more diverse and coca cul-
tivation accounts for only a marginal fraction of farmer’s
income. There are both direct and indirect indicators
that farmers are abandoning their coca fields in order to
avoid eradication. Once the risk of eradication disap-
pears, abandoned coca fields can be quickly reactivated
at a fraction of the cost of establishing a brand new field.  
Cultivation in Apurimac-Ene, which now accounts for
the largest portion (32%) of coca cultivation in Peru,
has been increasing since 1997.  It is thought that the
increase is due mainly to the rehabilitation and improve-
ment of abandoned coca fields, rather than the estab-
hishment of new crops. UNODC’s survey has found
that it costs approximately US$ 400 to rehabilitate an
abandoned coca field, with the first harvest ready after
3 or 4 months, whereas, the cost for establishing a new
hectare ranges from US$1,500 to US$1,800 and the
first harvest is produced only after 9 to 15 months.
In Colombia, coca cultivation is characterized by a high
degree of mobility, both within and across department
boundaries. With cultivation shifting tactically to avoid
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eradication and to exploit new growing areas. In
Putomayo cultivation declined 45%. Declines corre-
sponded roughly to aerial spraying activity and volun-
tary eradication. Unlike in other parts of the country,
this was not counterbalanced by the establishment of
new fields or the reseeding of sprayed areas. A high
degree of mobility of coca cultivation was noted within
the region of Guaviare, which in the 90’s, was the largest
coca growing area of Colombia, until most of the coca
migrated to Putumayo at the end of the decade and then
to the Nariño area. Guaviare remains one of the most
important coca growing regions in Colombia, despite
the 41% decrease in the level of coca cultivation
between 2002 and 2003. Nariño experienced a 17%
increase in cultivation , perhaps as a consequence of the
significant reduction in coca cultivation in Putumayo,
which drove landless labourers to move to Nariño.
Other factors would have included violence, insecurity,
proximity of the sea and international trafficking routes.
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Fig. 45: Global coca bush cultivation, 1990-2003 (in ha)
Fig. 46: Potential cocaine production, 1990-2003 (metric tons)
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Estimates for Colombia for 1999 and subsequent years come from the national monitoring system established by the Colombian
government with the support of UNODC.   Due to the change of methodology, figures for 1999 and after cannot be  directly compared
with data from previous years.
100
World Drug Report 2004 Volume I. Analysis
Colombia
Peru
Bolivia
Colombia
Peru
Bolivia
10
2,
00
0
24
,4
00
46
,7
00
60
160
580
Cultivation
in hectares
2002
2003
Production in
metric tons
2002
2003
86
,0
00
44
,2
00
23
,6
00
440
155
60
Map 11. Coca bush cultivation (2002 - 2003)
Map 12. Potential cocaine production (2002 - 2003)
101
2. Trends Coca / Cocaine market
COLOMBIA - COCA BUSH CULTIVATION, 1990 - 2003 (ha) COLOMBIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2003 (mt)
PERU - COCA BUSH CULTIVATION, 1990 - 2003 (ha) PERU - POTENTIAL COCAINE PRODUCTION, 1990 - 2003 (mt)
BOLIVIA - COCA BUSH CULTIVATION, 1990 - 2003 (ha) BOLIVIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2003 (mt)
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Estimates for Colombia for 1999 and subsequent years come from the national monitoring system established by the Colombian government
with the support of UNDCP.  Due to the change of methodology, figures for 1999 and after cannot be directly compared with data from
previous years.
Fig. 47. 
Annual coca bush cultivation and cocaine production in main producing countries, 1990 - 2003
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Fig. 49: Potential cocaine production (in % of global total)
Fig. 48: Coca bush cultivation (in % of global total)
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1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
 Bolivia 2,400   1,100   5,493   7,512   7,000   11,620 15,353 7,653   9,395   11,839    10,089
 Colombia 946      4,904   25,402 23,025 44,123 69,155 44,157 61,574 95,898 126,933  136,828 *
 Peru 240      7,512   7,512   3,462   17,800 13,800 6,200   3,900   7,000      11,312
Fig. 6: Reported eradication of coca bush, in ha 
* Represents gross annual spraying area (aerial and manual). It does not take into account the effectiveness of spraying nor the fact that
some spraying paths can overlap, which explains that eradicated areas are larger than cultivated areas.  Coca cultivation estimates
presented in this publication are net, i.e. post-eradication.
Fig. 50: USA: Cocaine retail and whole sale prices,
1990-2002 (US$/gram)
Fig. 51: EUROPE: Cocaine retail and wholesale prices,
1990-2003 (US$/gram)
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The cocaine seizure trend was stable in 2002
Cocaine seizures remained stable in 2002, and were
some 10% less than in 1999, the latest peak year of
global cocaine production. After having increased dra-
matically, in tandem with cocaine production, in the
1980s, cocaine seizures have been stable to declining in
recent years, reflecting the global production trend.    
Trafficking remains concentrated in the Americas and,
to a lesser extent, in Western Europe
The bulk of cocaine continues to be seized in the Amer-
icas. In 2002, 55% of all cocaine seizures were made in
South America (including Central America and the
Caribbean), 32% in North America and 13% in Europe
(of which 99% were in Western Europe). 
While the trend has been stable/declining in North
America, increases have been reported from Western
Europe over the last decade  
The most striking trend in recent years has been the
strong increase in European cocaine seizures, reflecting
underlying shifts in trafficking. Although Europe's
record cocaine seizures of 2001 were not repeated in
2002, the proportion of cocaine seized in Europe (13%
of global seizures in 2002) was substantially higher than
in 1990 (6%) or in 2000 (8%). The increase in traf-
ficking went in parallel with rising levels of cocaine use
in a number of West European countries. Traffickers
appear to turning away from the saturated and high-risk
North American market to the lucrative, and possibly
less risky, West European market. 
2.2.2. Trafficking
1985 1990 1995 2000 2001 2002
Americas 97.80% 94.00% 92.80% 91.10% 83.00% 87.10%
Europe 2.10% 5.90% 7.00% 8.30% 16.30% 12.70%
Asia 0.09% 0.04% 0.04% 0.03% 0.32% 0.06%
Oceania 0.03% 0.04% 0.11% 0.41% 0.32% 0.03%
Africa 0.00% 0.02% 0.08% 0.12% 0.13% 0.15%
Total 100% 100% 100% 100% 100% 100%
Source: UNODC,  Annual Reports Questionnaire Data / DELTA.
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Fig. 53: Global cocaine seizures 1980-2002
Source: UNODC, Annual Reports Questionnaire Data / DELTA
Table 7. Distribution of cocaine seizures by region in % (1985-2001)
Fig. 54: Average* cocaine prices in North America and
Western Europe in 2002
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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A comparison of cocaine wholesale and retail prices sug-
gests that, from a trafficker's point of view, the Euro-
pean market is more attractive than the basically stable
US market.  The difference, however, has become less
pronounced over the last few years.   
Short-term trends are, however, similar in North Amer-
ica and Western Europe…
In both North America and Western Europe cocaine
seizures increased in 1999, fell in 2000, increased in
2001 and fell again in 2002. The decline in 2002 seems
to have been a consequence of two factors occurring in
parallel: an increase in coca eradication and more
enforcement action against cocaine trafficking in the
source countries. The total area under coca cultivation
across the Andean region fell by 18% in 2002. As most
of the eradication took place towards the end of the year,
the actual reduction in cocaine manufactured was much
less (-3%). More enforcement in South America, how-
ever, led to cocaine seizures rising by more than a fifth
in 2002, which, in turn, had an impact on global
cocaine availability.  Data collected among US students
also suggests that cocaine availability declined by 12%
between 2001 and 2003.    
… a consequence of strongly rising cocaine seizures in
the source countries in 2002
In the Americas, the relative importance of seizures in
the three source countries (Colombia, Peru and Bolivia)
increased significantly in 2002. In 2001 cocaine
(including cocaine base) seizures in the three countries
accounted for 28% of all cocaine seizures in the Amer-
icas; in 2002 this proportion rose to 44%. Seizures in
Colombia were the largest worldwide, even exceeding
those in the USA in 2002. Some of the seizures were
related to a large-scale destruction of cocaine manufac-
turing capabilities. Colombia dismantled 1,273 coca
base, 23 cocaine paste and 138 cocaine HCL laborato-
ries, which is by far the largest number of cocaine labo-
ratories destroyed worldwide.  As a result of these
events, seizures declined in the transit countries (notably
the Caribbean, Central America and Mexico) and the
main consumer markets of North America (USA and
Canada) and Europe.
Fig. 55: Cocaine seizures: North America and Western
Europe
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Fig. 56: Cocaine seizures in 2001 in the Americas
(N = 303 tons)
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Fig. 57: Cocaine seizures in 2002 in the Americas
(N = 316 tons)
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The main trafficking route continues to run from
Colombia to the USA 
The world's main cocaine trafficking route runs from
Colombia to the USA.  The cocaine is smuggled
through neighbouring countries, the Caribbean (on the
so called go-fast boats), Central America, or Mexico.
Some of it goes directly to the USA, either by air or by
boat to the east or west coast.  Venezuela, for instance,
reported that 72% of the cocaine it seized in 2002 was
destined for the USA, 14% for Mexico and the rest for
Europe (mainly the Netherlands). Central American
countries (Guatemala, Honduras) report that 80-85%
of their seized cocaine was destined for the USA. The
Caribbean countries report that 60-100% of the cocaine
transiting their territories was for the USA. The Mexi-
can authorities report that 90% of the cocaine they
seized was meant to go to the USA.
Colombian criminal organizations are still heavily
involved in smuggling cocaine from Colombia to the
United States. These organizations also control much of
the wholesale-level distribution in the North-East of the
USA. Over the last decade, however, Mexican traffick-
ing organizations have taken an increasing portion of
the market, smuggling the drug from Mexico across the
land border and controlling distribution networks
throughout the West and the Mid-West of the USA.
The primary entry points for cocaine in the USA are:
Miami, Houston and New Orleans for maritime ship-
ments and the South-West border states for land ship-
ments. Chicago has emerged as one of the key
distribution hubs for Mexican trafficking organizations,
while New York remains under the control of Colom-
bian organizations.
The situation is different for many of the countries
south of Colombia. The dismantling of cocaine labora-
tories reveals that cocaine-manufacturing capacities exist
not only in Colombia, but also in Bolivia, Peru,
Argentina, Chile and Venezuela. In Peru and Bolivia
most of the cocaine is of domestic origin (100% in Peru,
78% in Bolivia, with the remaining 22% of the cocaine
seized in Bolivia originating in Peru in 2002). The
authorities in Chile report that 43% of the cocaine they
seized came from Peru and 28% from Bolivia. In
Argentina, 60% of the cocaine is believed to have come
from Bolivia, 15% from Peru and only 25% from
Colombia in 2002. In Uruguay the proportion of
Colombian cocaine is apparently even lower: 70% of
the cocaine is reported to come from Bolivia, 15% from
Peru and 15% from Colombia. 
In contrast, Colombian cocaine dominates the markets
to the east of Colombia. In 2002, Venezuela reported
that all cocaine seized originated in Colombia. Brazil
estimated that about 70% of the cocaine originated in
Colombia, 20% in Bolivia and 10% in Peru (2000). In
Suriname about 60% of the cocaine seized in 2002
could be traced back to Colombia, 20% to Venezuela
and 20% to Brazil. Suriname is one of the few countries
in South America where the bulk of the cocaine seized
was not going to the USA (20%) but to Europe
(Netherlands 80%).   
Spain and the Netherlands continue to be Europe's
main entry points for cocaine…  
Throughout the last decade Spain and the Netherlands
reported the highest cocaine seizures in Europe; both
were also mentioned as important transshipment points
by most other European countries. Data for 2001 and
2002 confirmed this pattern. From exceptionally high
levels in 2001, cocaine seizures in Spain declined in
2002 to levels reported in the second half of the 1990s.
In the Netherlands, traditionally the second largest
entry point, seizures declined slightly in 2002. Measures
taken since early 2002 reduced the number of cocaine
couriers coming into Amsterdam airport. Despite these
declines the two countries together accounted for more
than half of all European cocaine seizures in 2002. Sig-
nificant increases in cocaine seizures in 2002 were
reported from Italy, France, Belgium, Germany and -
starting from low levels - the countries of Eastern
Europe. Italy recorded the third largest cocaine seizures
in Europe in 2002, slightly ahead of France, Belgium
and Portugaln.
… but direct cocaine imports to other countries are
rising
Direct overseas imports of cocaine play an important
role in supplying the European market. South American
groups are often involved in these shipments. Colom-
bia, followed by Peru and Bolivia, are the most fre-
quently mentioned source countries. Venezuela, Brazil
n) At the time of writing, these data do not include the UK as the country has not yet reported 2002 seizure data.  If it is assumed that seizures remained
roughly stable between 2001 and 2002, the UK's cocaine seizures would be slightly less than those reported by Portugal.   
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and, to a lesser extent, Ecuador, Suriname, Aruba, the
Netherlands Antilles and Jamaica have been mentioned
as significant overseas transit countries. Along with
Spain (reporting cocaine imports from all three coca
producing countries) and the Netherlands (often
obtaining cocaine via Suriname and the Netherlands
Antilles), significant direct imports from South America
in 2002 were also reported from Italy (from Colombia
and Venezuela), France (from Colombia and Peru), Bel-
gium (from Colombia) and Germany (from Colombia
and Ecuador). In most cases the role of the South-Amer-
ican trafficking groups stops once the cocaine has
entered Europe. 
Trafficking across countries within Europe is increasing
Cocaine trafficking across countries within Europe is
increasing. Most of the cocaine seized in Italy transited
Spain or the Netherlands.  The cocaine seized in the UK
is increasingly transiting Spain and France, following
some successes in dismantling networks that shipped it
directly from South America and the Caribbean.
French authorities reported that significant amounts of
the cocaine found on their market usually came through
the Netherlands; they also found that 44% of the
cocaine they seized in 2002 was actually destined for the
Netherlands.  Belgium reported that only 5% of the
cocaine seized was for the local market; 30% was des-
tined for the Netherlands and the rest for other EU
countries. Germany reported that significant amounts
entered the country via the Netherlands.  About two
thirds of the cocaine seized in Germany in 2002, how-
ever, was actually destined for Spain, with much of the
remainder intended for Italy. Austria reported that
cocaine entered its territory via Germany and via Serbia
& Montenegro and that most of it was destined for Italy
and the Netherlands.   
Prior to their entry into the EU, some of the new acces-
sion countries had already been integrated into Pan-
European trafficking networks. There have been direct
shipments of cocaine from South America to these
countries for re-export to other European countries. In
addition, the Polish authorities mentioned Turkey as an
important transit country for cocaine found on their
market, destined for Germany, the Netherlands and the
UK. The Czech Republic reported that its seized
cocaine frequently transited France and the Netherlands
with the final destination being Germany. Hungary
reported imports of cocaine via Austria, the Netherlands
and Spain, for final destinations in Italy. 
These trafficking patterns indicate that trafficking
routes within Europe have become highly diversified
and are now far less predictable than in previous years.
Another feature, reported from several countries of con-
tinental Europe, has been the increasing importance of
criminal groups of West African origin in the local dis-
tribution of cocaine (and other drugs). In the UK
groups originating in the Caribbean continue to play a
dominant role.  
Fig. 58: Cocaine seizures in Europe in 2001 and 2002
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Some trafficking to Europe is via Africa 
Between 1999 and 2002, there were a number of reports
from several African countries, including Nigeria, Togo,
Ghana, Gambia, the Republic of South Africa, Zim-
babwe, Swaziland, Tanzania, Kenya, and Uganda, that
South American cocaine was being transshipped via
their territory to Europe. The large number of countries
reporting seizures of cocaine in Africa indicates that traf-
ficking in cocaine is already widespread. From 1992-
2002, 52 African countries reported seizures of cocaine,
up from 24 countries over the 1980-1990 period. The
largest cocaine seizures over the 2000-2002 period were
reported from South Africa and Nigeria. While they
declined in South Africa in recent years, they increased
in Nigeria. 
Cocaine trafficking in Asia remains limited  
The trafficking of cocaine in Asia is still at a low level
(0.1% of global seizures in 2002). The number of Asian
countries reporting cocaine seizures rose, however, from
an average of 10 in the 1980s to 15 in the 1990s and 18
in 2002. Of all the cocaine seized in Asia in 2002, 70%
was in the Near and Middle East, notably Israel, Syria
and Lebanon. Japan and Thailand, followed by Hong
Kong SAR of China, and the Philippines reported the
highest cocaine seizures in East & South-East Asia.
There were also few attempts to manufacture cocaine in
the Asia region. Hong Kong SAR of China dismantled
two cocaine-manufacturing laboratories in 2001 and
another two in 2002. One cocaine-manufacturing lab-
oratory was dismantled in Thailand in 2001.  
Cocaine seizures declined in Oceania in 2002 
Cocaine seizures in Oceania fell by some 90% in 2002
(after having grown strongly since 1999), largely reflect-
ing declining seizures in Australia, the main cocaine
market in the region. Most of the cocaine in 2002 was
reported to have been shipped to Australia from Peru,
sometimes via Argentina. Smaller amounts were shipped
to Australia also via the UK and via the USA. The
cocaine market within Australia is largely concentrated
in New South-Wales, particularly in Sydney. 
Despite the decline, cocaine prices and purities
remained basically stable over the first two quarters of
2002 compared to previous quarters. This suggests
either that cocaine seizures in Oceania only amount to
a small fraction of supply and that changes do not have
a measurable impact, or that the fall in seizures was
prompted by a decline in supply and demand, leaving
prices unchanged. The analysis of blood test results of
police detainees seems to lend some support to the
second hypothesis, that the cocaine market actually
declined in 2002. Results from selected locations of
Sydney (Bankstown and Parramatta) show that 18%-
20% of police detainees tested positive for cocaine in
the third and fourth quarters of 2001. By the third quar-
ter of 2002, this rate had fallen to around 1.5%o.  What
prompted this shift is still not entirely clear. 
Cocaine interception rates continue rising 
Over the last two decades interception rates for cocaine
increased, from 37% of the cocaine produced over the
1986-95 period to 45% over the 2001-2002 period.
This suggests that law enforcement has become more
effective. 
The absolute level of the calculated interception rate
could be misleading, however, because it implicitly
assumes that cocaine has the same level of purity at the
production and the seizure stages.  This is not the case
in reality: cocaine is frequently produced at purity levels
of around 90%, while purity levels found in seizures
fluctuate, on average, around 60%p. Based on these
considerations, the purity adjusted interception rate of
cocaine in 2001-2002 is estimated to have been around
30%, up from less than 25% over the 1986-95 period.   
Fig. 59: Cocaine interception rate
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o) Australian Institute of Criminology, Drug Use Monitoring in Australia (DUMA), Drug Use Amongst Police Detainees.    
p) The US reported that the purity of cocaine found on their market was around 56% at the retail level and 69% at the wholesale level in 2002.
Similarly, the UK Customs and Excise reported that they seized cocaine at purity levels around 70% while the police seized it at average purity levels
of around 50% in 2002.                                                                                                         
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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*excluding seizures in liquid form
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2.2.3.1. Extent
Cocaine is the second most common problem drug in
the world and the main problem drug in the Americas.
In several countries of Western Europe, it is the second
or third most common problem drug.
Cocaine consumption is estimated to affect more than
13 million people or 0.3% of the population age 15-64.
Most cocaine continues to be consumed in the Ameri-
cas (65%), notably in North America (48%). The over-
all prevalence rate of cocaine use in the Americas is
1.6%. The single largest cocaine market in the world
continues to be the USA (5.9 million people in 2002,
equivalent to 2.5% of the population age 12 and above
or 3.1% of the population age 15-64). Cocaine use in
the countries of South America (including Central
America and the Caribbean) affects 2.3 million people
or 0.8% of the population age 15-64. Above average
levels of cocaine use are found in Argentina, Chile,
Colombia, Bolivia, Venezuela, Panama, Guatemala,
Jamaica, the Dominican Republic and some other coun-
tries of Central America and the Caribbean.
The 3.3 million cocaine users in Europe account for
about a quarter of global cocaine use (0.6% of the pop-
ulation age 15-64). More than 90% of Europe's cocaine
users are in Western Europe (1% of the population age
15-64). The highest cocaine prevalence rates in Europe
(age 15-64) have been reported from Spain (2.6% in
2001),  Ireland (2.4% in 2002),  the UK (2.1% in
2003)  and the Netherlands (1.1% in 2001).
In Oceania the level of cocaine use is 1.1% of the pop-
ulation age 15-64. Most cocaine use in this region takes
place in Australia (1.5% of the population 15-64 in
2001).
In all other regions, cocaine use is below the global aver-
age of 0.3%.  The lowest level of cocaine use is in Asia.
Cocaine use in Africa is largely linked to spill-overs of
cocaine being shipped from South America via Africa to
Europe. Concentrations can be identified in South
Africa and in some countries of Western Africa. 
Importance of cocaine use compared to other drugs
Most countries in the Americas see cocaine as the
second or third most widely used illicit substance in
their territories. In most countries of Western Europe,
cocaine is the third most widely consumed drug after
cannabis and the ATS. Cocaine is of less importance in
the Nordic countries and in  most of the new EU
member states or candidate countries where it ranks 4th
to 6th. In the C.I.S. countries, including the Russian
Federation,  it is of less importance.  The same applies
to a number of Asian countries. In Western and South-
ern African countries, in contrast, its relative impor-
tance is significantly higher.  
2.2.3. Abuse
Number of  people in % of  population
(in million)  age 15 - 64
AMERICAS 8.70 1.57
- North America 6.38 2.30
- South America 2.32 0.84
OCEANIA 0.21 1.05
EUROPE 3.34 0.62
- West Europe 3.11 1.01
- East Europe 0.23 0.10
AFRICA 0.94 0.21
ASIA 0.15 0.01
GLOBAL 13.34 0.34
            Cocaine abuse above global average
            Cocaine abuse below global average
Table 8:     Annual prevalence estimates of cocaine use: 2001-2003
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
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> 1-1.5% of  population
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> 0.1 - 0.5%  of  population
Main cultivation areas
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Level of abuse (Annual  Prevalence)
> 1.5-2% of  population
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Data not available
Map 12: Use of cocaine 2001 - 2003 (or latest year available)
Map 13: Ranking of cocaine in order of prevalence in 2002
(1993)
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Sources: UNODC Annual Reports Questionnaires data, SAMSHA US National Household Survey on Drug Abuse, Council of Europe, ESPAD.
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2.2.1.2. Trends
Spread of cocaine expansion loses momentum  
Throughout the 1990s and in subsequent years there
have been more countries reporting increases in cocaine
use than countries reporting declines. The spread of the
cocaine expansion, however, is loosing momentum. In
2002,  there was a decline in the number of countries
reporting increases (from 49 to 42) and an increase in
the number of countries reporting falling levels of
cocaine use (from 6 to 13). While in 2001 57% the
countries reporting cocaine consumption trends saw an
increase, this proportion declined to 46% in 2002. In
other words, more than half of all countries (54%) saw
cocaine use levels stabilize or decline in 2002. 
AMERICAS
Largely stable in North America 
In terms of regional patterns, the use of cocaine appears
to have been basically stable in North America. The
annual prevalence of cocaine use in the USA was 2.5%
of the population age 12 and above in 2002. Cocaine
use is rather evenly spread across the USA, with the
highest levels found in the state of New Mexico, some
of the neighbouring states and a few states on the East
coast. Cocaine use remains primarily an urban phe-
nomenon (2.5%-2.9% versus 1.4% in rural areas).
Local concentrations -- as reflected in cocaine related
emergency room visits (2002) -- are found in Chicago,
Philadelphia, Baltimore, Miami, Atlanta, Newark,
Detroit, Buffalo and New York. 
Given changes in the methodology, the results of the
2002 survey are not directly comparable with previous
household surveys. The results (5.9 million people using
cocaine, equivalent to 3.1% of the population age 15-
64) are, however, in line with previous estimates of the
overall (chronic and occasional) cocaine abusing popu-
lation in the USA produced by the Office of National
Drug Control Policy (3.1% of the population age 15-64
in 2000, down from 4.8% in 1990 and 6% in 1988). 
The Monitoring the Future study, conducted among
US high school students, found a marginal  increase in
the annual prevalence rate of 12th graders in 2002 and
a marginal decline in 2003. The prevalence rate of
cocaine use amounted to 4.8% in 2003 and was thus
more than 20% lower than in 1999 (6.2%) and more
than 60% lower than in 1985 (13.1%). 
Fig. 62: Cocaine consumption trends, 1993 - 2002 
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Fig. 63: Cocaine consumption trends in 2001
(n =65)
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Fig. 64: Cocaine consumption trends in 2002
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Canada reported a stabilization of cocaine use in 2002.
Trends observed in 2003 show a more complex pattern.
Student surveys undertaken in Canada's largest
province of Ontario (which accounts for 38% of
Canada's total population) found a stabilization of
cocaine use among 11th graders in 2003, a decline
among 8th and 10th graders, but increasing levels
among 7th,  9th and 12th graders. The net result of
these opposing trends was an increase. Cocaine use
among high-school students in Ontario is now back to
the levels observed in the late 1970s. Prevalence rates of
cocaine use among high-school students in Ontario are
Fig. 65: Cocaine use in the USA: 1985-2003 annual prevalence rates among the general population, age 12 years
and above, and among high-school students (12th graders)
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Fig. 66: Cocaine use among high-school students in Canada (Ontario) and in the USA
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now higher than in the USA, reversing the previous pat-
tern which, until 1999, had shown higher levels of
cocaine use among US high school students.      
A recently published household survey in Mexico
showed not only that the overall level of cocaine use in
that country  (0.4% of the general population age 12-
65  in 2002) was still significantly lower than in the
USA, but that cocaine use - in contrast to previous peri-
ods - remained basically stable over the 1998-2002
period (showing a statistically non-significant decline
over this period).  Most of the cocaine use in Mexico is
concentrated in the northern states. 
Trends in Southern America show an ongoing rise in
cocaine use 
In contrast to a stable trend in North America,
UNODC's Drug Abuse Trend Index showed an ongo-
ing  increase of cocaine use in the rest of the continent.
In 2002, fourteen countries reported an increase,  eight
a stablization and two a decline. The number of coun-
tries reporting increases less those reporting declines
(12) was, however, lower than a year earlier (19). 
In Brazil, the largest country in the region, a compre-
hensive national household survey was conducted for
the first time at the end of 2001. It revealed an annual
prevalence of cocaine use of 0.4% of the population age
12-65 (including 0.1% for crack cocaine),  similar to
the level in Mexico but less than in Chile (1.6% in
2002) or in Argentina (1.9% in 1999). Life-time preva-
lence of cocaine use amounted to 2.3%, suggesting that
about 1 million people had experimented with this
drug. Cocaine use is high in southern Brazil (3.1%) and
in south-eastern Brazil (2.6%) which includes the state
of Sao Paulo. Two years earlier, a household survey con-
ducted in the state of Sao Paulo revealed a cocaine life-
time prevalence of 2.1%, suggesting that cocaine use
had increased in south-eastern Brazil and thus, most
probably, in Brazil as a whole. (Two thirds of all Brazil-
ian cocaine users live in the highly populated areas of
south-eastern Brazil).   
Cocaine use in Colombia, the main cocaine producing
country in the region, seems to be significantly higher
than in Brazil and is also increasing. Studies among
youth in Colombia (age 10-24) showed a life-time
prevalence rate of cocaine use of 4.5% in 2001, up from
3.6% in 1999. Use of 'basuco' (a byproduct in the man-
Source: Instituto Nacional de Estadística, Geografía e Informática
(INEGI) y la Secretaría de Salud, Encuesta Nacional de Adicciones
2002,  Mexico City, March 2004. 
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Fig. 67: Mexico: cocaine use among the general
population
Source: Instituto Nacional de Estadística, Geografía e Informática
(INEGI) y la Secretaría de Salud, Encuesta Nacional de Adicciones
2002,  Mexico City, March 2004. 
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Fig. 68: Life-time prevalence of cocaine use in Mexico
in 2002
Fig. 69: Cocaine consumption trends in Southern
America, Central America and the Caribbean,
based on national experts' perceptions
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ufacture of cocaine), however,  declined. For 2002, the
Colombian authorities reported a further rise in cocaine
use, of both powder cocaine and crack-cocaine.  While
treatment demand, in general (including for basuco)
remained stable, cocaine-related treatment demand con-
tinued to rise in Colombia in 2002.
Increases in cocaine use in 2002 were also reported from
neighbouring Venezuela and Panama as well as from
Argentina, Paraguay and in the Caribbean region from
Haiti and the Dominican Republic. 
There are, however, also some positive trends. Cocaine
use in Chile - after having grown strongly in previous
years - stabilized at less than 1.6% of the general popu-
lation (age 12-64) between 2000 and 2002.  Use of coca
paste declined. This stabilization appears to be the result
of increased demand reduction efforts and is probably
associated with the lower levels of coca production in
Peru and Bolivia as compared to the late 1990s.  
Fig. 70: Brazil, life-time prevalence of cocaine use
among the general population (age 12-65) in
2001
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Fig. 72: Brazil, cocaine consumption trends, 1987-
2001
Sources: CEBRID, I Levantamento Domicilia Sobre O Uso de Drogas Psicotrópicas no Brasil 2001 and CEBRID, I Levantamento domiciliar
Nacional Sobre O Uso de Drogas Psicotrópicas - Estudo envolvendo as 24 Maiores Cidades do Estado de São Paulo 1999, CEBRID, IV
Levantamento Sobre O Uso de Drogas entre Estudantes de 1e 2e graus em 10 Capitais Brasileiras, 1997. 
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Fig. 71: Colombia: cocaine use among youth (age 10-
24)
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Fig. 73: Chile: Annual prevalence of cocaine  and coca
paste use in the general population (age 12-
64), 1984-2002 
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Similarly, cocaine consumption stabilized in Peru over
the 1998-2002/2003 period and is now lower than in
1997. Use of coca paste ('pasta basica'), an intermediate
product in the manufacture of cocaine,  declined signif-
icantly over the 1998-2002/2003 period. Annual preva-
lence of cocaine use affected 0.7% of the population age
12-64 in 2002/03. This is a higher percentage than in
Brazil (0.4% in 2001) but less than in neighbouring
Bolivia (1.1% of the  urban population age 12 and
above in 2000) or in neighbouring Chile (1.6% of the
population age 12-64 in 2002).  Annual prevalence of
the use of coca paste in Peru fell to  0.7% of the general
population in Peru in 2002/03 and is now less than in
Bolivia (1.1%) but still more than in Brazil (less than
0.1%) or in Chile (0.5%). 
Studies in Bolivia also showed that, following strong
increases during the 1990s, a stabilization of cocaine use
took place over the 1998-2000 period, i.e. at the time
when coca production in the country declined.  Unfor-
tunately, no new epidemiological surveys have been
undertaken which would reveal whether the stabiliza-
tion continued in subsequent years. 
Cocaine use continues to rise in Europe, though at a
lower pace than in previous years 
UNODC's  Drug Abuse Index showed a strong rise of
cocaine use over the last decade. The overall increase in
the 1990s appears to have been similar to that observed
in South America (incl. Caribbean and Central Amer-
ica). Over the last two years, however, signs of stabiliza-
tion have occurred. While in 2000 the number of
European countries reporting increases less those report-
ing stable or declining trends was 5, this number fell to
1 in 2001 and to -4 in 2002.
This positive development, however, has been partially
offset by the emergence of crack-cocaine, a particularly
dangerous form of cocaine (often associated with vio-
lence and crime) in several European markets over the
last few years. Out of 29 European countries reporting
on cocaine, 16 countries had already provided informa-
tion on trends in abuse of crack-cocaine in 2002 (two
thirds of these were located in Western Europe). Seven
countries saw an increase in crack-cocaine use,  7 coun-
tries reported no great change and 2 saw a decline.
Crack cocaine is still concentrated in a few locations in
Europe, but there is a risk that, once established in local
markets, it could spread across the continent.      
The general upward trend in the use of cocaine over the
last decade in Europe is well documented in a number
Fig. 74: Peru: Cocaine use among the urban
population, age 12-50, 1995-2001
Fig. 75: Peru: Cocaine use among the general
population, age 12-64, 1998-2002/03
Source: CEDRO, Epidemiologia de Drogas en la Población Urbana
Perruana 2001.
1.7% 1.8%
3.9%
2.1%
0%
1%
2%
3%
4%
1998 2002/2003
Cocaine Pasta basica
Fig. 76: Cocaine consumption trend in Europe (based
on national experts' perceptions)
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of household and student surveys across the continent,
including those conducted in Spain, the Netherlands,
Switzerland, France and Ireland.     
Most of the increase of cocaine use in 2002 was found
in south-western Europe, including Spain, France, the
Benelux countries, Italy, Switzerland and Austria, as well
as in south-eastern Europe (most Balkan countries). 
In much of the rest of Europe, cocaine use was reported
as stable in 2002. This was the case in Germany and the
UK  -  following years of large increases -,  as well as in
Sweden, Finland and in most of the new EU member
states. Declines in the use of cocaine in 2002 were
reported from Hungary and Ukraine. 
Fig. 77: Annual prevalence of cocaine use in Spain
among the general population (age 15-64,
1995-2001
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Source: EMCDDA, Data Library. 
Fig. 78: Ireland: Cocaine use among the general
population age 18 and above
Source: Centre for Health, Promotion studies, The National Health
and Lifestyles Surveys, April 2003.
Fig. 79: Netherlands: Cocaine use in general
population and admissions to outpatient
drug treatment with cocaine as primary
problem, 1990-2001
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Fig. 80: Cocaine use in France
Sources: Trimbos Instituut, National Drug Monitor - National
Report 2003 and 2002 and EMCDDA, Data Library
Fig. 81: Switzerland, cocaine use among 15-16 year
olds
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Source: SFA/ISPA, Trends im Konsum  psychoaktiver Substanzen
von Schülerinnen und Schülern in der Schweiz, Lausanne 2003.
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AFRICA
Signs of stabilization following years of increase
Following years of increases, UNODC's Drug Abuse
Trend Index showed signs of a stabilization of cocaine
use in Africa in 2002. Out of 14 African countries
reporting  cocaine consumption trends in 2002,  6 expe-
rienced an increase, 6 a decline and 2 reported no great
change.  Reported data over the 2000-2002 period indi-
cate that cocaine use is now encountered in all sub-
regions of the continent. There are locations within
some Western and Southern Africa countries where
prevalence is particularly high, mostly in urban areas.  
South Africa remains one of the main cocaine markets
in Africa, although a decline of cocaine use was noticed
for 2000, 2001 and  2002. These declines followed years
of large increases in the 1990s. Slightly less than 6% of
all treatment demand in South Africa is now related to
the abuse of cocaine, which is down from 8% in 1999.
In 2003, cocaine abuse levels appear to have remained
largely stable. Cape Town and Gauteng (Johannes-
burg/Pretoria region), followed by Durban, continue to
be the main cocaine markets in South Africa. 
Treatment data from other SADC countries, collected as
part of the SENDU project (SADC Epidemiology net-
work on Drug Use), also show some decline of cocaine
use. In Namibia, which saw an increase in cocaine use
in 2002, as compared to a year earlier, the proportion of
people treated for cocaine abuse actually declined from
6% in the first half of 2002 to 3% in the first half of
2003. In Botswana, the proportion fell from 0.5% to
0% over the same period. In Mozambique,  it declined
from 0.9% (second half of 2002) to 0% in the first half
Fig. 82: Italy: Cocaine use among high-school
students, age 15-19 year olds
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Fig. 83: Germany: Annual prevalence of cocaine use
among 18-59 year olds and newly identified
cocaine users 
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Fig. 84: England and Wales: Annual prevalence of
cocaine use in the UK in the general
population (age 16-59)
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Source: UK Home Office, Prevalence of Drug Use: Key findings
from the 2002/2003  British Crime Survey,  and previous years.
Fig. 85: Cocaine consumption trend in Africa: 
based on national experts' perceptions 
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Source: UNODC, Annual Reports Questionnaire Data.
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of 2003. No people treated for cocaine abuse were
reported from Lesotho,  Malawi or Mauritius. 
In eastern Africa (Tanzania, Kenya, Somalia, Rwanda)
the authorities reported either stable or falling levels of
cocaine use in 2002.   
Reported trends in western Africa were more mixed.
While Cameroon and Togo saw a rise in cocaine use in
2002 (like Benin and Gambia a year earlier), Ghana saw
no great change and authorities in Côte d'Ivoire per-
ceived that cocaine use declined.   
A mixed picture was also reported from northern Africa.
While Tunisia reported an increase, Morocco saw a
decline of cocaine use in 2002. Subsequent reports sug-
gest that cocaine use in Morocco may have increased
again in 2003, mainly among youth of the country's
upper class. 
ASIA
Cocaine use remains low, but increases are seen in the
Near East and in South Asia while cocaine use in East
and South-East Asia shows stable or declining trends  
Some increase in cocaine use has been reported in recent
years from the Near East as well as from South Asia.
Cocaine use in East and South-East Asia,  in contrast,
has remained stable or is declining,  probably a conse-
quence of the popularity of methamphetamine in this
region. (Methamphetamine is abundantly available, rel-
atively cheap and is used as a potential substitute for
cocaine). In 2002, Syria and Saudi Arabia reported
increases in the use of cocaine, as well as India and
Bangladesh. All other Asian countries reported either
stable or declining trends in 2002. 
Overall cocaine use in Asia, however, continues to be
limited. Despite increases reported from India, the
world's second most populous country, recent studies
have not found cocaine to be among the main sub-
stances abused. As drugs with a life-time prevalence of
at least 0.1% were investigated, it can be assumed that
life-time prevalence of cocaine use among the general
population must be still less than 0.1% in India (and
other Asian countries). However, data from India's
Drug Abuse Monitoring System  (DAMS) found that,
for 2000, 1.7% of all treatment demand was already
related to cocaine abuse -- mainly concentrated in the
state of Maharashtra (which includes Mumbai/former
Bombay), the neighbouring state of Madhya Pradesh
and in Uttar Pradesh (neighbouring Madhya Pradesh).   
Reports from Thailand suggest that cocaine use is
mainly encountered in tourism centres and that it is
linked to the entertainment sector. It is mainly perceived
to be one among a number of 'club drugs'. Cocaine is
still less easily available than methamphetamine or opi-
ates. Domestic use by Thai people appears to be still
limited to some experimental use by a few upper class
people attending night clubs. Similar patterns are also
found in several other Asian countries. 
Fig. 86: South Africa*: People in treatment for cocaine/crack abuse as a proportion of all treatment for
substance abuse, including alcohol, 1996-2003 
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OCEANIA
After massive increases in the 1990s cocaine use has sta-
bilized in recent years 
Cocaine use in Oceania is mainly concentrated in Aus-
tralia and, within Australia, in New South Wales
(notably in Sydney). Household survey data showed
almost a tripling in the number of cocaine users between
1993 and 1998, followed by a marginal decline of
cocaine use over the 1998 to 2001 period (from 1.4%
to 1.3% of the general population age 14 and above).
Following a temporary rise in 2001, cocaine consump-
tion fell  back to the levels seen in 2000
Trends for 2001 and 2002 can be deduced from other
indicators. They all show an increase in cocaine use in
2001, mainly reflecting the heroin drought of 2001 and
thus some shifts into cocaine (and methamphetamine),
followed by a decline in 2002. The Drug Use Monitor-
ing in Australia (DUMA) data, for instance, revealed
that the proportion of male police detainees testing pos-
itive for cocaine in four sites across Australia
(Bankstown, Parramatta, South Port and East Perth)
increased from, on average, 2.4% in 2000 to 6.6% in
2001, but declined again to 3.1% in 2002. Based on
interviews among injecting drug users (IDUs), the Illicit
Drug Reporting System (IDRS), found that the pro-
portion of IDUs taking cocaine rose from 24% in 2000
to 35% in 2001, but fell again to 27% in 2002.    
The increase in 2001 and the fall of cocaine use in 2002
do not appear to have been caused by changes in cocaine
availability. Cocaine prices remained largely stable and,
importantly,  cocaine availability was also perceived by
drug users to have remained largely stable in 2002.
Cocaine purity, however, appears to have declined in
2002q.
q) National Drug and Alcohol Research Centre (NDARC), Australian Drug Trends 2002  - IDRS - Findings from the Illicit Drug Reporting System
(IDRS), NDARC Monograph No. 50,  Sydney 2003.
Fig. 87: Cocaine consumption trend in Asia 
(based on national experts' perceptions)
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 88: Percent testing positive for cocaine among
police detainees* in Australia, 1999-2002
Fig.89: Annual prevalence of cocaine use in Australia
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Source: AIHW, Statistics on Drug Use in Australia 2002, Canberra
2003.Source: Australian Institute of Criminology, "Drug Use Monitoring
in Australia (Duma) Collection 1999-2002".
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2.3.1.1.  Cannabis herb
Production is globally dispersed 
Over the 1992-2002 period, 79 countries provided
UNODC with cannabis production estimates, indicat-
ing that cannabis production took place on their terri-
tory. The total number of cannabis producing countries
is, however, still larger. Ninety four countries providing
information on the origin of  seized cannabis herb cited
82 different source countries for the year 2002. Over
the 1998-2002 period, 111 cannabis herb source coun-
tries were identified with this approach. If cannabis
plant seizures are used as an indicator of domestic
cannabis production (the plant as such is not usually
shipped across borders), 124 source countries over the
1998-2002 were identified, or 142 source countries over
the 1992-2002 period. 
Based on the number of countries which provided
cannabis production estimates and cannabis plant
seizures to UNODC, data suggest that the majority of
cannabis source countries are located in the Americas.
The largest number of countries cited as a source for
cannabis herb by other countries are, however, found in
Africa.  At the same time, data also show that the
cannabis source countries are distributed across the
world fairly evenly, clearly showing that cannabis pro-
duction is a truly global problem. 
Nonetheless, some concentrations can be identified.
North America seems to be the world's largest cannabis
market, accounting for 2/3 of global cannabis herb
seizures over the 2001-2002 period. US authorities
report that two thirds of cannabis herb is domestically
produced. Out of cannabis herb imports into the USA,
63% came from Mexico and 23% from Canada in
2002. Mexico reported that  95% of the cannabis herb
on its market came from domestic sources; 5% was
imported from Guatemala. The Canadian authorities
reported all seized cannabis herb as having originated
from domestic sources.   
In South America, Colombia is a main source country
(for Venezuela and several other countries in the Amer-
icas).  In addition, Paraguay seems to play a key role in
supplying the markets of Brazil, Argentina (99%),
Uruguay (100%) and Chile (79%).  Local production
also takes place in all of these countries. Jamaica is fre-
quently mentioned as a major source country in the
Caribbean region. In addition, significant levels of
2.3. Cannabis market
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Fig. 90: Spread of cannabis production around the
world
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Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
domestic cannabis production seem to take place in
other countries of the Caribbean region as well. Practi-
cally all of the Central American countries are men-
tioned as major source countries for cannabis herb
within Central America. 
Cannabis production in Africa is reported from practi-
cally every country. There are also important move-
ments of cannabis herb across borders in Africa.
Significant source countries in central and western
Africa are - inter alia - Ghana,  Nigeria, Cameroon,
Côte d'Ivoire, the Democratic Republic of Congo,
Congo and Senegal; in southern Africa: the Republic of
South Africa, Malawi, Lesotho, Swaziland and Zambia;
in eastern Africa: Tanzania, Uganda and Kenya;  and in
northern Africa: Egypt and Morocco.  Cannabis herb
exports to Europe are mainly from countries in Western
Africa (notably for exports to France) and from the
Republic of South Africa (notably for exports to the
UK,  Ireland and Belgium).  
Most countries in Europe also report domestic produc-
tion of cannabis. The most frequently cited source
country in Europe is Albania which supplies most coun-
tries in the Balkan region (Bulgaria, FYR of Macedonia,
Serbia and Montenegro, Croatia) as well as Greece, Italy,
Slovenia, Austria and Sweden. The Netherlands was the
second most frequently cited source country in Europe
in 2002. In addition, criminal groups importing
cannabis herb from the Russian Federation were identi-
fied as the main source of the cannabis herb by several
East European countries. The Central State Drugs
Committee of the Russian Federation estimated, how-
ever, that only 30% of the cannabis herb on its market
was of Russian origin; 70% was from Kazakhstan.  
In Central Asia all of the countries reported cannabis to
have been of domestic origin, with Russia being the
main export market. In the countries of the Near and
Middle East,  Lebanon and Egypt were identified as the
main source countries. Lebanon was also the main
source for cannabis found in Turkey. The main source
country in South Asia is India. The main source coun-
tries in South-East Asia are Cambodia, Thailand and the
Philippines. With regard to cannabis herb exports from
South-East Asia to Europe, Thailand was most fre-
quently mentioned in 2002. 
Most of the cannabis herb in the Oceania region is of
domestic origins.  In addition, North America  (33% of
imports) and the UK (20% of imports) were mentioned
as source countries. 
Production has been rising and may have reached some
32,000 tons in 2002
Previous UNDCP estimates for the mid 1990s sug-
gested that global cannabis production (cannabis herb
and cannabis resin, expressed in cannabis herb equiva-
lents) was around 30,000r tons.  More recent estimates
seem to confirm these orders of magnitude, though
showing slightly higher figures. 
According to US government estimates cannabis herb
production outside the USA was around 15,400 tons in
2002, up from 11,200 tons in 1999s. Annual produc-
tion of marijuana in the USA was estimated by the US
authorities to amount to more than 10,000t tons  in
2001/2002. This would result in a global cannabis herb
production of more than 25,000 tons. This includes an
estimate for cannabis herb production of 3,500 tons for
countries other than the USA, Mexico and Colombia.
The latter estimate, however, appears to be rather con-
servative. US authorities also reckon that "there may be
considerable amounts of undetected cannabis cultiva-
tion in Central and East Asia, and on the African con-
tinent.u" Estimates provided by member states over the
last few years to UNODC suggest that the latter figure
could be substantially higher, probably close to 9,000
tons (still conservatively estimated). Global cannabis
herb production could thus amount to some 32,000
tons.  (This is a tentative estimate which could change
substantially as more information becomes available). 
If available estimates from various sources are com-
bined, data show a strong decline of cannabis herb pro-
duction over the 1989-1992 period,  followed by an
increase over the subsequent decade so that global
cannabis herb production in 2002 has again reached
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r) UNDCP, “Cannabis as an Illicit  Narcotic Crop:  A review of the Global Situation of Cannabis Consumption, Trafficking and  Production" in
UNDCP,  Bulletin on Narcotics, Double Issue on Cannabis: Recent Development, Vol XLIX No. 1 and 2, 1997 and Vol. L, Nos. 1 and 2, 1998, pp.
45-83.
s) Department of State, International Narcotics Control Strategy Report,  March 2003.  
t) ONDCP, National Drug Control Strategy,  February  2003, p. 30. 
u) A survey conducted in 1998 in Kazakhstan revealed a (minimum) harvest of 1,517 tons (though the potential harvest could have been as high as
148,000 tons). The (minimum) production in Kyrgyzstan amounted to 677 tons (with a potential production of 4250 tons).  Paraguay reported
the production of  1,415 tons (1998), the Philippines 1,353 tons (2000), Brazil 1,110 tons (2000); India 663 tons (1998), Indonesia 512 tons
(1997), South Africa 467 tons (2002), Lebanon 218 tons (2000), Swaziland 210 tons (2001), Nigeria 200 tons (1999), Malawi 175 tons (2000),
Guatemala 150 tons (2000), Kenya 130 tons (1999), the Russian Federation 90 tons (1999), Honduras 52 tons (2002), Thailand 25 tons (1997),
Tanzania 22 tons (1992), Uganda 21 tons (1999), etc.
levels similar to the late 1980s. It may also be interest-
ing to note that the trend of global cannabis herb
seizures exhibits a very similar pattern over the same
period.
A global production of 32,000 tons of cannabis herb
would result in a global interception rate of 15%. An
estimate of 32,000 tons is thus probably a minimum
estimate. A production any lower than this would mean
an even higher interception rate - which does not seem
to be very likely in the case of cannabis. An estimate of
32,000 tons would be equivalent to an average annual
consumption of around 220 grams of cannabis herb per
cannabis user. 
It should be noted that the current production estimates
do not tally with consumption estimates for individual
countries. Supply side estimates for the USA, for
instance, see a cannabis herb market (including imports)
of close to 18,000 tons (range: 10,000 to 24,000 tons)
for 2001/2002, consisting of a domestic production of
more than 10,000 tons and imports of more than 7,000
tons. Consumption based estimates see a cannabis herb
market of around 1,000 tons for the USAv.  Thus far,
this discrepancy has not been resolved.  
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Sources: United States Department of State, International Narcotics Control Strategy Report,  March 2003, Drug Availability Steering
Committee, Drug Availability Estimates in the United States, December 2002, Office on National Drug Control Policy,  National Drug
Control Strategy,  February  2003, UNODC, Annual Reports Questionnaire Data.
Country mid range estimates
USA* 11,150 5,577 16,731
Mexico 7,900
Colombia 4,000
Others (conservative estimate) 3,500
Sub-total (based on US estimates) 26,550 20,900 43,300
Others (not included above) 5,500
Total (rounded) 32,000
range:
Table 9: Cannabis herb production in 2002 in metric tons
Fig. 91: Global cannabis herb production estimates,
1988/89 - 2002
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Sources: United States Department of State, International
Narcotics Control Strategy Report,  March 2003, Drug Availability
Steering Committee, Drug Availability Estimates in the United
States, December 2002, Office on National Drug Control Policy,
National Drug Control Strategy,  February  2003, UNODC, Annual
Reports Questionnaire Data.
Fig. 92: Global cannabis herb seizures, 1989-2002
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Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
v) Drug Availability Steering Committee, Drug Availability Estimates in the United States, December 2002.
2.3.1.2.  Cannabis resin
Global cannabis resin production is concentrated in
Morocco as well as in Pakistan and Afghanistan
Over the period 1999-2002, Morocco followed by Pak-
istan and Afghanistan were the most often cited source
countries for cannabis resin.  In Western Europe, the
world's largest cannabis resin market, where more than
two thirds of all cannabis resin seizures were made in
2002, about 80% of the cannabis resin is estimated to
originate in Moroccow. The Near and Middle
East/South-West Asia region accounted for more than
20%  of all cannabis resin seizures in 2002.  The main
source countries for this region are Pakistan and
Afghanistan.
Other important source countries identified are India,
Lebanon, Albania, the Central Asian countries (notably
Kazakhstan and Kyrgyzstan), Nepal, a number of
African countries and the Russian Federation. The only
country in the Americas cited as an important country
of origin for cannabis resin is Jamaica. In addition to the
countries mentioned above, a significant number of
European countries identified Spain and the Nether-
lands as the countries where criminal groups obtained
their cannabis resin. 
In 2003, UNODC and the Government of Morocco,
conducted the country's first comprehensive cannabis
resin survey. The survey revealed a potential production
of cannabis resin of 3,080 tons (out of 47,400 tons of
cannabis plant material), produced on some 134,000
hectares of land in the Rif region by some 96,600 fam-
ilies.   
These are substantial amounts. For comparison, previ-
ous UNDCP surveys on cannabis production, con-
ducted in Central Asia (1998) revealed a cannabis resin
production of 53 tons (on 2,500 ha) in the Shuy valley
of Kazakhstan and of 24 tons in Kyrgyzstan (on 770
ha), suggesting that cannabis resin production in Cen-
tral Asia is less than 100 tons a year. 
Based on the Moroccan results and an analysis of global
cannabis resin seizure data, a tentative estimate of global
cannabis resin production can be made. Available data
for 2002 suggest that about 60% of seized cannabis
resin was of Moroccan origin. (The same percentage is
also obtained if the analysis is extended to the 1992-
2002 period). Global cannabis resin production could
thus be estimated at around 5,100 tons.  
However, this is a conservative estimate. The intercep-
tion rate of cannabis resin in Western Europe (where
most of the Moroccan cannabis resin is seized) is prob-
ably higher than in other parts of the world. It is there-
fore likely that the proportion of Moroccan cannabis is
less than the proportion of Moroccan cannabis inter-
cepted. Consequently, it would be reasonable to assume
that global cannabis resin production is higher than
5,100 tons.  Indeed, a comparison of  cannabis herb and
resin seizures shows that in 2002 (as well as over the
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Fig. 93: Main source countries of cannabis resin, 1999-
2002 (based on information from 85
countries)
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Afghanistan
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number of times countries were identified as source 
countries, as a proportion of countries reporting 
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
w) Most of Europe's cannabis resin originates in Morocco, accounting for some 80% of West Europe's cannabis resin imports. France, for instance,
reported that 82% of the cannabis resin found on its market in 2002 originated in Morocco. Belgium saw 80% to come from Morocco, Sweden
85%, the Czech Republic 70%; Spain, Italy, Denmark, Finland and Ireland reported that almost all of the cannabis resin originated in Morocco.
Authorities in the UK reported that the bulk of the cannabis resin found on the UK market is shipped from Morocco via the Iberian Peninsula,
France and the Benelux countries to the UK. Similarly, the German authorities see the bulk of the cannabis resin to have originated in Morocco and
to have transited Spain and the Netherlands before arriving in Germany. 
1998-2002 period)  cannabis resin seizures amounted to
23% of cannabis herb seizures. Applying the estimate of
32,000 tons for cannabis herb, the corresponding pro-
duction figure for cannabis resin could be around 7,400
tons. Based on this estimate Morocco would account for
some 40% of global cannabis resin production, but less
than 10% of global cannabis herb and resin production
taken together.       
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Table 10: Tentative estimates of global cannabis resin  production, 2003   
Western Europe 732 80% 585
North Africa 71 90% 64
Seizures related to Moroccan cannabis resin 649
Global seizures 1,073
  in % 60%
Cannabis resin production in tons 60% 3,080
Estimate of global cannabis resin production, rounded 5,100
Cannabis seizures in tons (2002 data ) 4,741 1,076 23%
Cannabis production estimates, rounded 32,000 23% 7,400
Sources: UNODC, Annual Reports Questionnaire Data 
Seizures in tons 
(2002)
Cannabis resin 
production in 
tons
Cannabis resin
Cannabis resin 
production in 
tons
2. Estimate based on cannabis herb estimates and seizures 
Cannabis herb  Proportion
1. Estimate based on Moroccan cannabis resin production and seizures 
Estimated proportion 
related to cannabis 
resin originating in 
Morocco
Potential seizures 
related to Moroccan 
cannabis in tons
Cannabis is the most extensively trafficked drug world-
wide
The two cannabis products, cannabis herb (marijuana)
and cannabis resin (hashish) remain the most exten-
sively trafficked drugs worldwide. Practically all the
countries of the world are affected by cannabis traffick-
ing.  Seizures of cannabis exceed those of other drugs in
almost all countries. In 2002, a total of some 5,800 tons
of cannabis products were seized globally.  This total
includes more than 4,700 tons of cannabis herb, more
than 1,000 tons of cannabis resin and more than 1 ton
of cannabis oil.  The volume of seized cannabis products
was more than 15 times the volume of cocaine and more
than 100 times the amount of heroin seized. 
Cannabis herb seizures were stable but cannabis resin
seizures rose in 2002 
The upward trend in cannabis seizures, which began in
the early 1990s, continued in 2002. Cannabis herb
seizures remained generally stable, but cannabis resin
seizures increased in 2002, offsetting the decline
reported the previous year. Overall cannabis seizures
were almost twice as high in 2002 as a decade earlier.  
Cannabis seizures concentrated in the Americas and in
Africa
Over the 2001-2002 period, 55% of all cannabis
seizures were reported from the Americas, 20% from
Africa, 16% from Europe, 9% from Asia and less than
1% from Oceania. In 2002 cannabis seizures fell in
Oceania and in Africa but increased in Asia, the Amer-
icas and in Europe.
2.3.2.1. Trafficking in Cannabis herb
Cannabis herb seizures rose strongly in recent years, but
were stable in 2002 
Cannabis herb is by far the most widely trafficked drug
worldwide. Over the 2000-2002 period, 169 countries
reported seizures of cannabis herb, more than heroin
(143 countries), cocaine (140 countries), cannabis resin
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2.3.2. Trafficking
Fig. 94: Cannabis seizures, 1985-2002
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Source: UNODC, Annual Reports Questionnaire Data / DELTA.
Fig. 95: Cannabis seizures, regional distribution,
1985-2002
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Fig. 96: Cannabis herb seizures, 1985-2002
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Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Metric tons 2,355    3,361    2,359     3,211     3,078     195        2,985     3,992     4,544     4,678    4,741    
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Fig. 97: Global seizures of cannabis herb, 1992 -2002
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(115 countries), amphetamines (97 countries) or ecstasy
(84 countries). Following a decline in the 1980s,
cannabis herb seizures doubled over the 1992-2002
period. In 2002, however, seizures remained basically
stable. This was a consequence of declines reported from
Africa and Oceania, offsetting increases in Europe and
in the Americas.
Trafficking is concentrated in the Americas and in
Africa
There is a concentration of cannabis herb seizures in the
Americas (66% of all seizures over the 2001-2002
period), notably in North America (58%), and in Africa
(23%).  Asia accounted for 6%, Europe for 5% and
Oceania for less than 1% of global cannabis herb
seizures.  
The largest cannabis herb seizures in 2002 were, once
again, reported from Mexico (34% of global seizures)
and the USA (23%), followed by Nigeria (11%), Brazil
(4%) and South Africa (2%).   
2.3.2.2.  Trafficking in cannabis resin
Cannabis resin seizures increased in 2002  
At the global level slightly more than 1,000 tons of
cannabis resin were seized in 2002, about the same as in
2000, though more than in 2001 (+18%). Seizures
increased in Europe in 2002 (6%), in North Africa
(9%) and strongly in South-West Asia (22%), reflecting
a strong increase of cannabis production in Afghanistan.
The long-term trend of cannabis resin seizures showed
a strong increase between 1980 and the mid 1990s, fol-
lowed, despite the 2002 increase, by stabilization there-
after.
Seizures are concentrated in Europe … 
Europe accounted for 68%, South-West Asia for 22%
and North Africa for 7% of global cannabis resin
seizures in 2002. The largest seizures at the global level
have been reported repeatedly from Spain (53% of
global cannabis resin seizures in 2002), followed by Pak-
istan (8%) and Morocco (6%).  High levels of cannabis
resin seizures in the Near & Middle East / South-West
Asia region were also reported from Iran, Afghanistan,
Lebanon and in Europe from the UK and France. The
largest cannabis resin seizures in Eastern Europe were
reported by the Russian Federation. 
… and production in North Africa and South-West Asia 
In contrast to cannabis herb, production and trafficking
of cannabis resin is more concentrated. There were 40
countries identified as sources of cannabis resin in 2002.
Most of these countries, however, only produce small
amounts.  Large-scale production is concentrated in two
areas: Morocco in North Africa and
Pakistan/Afghanistan in South-West Asia. In addition,
significant amounts of cannabis resin production have
been reported from Central Asia, Lebanon, Nepal, and
India and, in the Americas, from Jamaica. 
Europe is the main destination 
Outside the main production areas, Europe is the main
consumer region. (Within Europe only Albania has
been cited by some of its immediate neighbours as a
source of cannabis resin). The vast majority of West
Europe's cannabis resin imports (some 80%) come from
Morocco. France, for instance, reported that 82% of the
cannabis resin found on its market in 2002 originated
in Morocco. Belgium estimated 80% coming from
Morocco, Sweden 85%, and the Czech Republic 70%.
Spain, Italy, Denmark, Finland and Ireland reported
that almost all of their cannabis resin originated in
Morocco. The UK estimated that the bulk of their
cannabis resin came from Morocco via the Iberian
Peninsula, France and the Benelux countries. Similarly,
Germany found much of its cannabis resin coming from
Morocco, via Spain and the Netherlands.   
The second largest source of cannabis resin for coun-
tries in Europe is Afghanistan/Pakistan (10% of seizures
in Belgium; 30% in the Czech Republic; and about half
in the Russian Federation).  Though several European
Fig. 99: Cannabis resin seizures, 1980-2002
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countries cite Pakistan (and not Afghanistan) as a
source, the Pakistani authorities estimate that much of
the cannabis resin found on their market originates in
Afghanistan. Iran also reported a strong increase of
cannabis resin imports from Afghanistan in recent years.
Turkey reported that traffickers obtained cannabis resin
in Iran for final destination in Germany.  Afghan
cannabis resin also leaves the country via its northern
borders. Tajikistan reported that 80% of seized cannabis
resin, which originates almost exclusively from
Afghanistan, was destined for the Russian Federation
and a further 10% for other Central Asian countries. 
Cannabis resin produced in Central Asia also plays an
important role in the CIS region. The Russian authori-
ties estimate that about 30% of cannabis resin imported
into their country originates Kazakhstan and 20% in
Kyrgyzstan. Some 30% of imports are destined for re-
export to the Baltic countries. This is confirmed indi-
rectly by reports from some of the Baltic countries.
Lithuania, for instance, reported that 50% of the
cannabis resin on its market originated in Central Asia.
(Estonia, in contrast, reported that the bulk of cannabis
resin seized in the country was shipped via Spain). Some
cannabis resin is re-exported from Russia to the Czech
Republic as well as to the Netherlands and the UK.
Overall cannabis resin exports to Europe are estimated
to amount to some 10% of Russian Federation’s total
supply (domestic production and imports). 
Trafficking to other regions remains limited
Trafficking of cannabis resin to other regions remains
limited. Just 3% of global cannabis resin seizures were
made in countries outside Europe, South-West Asia and
North Africa in 2002. Of these other regions, the largest
trafficking areas are South Asia, followed by Eastern
Africa. Cannabis resin trafficked in South Asia origi-
nates mainly in Pakistan and in Nepal.  Cannabis resin
found in Eastern Africa was reported to have been
smuggled from Pakistan and India. 
Most of the cannabis resin found in Oceania is shipped
to Australia via Europe (mainly via the UK, Spain and
the Netherlands).  Similarly, most of the cannabis resin
in the USA was reported to have been trafficked via
Europe (90% via the Netherlands) to the USA. Ship-
ments via Canada accounted for 5% of all cannabis
resin imports. The main source for Canada's cannabis
resin was reported to be Pakistan. Jamaica was reported
to be the main source for cannabis resin in the
Caribbean region.   
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Cannabis is the most widely consumed illicit drug.
Some 146 million people or 3.7% of the population 15-
64 consumed cannabis in 2001-2003. 
The number of people treated for cannabis abuse is
much smaller than for opiates or cocaine. The propor-
tions of patients treated for cannabis abuse, has, how-
ever, shown an upward trend in several parts of the
world in recent years, reflecting growing consumption,
almost unlimited supply and the availability of more
potent varieties with a higher THC content. 
Though cannabis use continues rising,  UNODC's esti-
mate on global cannabis consumption had to be revised
downwards compared to last year's estimate (published
in Global Illicit Drug Trends 2003). Some of the 'decline'
was  due to a methodological change prompted by the
new Annual Reports Questionnairex.   Moreover, some
UNODC estimates, when replaced with actual house-
hold survey data, turned out to be smaller than previ-
ously expected. The most striking example in this regard
was Brazil, which affected estimates for South America
as a whole. While previous estimates, derived from stu-
dent studies, suggested that Brazil's cannabis consump-
tion was significantly above the global average, estimates
reported by the Brazilian authorities last year (based on
a national household survey) showed an annual preva-
lence rate of just 1% among the adult population. This
was clearly below the global average. As a result,
UNODC's overall estimates for South America (includ-
ing the Caribbean and Central America) had to be cut
by half (to 6.5 million persons or 2.4% of the popula-
tion age 15-64).
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2.3.3. Abuse
2.3.3.1. Extent
x) In line with a change in the question on prevalence asked in the new Annual Reports Questionnaire, the population base used for calculating the
total number of drug users was reduced from 'age 15 and above'  to age 15-64', implicitly assuming that no or only negligible cannabis use takes
place among the population age 65 and above. As many countries did not increase the reported proportions of drug users among the adult
population, the calculated total number of drug users declined.   
Number of  people in % of  population
(in million)      age 15 - 64
OCEANIA 3.40 16.40
AFRICA 34.60 7.70
AMERICAS 34.90 6.30
- North America 28.50 10.30
- South America 6.50 2.40
EUROPE 28.80 5.30
- West Europe 20.40 6.70
- East Europe 8.40 3.60
ASIA 44.70 1.90
GLOBAL 146.30 3.70
            Cannabis abuse above global average
            Cannabis abuse close to global average
            Cannabis abuse below global average
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
Table 11: Annual prevalence estimates of use of  cannabis: 2001-2003
In terms of average annual prevalence, the reported rates
are highest in the Oceania region (16.4%), followed by
Africa (7.7%),  the Americas (6.3%) and Europe
(5.3%). In North America and in Western Europe the
rates are 10.3% and 6.6% respectively. The highest
levels in the Americas  were reported from the USA
(11% of the population age 12 and above or more than
13% of the population age 15-64 in 2002). The high-
est levels in Europe were reported from the UK (10.9%
of those age 16-59 in 2003), the Czech Republic
(10.9% in 2002), France (9.8% in 2002) and Spain
(9.7% in 2001). Cannabis use in Australia affected 15%
of  the population age 15-64 in 2001. 
Relatively low cannabis prevalence rates, in contrast, are
reported from countries in Asia (1.9%) mainly reflect-
ing low levels of cannabis use in China and other coun-
tries of South-East Asia. In Thailand, for instance, a
household survey conducted in 2001 revealed an annual
prevalence rate of cannabis use of 1.5% among those
age 12-65. Nonetheless, the largest numbers of cannabis
users are found in Asia (some 45 million people), which
accounts for more than 30% of global cannabis use. 
The Americas and Africa account for 24% each of all
cannabis use worldwide and Europe for 20%. Cannabis
use in Africa is widespread across the continent and par-
ticularly high in countries of Western and Southern
Africa.
Importance of cannabis use compared to other drugs
In the vast majority of countries, cannabis is the most
widely consumed drugy. This applies to all countries in
the Oceania region, almost all countries in western
Europe and North America, most countries in Africa
and a majority of countries in Asia. Given this, it is
more interesting to identify the countries in which
cannabis does not rank 1st. 
In some of the East and South East Asian countries,
including China, cannabis is reported to rank  3rd after
opiates and ATS. In Japan it was reported to rank 3rd
after methamphetamine and solvents. 
The authorities in the Ukraine report cannabis ranking
third after the use of 'kompot'  an opium straw extract
which is usually injected, and ephedrone (methcathi-
none) which is often injected as well. In Sweden, Hun-
gary and Slovakia cannabis was reported to rank 2nd
after sedatives & tranquilizers (mostly benzodiazepines)
and in Croatia, Serbia & Montenegro as well as in
Latvia and Lithuania authorities reported cannabis 2nd
after opiates. 
In Venezuela and El Salvador cannabis use was reported
to rank second after cocaine. In Brazil, Panama and
Guatemala cannabis use was reported to rank 2nd after
benzodiazepines.
In countries around the Horn of Africa, notably in
Yemen, Somalia and Ethiopia, rapid assessment studies
revealed that Khat was more widespread than cannabis.
In some countries of the Near and Middle East use of
benzodiazepines,  opiates or ATS (notably fenetylline)
appear to be close to, or exceeding cannabis use.  
The cannabis ranking for some of the countries men-
tioned above, however, could change if all of the infor-
mation were based on household surveys. This is
because registration systems in place often have a built-
in bias for the identification of drugs other than
cannabis.
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y) Reference is made to the 'unadjusted ranking' provided by Member States. Subsequent adjustments, as reflected in the ranking of the cannabis map,
have been  made in order to improve comparability as some countries include alcohol and tobacco as 'drugs', so that cannabis only ranks third in
these countries, while most of the countries do not have alcohol and tobacco included in their drug rankings.  
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Map 17: Use of cannabis 2001 - 2003 (or latest year available)
> 8% of  population
1 - 5% of  population
< 1% of  population
5 - 8%  of  population
Main cultivation areas
Level of abuse (Annual prevalence)
Abuse, extent unknown
Data not available
2
1
Ranking
(1 = most prevalent drug)
7 or more
4 - 6
3 No data provided
Sources: UNODC Annual Reports Questionnaires data, SAMSHA US National Household Survey on Drug Abuse, Iranian Ministry of Health,
Rapid Assessement Study and UNODC ARQ,Council of Europe, ESPAD.  
Map 18: Ranking of cannabis in order of prevalence  in 2002  (or latest year available)      
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Overview
Cannabis use rises again strongly… 
Based on UNODC's  Drug Abuse Trend Index global
cannabis consumption continued its steep increase over
the 2000-2002 period.  This follows a gradual increase
in the early 1990s (1991-1997) and some stabilization
over the 1997-2000 period.
There are significantly more countries reporting rising
levels of cannabis use than there are countries reporting
falling levels. Overall, 54% of countries reporting per-
ceived cannabis consumption trends in 2002 (n = 95
countries) saw an increase, while only 11% reported a
decline.  A year earlier, 53% of those countries reported
an increase and 14% saw a decline. 
Increases for 2002 were reported from a majority of
countries in Africa, South America, Europe and several
parts of Asia, excluding most countries in South-East
Asia and Australia. In North America, the trend was
basically stable. 
AMERICAS
Cannabis use remains largely stable in North America 
Data for the USA, the world's largest cannabis market
in economic terms, showed strong increases in the
1960s and the 1970s, followed by significant declines in
the 1980s and increases in the 1990s. Annual prevalence
of cannabis use among the general population (age 12
and above) fell from 16.6% in 1979 to 7.9% in 1992,
and rose again to 9.3% in 2001. 
In 2002 11% of the US population age 12 and above
consumed cannabis. This figure is not directly compa-
rable with the results of previous years due to changes in
methodology which were aimed at reducing under-
reporting. Based on life-time prevalence data collected
in 2002, it was found that there was some increase in
life-time prevalence among those 18-25 year olds (53%
in 2001 to 53.8% in 2002) and some decline among
those 12-17 year olds (from 21.9% to 20.6%). This sug-
gests that overall the level of cannabis use remained
largely stable in 2002 as compared to a year earlier. 
Regular high-school surveys revealed a gradual decline
in cannabis consumption after 1997. Annual prevalence
of cannabis use among 12th grade high-school students
fell slightly from 38.7% in 1997 to 37% in 2001,
2.3.3.2. Trends
Fig. 102: Cannabis consumption trend based on
national experts' perceptions 
0
1
2
3
4
91 92 93 94 95 96 97 98 99 00 01 02
d
ru
g
 a
b
u
se
 t
re
n
d
 in
d
ex
Source: UNODC, Annual Reports Questionnaire Data.
Fig. 103: Cannabis use trends in 2001 
(n = 95 countries)
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Fig. 104: Cannabis use trends in 2002 
(n = 95 countries)
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36.2% in 2002 and  34.9% in 2003.   There is a strong
negative correlation between perceived harmfulness
('great risk to smoke marijuana occasionally') and
annual prevalence of cannabis use (R = -0.96 over the
1975-2003 period) and a positive correlation between
perceived availability ('easy or fairly easy to get') and
annual prevalence of cannabis use (R = +0.67 over the
1975-2003 period or +0.96 over the 1990-2003
period).  Data suggest that the decline of cannabis use
in the 1980s was a consequence of a rising awareness of
the negative consequences of cannabis consumption and
some reductions in availability (reflecting large-scale
eradications in Latin America). Similarly, the strong
increase in cannabis use in the early 1990s occurred in
parallel to a decline in perceptions that cannabis was
harmful (as prevention campaigns of the 1980s became
outdated) and a rising market supply (due mainly to a
rise in domestic production). Finally, the stabilization /
decline of cannabis use after 1997 took place in parallel
to some reduction in availability (reflecting inter alia
intensified domestic eradication and eradication of
cannabis plant in Mexico). The downward trend in the
harmfulness perceptions of the early 1990s  gave way to
a stabilization, following major investment into new
prevention efforts. All of this led to declining levels of
consumption among high-school students over the
1997-2003 period. 
However, data also show that availability of cannabis
remains high and that the perceived harmfulness is lim-
ited as compared to other drugs. In 2003 16% of 12th
grade students considered it to be a 'great risk' to use
cannabis once or twice. The corresponding ratios for
considering it a 'great risk' to use amphetamines,
cocaine or heroin, once or twice, were significantly
higher (37%, 46% and 58%, respectively). While 87%
of the students surveyed reported that cannabis was
easily available, the corresponding ratios for ampheta-
mines, cocaine or heroin were significantly lower (55%,
37% and 28%, respectively). Probably as a consequence
of this, the use of cannabis (annual prevalence of 34.9%
among 12th graders in 2003) is significantly more wide-
spread than that of amphetamines (9.9%) cocaine
(4.8%) or heroin (0.8%).   
In Canada's most populous province, Ontario, high-
school surveys revealed a pattern largely similar to that
observed in the USA: increases in the 1970's, declines
in the 1980's, followed by significant increases in the
Fig. 105: USA: cannabis prevalence, perceived harmfulness and availability among 12th graders 
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Fig. 106: Cannabis use among high-school students in
Ontario (Canada) and in the USA
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1990s and a stabilization in subsequent years. Over the
1999-2003 period, stable to slightly increasing levels
were reported from Ontario. With an annual prevalence
rate of 27.8% among Ontario high-school students
(7th, 9th and 11th graders), cannabis use was still lower
than in the late 1970s (29.1% in 1979). However, the
prevalence rate was - for the first time - higher than in
the USA, mainly a consequence of the decline of
cannabis prevalence rates in the USA over the 1997-
2003 period (from 30.3% to 25.3% among
8th,10th,12th graders).  One in ten of Ontario high-
school cannabis users was found to have a dependence
problem with cannabis. Annual prevalence of cannabis
use among the general population affected 11.2% (age
18 and above) in Ontario in 2001, about the same level
as reported from the USA and about the same level as
reported a year earlier (10.8%), though up from 6.2%
reported in 1992. 
In Mexico, one of the largest source countries of
cannabis herb, household surveys conducted in 2002
showed a decline in marijuana use following years of
increase in the 1990s. Annual prevalence among the
general population age 12-65 fell from 1% in 1998 to
0.6% in 2002. It  continues to be significantly lower
than in the USA or Canada. Cannabis use is lower in
southern Mexico (lifetime prevalence of 2.2% in 2002)
and in central Mexico (3%) than it is in the northern
states (5.8%). 
Cannabis use continues rising in South America (incl.
the Caribbean and Central America)
In contrast to stable trends in North America, cannabis
consumption (according to  national experts'  percep-
tions reflected in UNODC's Drug Abuse Trend Index)
continues rising in South America (including the
Caribbean and Central America). A rising trend in
cannabis use across the region  was observed as of the
mid 1990s. In 2002 14 out of 18 reporting countries
experienced a rise in cannabis use,  and only one coun-
try (Chile) reported a decline. 
In Brazil, the largest country of South America, a
national household survey was conducted in 2001. The
survey revealed a life-time prevalence among the general
population (age 12-65) of 7.6% in south-eastern Brazil,
up from 6.6% in 1999 (state of Sao Paulo which forms
part of the region of south-eastern Brazil).  This con-
firmed the upward trend previously seen in school sur-
veys.  Annual prevalence of cannabis use was found to
affect 1% of the  population age 12-65 in 2001. The
prevalence of cannabis use is thus clearly lower in Brazil
than in the USA, but higher than in Mexico.     
A regional breakdown shows that the highest levels of
cannabis use are found in  southern Brazil (close to the
border with Paraguay, a major cannabis producer in the
region), followed by the neighbouring region of south-
eastern Brazil which includes the states of Sao Paulo,
Rio de Janeiro, Minas Gerais and Espirito Santo.  In
contrast, cannabis use seems to be relatively low in the
northern parts of the country. 
Fig. 107: Mexico: cannabis use, 1989-2002
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Fig. 108: South America: cannabis consumption trend
based on national experts' perceptions 
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Argentina reported higher levels of cannabis use than in
Brazil. A national household survey conducted in 1999
found an annual prevalence rate of 3.7% and a life-time
prevalence rate of 8.5% among the general population
(age 16-64).  Argentina reported an continuous increase
of cannabis use in 2000, 2001 and 2002. 
In neighbouring Chile, 5.2% of the general population
(age 12-64) used (annual prevalence) cannabis  in 2002,
i.e. more than in Brazil or Argentina.  Following
increases of cannabis consumption in the 1990s there
was, however, some decline in the annual prevalence
rate of cannabis use between 2000 and 2002. Yet,
monthly prevalence rates of cannabis use remained
stable between 2000 and 2002 suggesting that the
decline affected mainly experimental users.    
In Bolivia cannabis use was lower than in Chile or
Argentina. A general population survey conducted in
2000 by the Centro Latinoamericano de Investigación
Cientifica (CELIN)z found an annual prevalence rate of
2.2% among the population age 12 and above and a
life-time prevalence rate of 3.7% in 2000 (which was
still lower than that reported from Brazil). Cannabis use
was, however, increasing in Bolivia throughout the
1990s. The monthly prevalence rate of cannabis use rose
from 0.2% of the population age 12-50 in 1992 to
1.4% in 2000.  School surveys, conducted in 2000 and
in 2002, suggest that the upward trend continued. 
In contrast, studies conducted in Peru suggest that
cannabis use has remained basically stable since the mid
1990s. The life-time prevalence rate of cannabis use was
5.8% of the general population age 12-64 in
2002/2003, which was almost the same as in 1995,
1998 and 2001 (and less than in 1997). Annual preva-
lence of cannabis use concerned 1.8% of the population
age 12-64 and was thus slightly lower than in Bolivia.    
In Ecuador, on the other hand, school surveys suggest
Fig. 109: Brazil: Life-time prevalence of cannabis use,
1987-2001
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Fig. 110: Brazil: Life-time prevalence of cannabis use
among the general population (age 12-65)
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Fig. 111: Chile: Cannabis use among the general
population (age 12-64), 1994-2002
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Cuadros Estadísticos.
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that cannabis use continued to rise (from a life-time
prevalence of 3.9% among those 13-18 year olds sur-
veyed in 1998 to 8.6% of those 12-18 year olds sur-
veyed in 2001/02). Similarly, strong increases among
secondary school students were reported from Panama
and Guatemala. 
Authorities in Colombia, Venezuela, Suriname,
Argentina, Paraguay, Uruguay, Costa Rica, El Salvador,
Guatemala, Barbados and Bahamas all reported rising
levels of cannabis consumption in 2002. 
High-school surveys conducted in recent years in Latin
America show that life-time prevalence of cannabis use
among secondary school students is particularly high in
some of the Caribbean countries (St. Lucia, Jamaica and
Barbados), where about a quarter of all students have
experimented with cannabis. The highest levels of any
South-American country were reported from Chile fol-
lowed by Colombia. The highest levels in Central Amer-
ica were reported by Belize and Guatemala. Despite
these high levels, cannabis use is still less prevalent than
in the USA. 
Table 12: Life-time prevalence of cannabis use among secondary school students in Latin America in 2002 or  
latest year available
Sources: UNODC, Annual Reports Questionnaire Data, UNODC, Global Assessment Programme (GAP), OAS/CICAD, Resumen Estadístico
sobre Drogas,  2003 and OAS/CICAD, Drug Prevalence Survey of Secondary School Students, 2003 - a comparison report of three
Caribbean countries: Barbados, Belize and Guyana.
Age group
Life-time 
prevalence in %
Source
St. Lucia 13 - 20 27.4 UNODC. GAP
Jamaica 12 – 16 26.9 UNODC, ARQ
Barbados 12 – 18 23.3 UNODC, ARQ
Chile 13 – 18 23 UNODC, ARQ
St. Vicent and the Grenadines 13 - 19 20.6 UNODC, GAP
Belize 12 – 18 20.5 CICAD
Bahamas 11 – 19 14.9 UNODC, ARQ
Guatemala 12 – 20 12.3 UNODC, ARQ
Uruguay 13 – 17 11.9 UNODC, ARQ
Colombia 10 – 24 8.9 UNODC, ARQ
Ecuador 12 – 18 8.6 CICAD
Brazil 10 – 19 7.6 UNODC, ARQ
Guyana 12 – 18 7.1 CICAD
Panama 12 – 18 6.9 CICAD
Nicaragua 13 – 18 6.7 UNODC, ARQ
Bolivia 12 – 21 6.4 UNODC, ARQ
Suriname 12 – 16 6 UNODC, ARQ
Mexico 12 – 20 5.8 UNODC, ARQ
Argentina 12 – 18 5.3 UNODC, ARQ
Paraguay 12 – 18 4.3 CICAD
Honduras 15 – 25 2.7 UNODC, ARQ
Venezuela 12 – 21 2.3 UNODC, ARQ
Dominican Republic 12 – 20 2.2 UNODC, ARQ
Costa Rica 12 – 18 1.7 UNODC, ARQ
11
7.4
33.3
NIDA, Monitoring the 
Future
Memo:
USA
2003 13-17/18
2000
2001
Average: unweighted
weighted by population
2001
2001/02
2002
2001
2002
2002
2002
2000
2001/02
1997
2002
2001/02
2002
2002
2001
2001
2002
2001
2002
2002
Year
2002
1997
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Approximately 11% (unweighted average) of  secondary
school students in Latin America experimented with
cannabis. This is a third of the corresponding rate
reported from the USA. However, data are not always
directly comparable. In some countries the age group of
students 17 years and above (which has the highest
prevalence rate) is under-represented because most
pupils leave the school earlier. Thus for some of the
countries showing a low cannabis use prevalence, the
actual reason is that older students, who would have
higher prevalence rates, are under-represented in these
countries.       
EUROPE
Cannabis use continues to rise in Europe 
Cannabis use has increased in Europe throughout the
last decade - as reflected in UNODC's Drug Abuse
Trend Index. This is unlike the situation in North
America where cannabis use stabilized or declined in
recent years. During that period several European coun-
tries have been softening their drug laws with regard to
cannabis.
A stabilization of cannabis consumption in Europe was
reported by the Nordic countries  (Finland, Norway and
Sweden), the UK (following a decade  of massive
increases) and a few other countries. Apart from these
exceptions, most countries of continental Europe con-
tinued reporting rising levels of cannabis use. 
In France, for instance, annual prevalence of cannabis
use more than doubled between 1992 and 2002 (from
3.9% of the population age 18-74 to 9.8% of the pop-
ulation age 15-64). Similarly, life-time prevalence of
cannabis use among 17 year olds more than doubled
between 1993 and 2002 affecting 44.7% of all students
age 17 in 2002.   
High prevalence rates among pupils were also reported
from Switzerland. School surveys conducted among 15-
16 year olds revealed a life-time prevalence rate of
44.5% for 2002, signalling a four-fold increase as com-
pared to 1990 or the mid 1980s. The prevalence of 15-
16 year old students  who used cannabis several times
rose from 25% in 1998 to 32% in 2002 period, equiv-
alent to a 25% increase over this period. Some of the rise
can be linked to availability which is, in general, better
than in several neighbouring countries. Apart from the
black market, Switzerland has some 200 retail outlets
across the country where a broad range of cannabis
products (for decoration purposes, etc.) can be bought,
Fig. 112: Europe: cannabis consumption trend based
on national experts' perceptions 
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Source: UNODC, Annual Reports Questionnaire Data. 
Fig. 113: France: annual prevalence of cannabis use
among the general population age 15-64,
1992-2002
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Sources: EMCDDA, Data Library and UNODC, Annual Reports
Questionnaire Data. 
Fig. 114: France: life-time prevaleence of cannabis use
among 17 year olds, 1992-2002
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including - until recently - cannabis products that had a
THC content sufficient to be suitable for smoking.
Against this background and the large spread of
cannabis in the country, the Swiss upper house passed a
bill to fully decriminalize cannabis, including consump-
tion, distribution and production. However, the bill was
rejected by the lower house in 2003.    Cannabis use in
Spain was stable during the 1990s but increased signif-
icantly over the 1999-2001 period (from 6.8% to 9.9%
among the general population age 15-64) to levels
slightly higher than in France. School surveys also con-
firmed an upward trend of cannabis use over the 1998-
2000 period. Given the existence of good prevention
programmes, the increase can possibly be explained as
the result of larger supply - probably due to  the
increases of cannabis production in neighbouring
Morocco and the role of Spain as a major transhipment
location. Cannabis prevalence rates above the national
average were reported - inter alia - from the Baleares
(18.3%), the Basque region, located close to France
(13.7%) and Madrid (12.7%).  
In Italy,  most of the increase in cannabis use took place
in the second half of the 1990s (1995-1999). Some
(minor) increases in cannabis use occured between 2000
and 2002. A general population survey conducted in
2001 found an annual prevalence of 6.4% among the
population age 15-44, suggesting that cannabis use in
Italy is less widespread than in Spain or France. 
Both general population surveys and youth surveys in
Germany  showed a clear upward trend of cannabis use
over the last decade.  The annual prevalence of cannabis
use among the general population and life-time preva-
lence among youth more than doubled.  Most of the
increase took place in the 'new provinces' (former East
Germany).  A continuation of this upward trend was
also reported by the German authorities for the year
2002. Nonetheless, data also show  that cannabis use in
Germany (annual prevalence of 6% among the popula-
tion age 18-59 in 2000) is lower than amongst its neigh-
bours - France, Switzerland and the Czech Republic -
and lower than in the UK or Spain.
Some increase in cannabis use was also reported from
the Netherlands between 1997 and 2001 (from 5.5% to
6.1% of the population age 15-64). In Amsterdam, the
city with the highest cannabis use levels in the Nether-
lands (more than twice the national average), annual
Fig. 115: Switzerland :Cannabis use among 15-16 year
olds, 1984-2002
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Fig. 116: Spain: annual prevalence of cannabis use
among the general population age 15-64,
1989-2001
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Drogas, Informe No 6 Nov. 2003 and  UNODC, Annual Reports
Questionnaire Data.
Fig. 117: Italy: Life-time prevalence of cannabis use
among secondary school students, 1995-
2002
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prevalence of cannabis use rose from 9.5% of the pop-
ulation age 12 and above in 1987 to 13.2%  in 1997. It
remained basically unchanged over subsequent years
(13.1% in 2001)aa.   Over the same period stricter reg-
ulations led to an (approximately) 20% decline in the
number of 'coffee shops' in Amsterdam (from 340 in
1997 to 280 in 2001 and 270 in 2002)ab .  Some 40%
of the cannabis in the Netherlands is bought by the end-
consumers in such 'coffee shops' (ranging from 37% of
the 12-17 year old cannabis users to 47% of cannabis
users age 18 and above)ac.  Increases in cannabis use
over the 1997-2001 period, in contrast, were reported
from Rotterdam, one of the main cannabis tranship-
ment locations, and several other locationsad.   The
Dutch authorities reported a stabilization of cannabis
use in 2002 (ARQ). 
Strong increases in cannabis use over the last decade
were reported from Belgium. Life-time prevalence
among 15-16 year olds rose in the Flemish part of the
country from less than 15% in 1994 to about 25% in
2002. Following increases in the 1990s, life-time preva-
lence among 15-16 year olds continues to be higher
among the 'French community' than among the 'Flem-
ish community'. In the French community it continued
rising  from 27.9% in 1997/98 (HBSC study) to 29%
in 2002 (ARQ). Among young adults in the French
speaking community, life-time prevalence of cannabis
use rose by some 70% (from 17.8% in 1996/97 to
30.9% in 2000 among the population age 18-34) and
was thus similar to levels reported from former West
Germany (30.8%) or the Netherlands (31.5% among
those 15-34), though still less than in Spain (35%),
France (35.7%) or the UK (43%) in 2000. (Percentages
for the latter countries refer to the age group 15-34).
Belgium introduced a new law in 2003 which partially
decriminalizes cannabis use and de-facto allows for the
Fig. 118: Germany: Cannabis use among the general
population and among youth, 1989-2001 
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Fig. 119: Netherlands: Cannabis use among the
general population age 15-64
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Fig. 120: Amsterdam (Netherlands): Annual
prevalence of cannabis use (age 12 and
above), 1987-2001
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Source: Licit and Illicit Drug Use in Amsterdam, 1987-2001
aa) CEDRO, Licit and Illicit Drug Use in Amsterdam, 1987-2001.  
ab) The decline in the overall number of coffee shops in the Netherlands over the 1997-2002 period was even more important: from 1179 to 782. 
(Trimbos Instituut, National Drug Monitor2003).
ac) CEDRO, Licit and Illicit Drug Use in the Netherlands 2001, Amsterdam 2002.
ad) Trimbos Instituut, National Drug Monitor2002 and 2003. 
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possession of small amounts of cannabis (less than 5
grams). Smoking in public places and in the presence of
minors, however, is still prohibited. For 'problematic
use' or if a 'public nuisance' is created, prosecutions
continue to take place. No retail outlets ('coffee shops')
are allowed.
In the United Kingdom, Europe's largest cannabis
market, strong increases in cannabis use in the early
1990s were followed by a de-facto stabilization at high
levels. Overall 10.9% of those age 16-59 in England &
Wales admitted to having consumed cannabis in
2002/03,  a similar proportion as reported from the
USA. If potential error margins are taken into account,
annual prevalence rates of cannabis use have remained
basically stable over the last few years: 1998: 10.3%,
2001/02: 10.6% and 2002/03: 10.9%. Regularly con-
ducted school surveys in England confirm that cannabis
use is widespread, even among low age groups (annual
prevalence of 13% among those age 11-15 in 2003).
These surveys also indicate that cannabis use has stabi-
lized over the last few years. Nonetheless,  overall
cannabis use among the general population is now twice
as high as in the early 1990s and five times as high as in
the early 1980s. 
The UK Government re-classified cannabis from a class
B to a class C drug as of January 2004, to enable
enforcement authorities to focus their resources on
fighting other drugs which have a stronger harm poten-
tial. It will be interesting to see whether intensified pre-
vention activities will be able to reduce cannabis
consumption, or whether the reduced levels of control
will entail a further rise - from existing high levels - over
the next couple of years. 
In Sweden regular surveys among (male) military
recruits (age 18) found a significant decline of cannabis
use in the 1980s, reflecting - inter alia - the decisive
anti-drug policies pursued by the Government. The
same policies, however, could not prevent cannabis use
from rising strongly among youth in the 1990s.
Increases in youth unemployment and budget cuts,
affecting inter alia subsidized leisure time activities for
youth, may have contributed to this. However, in line
with economic recovery, a decline in youth unemploy-
ment and a strengthening of prevention activities, the
upward trend flattened over the last few years and in
2003 the survey showed - for the first time in a decade
- a net decline in cannabis use (as well as for drug use in
general). Despite the increase of cannabis among young
males in the 1990s, Sweden still has one of the lowest
levels of cannabis consumption among the general pop-
ulation in Europe. General population surveys con-
ducted  in 1998 and in 2000 found an annual
prevalence of cannabis use of 1% among the population
age 15-64, equivalent to 1/10th of the level currently
reported from the UK.   
Similar to the situation in Sweden, youth surveys regu-
larly conducted in Norway revealed a decline in
cannabis use in the 1980s,  an increase in the 1990s and
a stabilization/decline over the 2000-2003 period.
However, the decline of cannabis use in the 1980s - as
compared to Sweden - was less pronounced, and so was
the subsequent increase of cannabis use in the 1990s.
Also, while in Sweden prevalence rates remained slightly
below the levels of the late 1970s, prevalence rates in
Norway (Oslo) clearly exceeded the rates observed in
the late 1970s. The overall level of cannabis use among
Fig. 121: Belgium (Flemish community) Cannabis use
among 15-16 year old
Source: Universiteit Gent, Health Behaviour in School Aged
Children, Jongeren en Gezondheit, Resultaten voor 2002.
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Fig. 122: Belgium - French Community: Life-time
prevalence of cannabis use among
population 18-34
9.2%
17.8%
30.9%
26.1%
0%
10%
20%
30%
40%
1994 1996-97 1998-99 2000
Li
fe
-t
im
e 
p
re
va
le
n
ce
Source: EMCDDA, Data Library. 
151
2. Trends Cannabis market
the general population (age 15-64) amounted to 4.5%
in 1999 and was thus significantly higher than in
Sweden (1% in 2000) or Finland (2.2% in 2000) but
lower than in Denmark (6.2% in 2000) and several
other European countries.   
General upward trend of cannabis use in Eastern
Europe 
Various school surveys conducted over the last decade in
Eastern Europe showed that the increase in cannabis use
in the 1990s (although starting from low levels) was sig-
nificantly stronger than in Western Europe, both in the
first and in the second half of the 1990s. In most East
European countries the ESPAD school surveysae, con-
ducted under the auspices of the Council of Europe,
found a doubling of life-time prevalence rates among
15-16 year olds between 1995 and 1999. Thus cannabis
use (as well as drug use in general) showed a trend
toward convergence with drug use levels observed in
Western Europe. Cannabis use in the Czech Republic,
for instance, was found to have been already as high as
in France or the UK (life-time prevalence of 35%
among 15-16 year olds) in 1999 and cannabis use in
Slovenia (25%) was already as high as in Italy. Rather
high levels were also reported from Moscow (22%), the
Ukraine (20%), the Slovak Republic (19%), Latvia
(17%) and Croatia (16%). Relatively  low levels, in con-
trast, were still reported from Romania (1%), the
Former Yugoslav Republic of Macedonia (8%),  Hun-
gary (11%) and Bulgaria (12%).   
Fig. 123: Sweden: Life-time prevalence of cannabis use among male military conscripts, age 18, 1976 - 2003 
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Fig. 124: Norway: Cannabis  use among youth 
(age 15-20)
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High levels of cannabis use in the Czech Republic were
also confirmed in a national survey, conducted in 2002,
which revealed an annual prevalence of cannabis use
among the general population (age 15-64) of 10.9%,
the same level as reported from England & Wales and
marginally higher than in France or Spain.  Cannabis
use in the Czech Republic is thus far more widespread
than in neighbouring Slovakia (3.6% of the general
population age 15-64 in 2002), Poland (2.4% of the
population age 16 and above in 1999) or in Hungary.
While the Czech Republic reported a life-time preva-
lence rate of cannabis use of 21.1% among the general
population, the corresponding rate in Hungary
amounted to 5.7% in 2001. 
There are, however, some positive trends. While
cannabis use continues to increase in rural areas (char-
acterized by low prevalence rates), in several larger
towns, where cannabis use levels already reached high
levels, consumption levels stabilized or declined. (This
appears to be the case in Warsaw and some cities in
Hungary and in the Czech Republic).  
Nonetheless, national school surveys conducted among
15-16 year old students in the Czech Republic continue
to show a clear upward trend. Life-time prevalence of
cannabis use among this age group rose from 22% in
1995 to 35% in 1999 and reached almost 44% in 2003
(ESPAD). This is definitely one of the highest rates and
could turn out to be among the highest cannabis preva-
lence rates among students across Europe in 2003. 
Increases in cannabis use have been also reported from
other countries in the region, notably from countries
which, so far, have had low prevalence rates. Thus, the
ESPAD studies showed a rising trend of cannabis use in
Hungary: life-time prevalence of 5% among 15-16 year
olds in 1995 (or 7% among secondary school students
in Budapest), rising to 12% in 1999 among 15-16 year
olds (or 25% among secondary school students in
Budapest), and increasing to 28.1% among 16-17 year
old Hungarian students  in 2002. Though there are dif-
ferences in the age groups analysed, it can be assumed
that overall cannabis use continued increasing among
Hungarian students over the 1999-2002 period. Simi-
larly, a school survey conducted in 2001-2002 in the
capital of Romania, Bucharest, already found a preva-
lence rate of cannabis use of 34% among 14-17 year old
students (ARQ 2002) while the 1999 ESPAD study,
conducted across Romania, found a lifetime prevalence
rate of cannabis use among 15-16 year old students of
just 1%. Even taking into account that prevalence rates
in capital cities are, in general, larger than in the  coun-
try as a whole and that the age groups investigated were
not identical, reported differences were so large that one
can take it for granted that cannabis use increased sig-
nificantly among high-school students in Romania over
the 1999-2002 period.     
Increases in cannabis use also took place in Bulgaria.
The 1999 ESPAD study found a life-time prevalence
rate of 12% among 15-16 year olds. A study conducted
in 2001 in Sofia found the life-time prevalence rate of
cannabis to have increased to 26.9%af.
Fig. 125: Czech Republic, Cannabis use among 15-16
year olds
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2003
Fig. 126: Hungary: Cannabis use among high-school
students, 1992-2002 
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af ) EMCDD, The State of the Drugs Problem in the Acceding and Candidate Countries to the European Union, Lisbon 2003.
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AFRICA
Cannabis use continues to increase …
Cannabis is the main drug of concern in Africa. It is
easily available and is the primary drug associated with
treatment demand in Africa. In most African countries,
for which information is available, cannabis also
accounts for the bulk of arrests for drug trafficking and
use.
Cannabis consumption in Africa has been increasing
steadily over the last decade. This is reflected in
UNODC's Drug Abuse Trend Index. If it were not for
limited levels of reporting UNODC's Drug Abuse
Trend Index would show even stronger increases for
Africa. Throughout the 1992-2002 period, 50% to
100% of countries reporting saw rising levels of
cannabis use. Out of 19 countries reporting in 2002, 16
countries (84%) reported rising levels of cannabis use.
Large increases in cannabis use in 2002 were reported by
Morocco in North Africa as well as by Malawi and Zim-
babwe in Southern Africa, by Tanzania and Somalia in
Eastern Africa, and by Côte d'Ivoire in Western Africa. 
The only comprehensive time series data available are
for South Africa. According to data collected by the
South African Community Epidemiology Network on
Drug Use (SACENDU) the proportion of people in
treatment for cannabis abuse in South Africa rose from
around 5% in 1996 to around 20% in 2002. Above
average proportions have been reported from Gauteng
(Johannesburg and Pretoria: 23% in 2002) and from
Durban (24%). The number of people treated for
cannabis abuse rose more than 3-fold in Cape Town,
more than 6-fold in Durban over the 1996-2002
period, and - over the 1998-2002 period - by a factor of
2.4 in Gauteng. There are more people in treatment for
cannabis abuse in South Africa (and most other African
countries) than for any other substance, except alcohol.
The next  most frequently encountered substance in
South Africa is Mandrax (a methaqualone preparation)
in combination with cannabis. Among adolescents (age
20 or less) cannabis is the main substance leading to
treatment demand, ahead of alcohol (on average 54% in
first half of 2003.) For the first half of  2003 some
declines in the number of people treated for cannabis
abuse were observed in Cape Town, Durban and Gaut-
eng, though increases continued in Mpumalanga,
located close to the border with Mozambique.
Increases in cannabis use over the last decade were also
reported for the countries forming part of the Southern
African Development Community (SADC).  However,
in the first half of 2003 the overall proportion of people
in treatment for cannabis abuse appears to have
remained rather stable as compared to 2002. Increases
reported from Malawi, a major cannabis producing
country in the region (from 67% to 80% of all treat-
ment demand) were offset by  declines reported from
South Africa, Namibia and Botswana. For other coun-
tries in the region the levels of people treated for
cannabis abuse remained basically unchanged. The
highest proportions of people in treatment for cannabis
abuse are found in Malawi (80%), followed by Lesotho.
Overall around 25% of treatment is cannabis related
(unweighted average of country results). 
Excluding alcohol, cannabis accounts for some 60% of
treatment demand.  In Lesotho, Malawi and Botswana
Fig. 127: Cannabis consumption trend in Africa based
on national experts' perceptions, 1991 -
2002
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 128: South Africa*: Proportion of people in
treatment for cannabis abuse, 1996-2003 
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Source: SACENDU, Research Brief, Vol. 6. 2003. 
154
World Drug Report 2004 Volume I. Analysis
practically all drug treatment was cannabis-related in
2002 and 2003. In Zambia the proportion amounted to
70% (2002) and in South Africa to around 40%
(2002/03). In Mauritius, in contrast, which suffers from
significant levels of heroin abuse, cannabis only
accounts for some 13% of drug treatment. The overall
largest number of people seeking treatment for cannabis
abuse are found  in South Africa.
Similarly, practically all of the countries forming part of
the East Africa Drug Information System (EADIS)
reported rising levels of cannabis useag and most of the
countries also reported high proportions of people in
treatment for cannabis abuse. High proportions of
people in treatment for cannabis abuse were reported by
countries located in the Indian Ocean such as Mada-
gascar (88% in 2001)ah or the Seychelles where practi-
cally all drug treatment was cannabis related (though
the authorities of the Seychelles reported that in 2002 -
for the first time - some of the cannabis users had also
consumed ecstasy, benzodiazepines and cocaine).  
High proportions of people in treatment for cannabis
abuse have been also encountered in most West African
countries.  In Nigeria, for instance,  92% of all drug
treatment demand (excl. alcohol) was linked to cannabis
abuse in 2002, in Ghana 86% in 2002 and in Togo 77%
in 2001 (ARQ). 
The overall numbers of people receiving treatment in
Africa for substance abuse are, however, small (a few
hundred people in the larger countries and a few dozen
in the smaller countries; only in South Africa the
number of people receiving treatment for substance
abuse (incl. alcohol) amounted to some 12,000 persons
in 2002). This is not a consequence of low levels of
treatment demand in Africa but of a limited availability
of treatment facilities. Many people in Africa receive
treatment outside the clinical system, or their cases are
dealt with in a psychiatric ward which is not recorded as
treatment. 
ag) Djibouti, Ethiopia, Kenya, Madagascar, Mauritius, Seychelles, Uganda, United Republic of Tanzania (UNODC, GAP - East Africa Drug
Information System, EADIS Second Annual Meeting, Nov. 2002.) 
ah) UNODC, GAP, op. cit.  
Fig. 130: Proportion of people in treatment for
cannabis abuse in countries of southern
Africa, 2002 and 2003 
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Fig. 129: Proportion of people in treatment for
cannabis abuse in countries of southern
Africa, 2002 and 2003 
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ASIA
Increases in cannabis use less pronounced  than in other
regions … 
UNODC's Drug Abuse Trend Index found some
increase of cannabis use in Asia over the last decade. The
increase was, however, less pronounced than in Africa,
Europe or the Americas. There was some increase over
the 2000-2002 period. 
This was mainly the result of large increases reported by
the two most populous countries, China and India. In
China prevalence of cannabis use still ranks only third
(after opiates and ATS). In India, in contrast, cannabis
is the most widely used illegal substance.  A national
household survey  conducted in India in  2001 found a
monthly prevalence of cannabis use of 3% among males
(age 12-60)ai, significantly more than for opiates (0.7%)
or for any other substance and equivalent to more than
80% of all illegal drug use (3.6%). India has thus appar-
ently a lower cannabis prevalence rate than the USA
(monthly prevalence of 8.9% of the male US popula-
tion in 2001) or several West European countries, but a
higher total number of male cannabis users than any
other country in  the world (8.8 million male cannabis
users in India versus 7.6 million male cannabis users in
the USA in 2001). In terms of treatment demand (incl.
alcohol), 11.6% was cannabis related in India (2000),
less than alcohol (43.9%) but more than heroin
(11.1%), opium (8.6%) or any other drug.  The high-
est proportions of cannabis related treatment were
reported from the states of Uttar Pradesh (20%) and
Bihar (19%) in northern India, bordering Nepal (a sig-
nificant cannabis producer) and from the state of Kerala
(16%) in southern India.     
Excluding data for China and India, which have a
strong weight for  UNODC's Drug Abuse Trend Index,
data for the rest of Asia show a basically stable trend over
the 1999-2002 period.
… mainly due to  falling levels of cannabis use in South-
East Asia 
While increases were reported from Pakistan and Iran,
reflecting Afghanistan's growing hashish production,
South-East Asia (with the exception of China) was char-
acterized by declining levels of cannabis consumption.
Falling levels of cannabis use in 2002 were reported by
Indonesia (just 1.4% of new drug users identified by the
authorities in Indonesia in 2002 were cannabis users),
the Philippines and Myanmar. Cannabis consumption
levels remained stable in Brunei Darussalam.
Bangladesh and Nepal reported stable levels of cannabis
consumption.  Stable levels of cannabis use were also
reported from the Republic of Korea.  Authorities in
Japan, in contrast, reported some increase.  Cannabis
use in Japan, however, continues to remain limited
(annual prevalence of 0.1% of the population age 15
and above in 2002; life-time prevalence: 1%).  
OCEANIA
Characterized by falling levels of cannabis use in recent
years 
UNODC's Drug Abuse Trend Index showed strong
increases in the Oceania region over the 1991-2000
period. Over the 2000-2002 period, however, a simi-
larly sharp decline was reported. 
Fig. 131: Cannabis consumption trend in Asia based
on national experts' perceptions 
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Source: UNODC, Annual Reports Questionnaire Data.
ai) UNDCP, National Survey on Extent, Pattern & Trends of Drug Abuse in India, National Report 2002.
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The index for the Oceania region reflects primarily
reported cannabis consumption in Australia. Annual
prevalence of cannabis use, as reflected in household
surveys, rose slightly between 1993 and 1995 and sig-
nificantly between 1995 and 1998, but fell between
1998 and 2001 by 28% to 12.9% among those age 14
and above. The rate is thus still marginally higher than
in the USA (11% of those age 12 and above in 2002) or
the UK  (10.9% of those age 16-59 in 2002/03), but the
differences are far less significant than they used to be in
the late 1990s. Studies conducted among school stu-
dents, age 15-16, revealed a life-time prevalence rate of
cannabis use of 20.6% in 2001 (ARQ) less than the
results of previous UN surveys. Similarly, drug tests
among detainees showed declines in cannabis use over
the 1999-2001 period. For 2002, however, there were
no indications that the downward trend continued. 
In New Zealand the annual prevalence in cannabis use
increased slightly over the 1990-1998 period and
remained basically stable over the 1998-2001 period.
With an annual prevalence rate of 20% among those
age 15-45 in 2001, the prevalence rate in New Zealand
was largely the same as the prevalence of cannabis use in
Australia for this age group.
Fig. 132: Cannabis consumption trend in Oceania
based on national experts' perceptions 
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 133: Australia: Cannabis use in % of population
age 14 and above
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Fig. 134: Australia: Percent testing positive for
cannabis among male police detainees*,
1999-2002
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Fig.135: New Zealand: Cannabis use among 15-45
year  olds
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Assessing the extent of the manufacture of synthetic
drugs such as amphetamine-type stimulants, is less
straightforward than estimating the production of plant
based drugs. For the plant based drugs,  cultivation area
can be estimated through ground surveys and/or the
analysis of satellite photos.  For production figures, the
results of the areas under cultivation are then multiplied
with typical yields per hectare (established through
interviews with farmers and/or by measuring the yields
on test fields). In the case of synthetic drugs indirect
methods must be used. 
2.4. Amphetamine-type stimulants
2.4.1. Production
ATS production:  larger than heroin but lower than cocaine in terms of weight
Table 12: Production estimates of amphetamine-type stimulants
Based on:
Amphetamine and 
methamphetamine
Ecstasy Total
Consumption* 516 100 - 125 616 - 641
Drug seizures** 340 - 490 50 -75 390 - 565
Precursor seizures*** 290 - 410 130 - 200 420 - 610
Mean and range 410 113 (50 - 200) 523
(290 - 516) [1.4 billion tablets] (390 - 641)
Estimated annual production (metric tons)
* Number of users and quantities consumed
Amphetamine and methamphetamine: In general, consumption volumes are not easy to estimate.  Doses vary widely, and the frequency
of dosing is not clear.  Based on an average dose of 30mg every day (the content of an average methamphetamine tablet; and twice the
defined daily dose of amphetamines), and an estimated number of 34 million users worldwide (UNODC, Global Illicit Drug Trends 2003),
there would be an annual requirement for about  375  tons of drug. The estimate is somewhat higher if the wrap size for amphetamine
is used as a measure of dose.  A "wrap" in this context is understood to be a quantity of drug packaged for distribution at street level:
from data available from the UK, the majority of wraps (80%) contain not more than 1g of powder with an average purity of about 13%
(i.e. a wrap contains about 130 mg pure amphetamine).  Other estimated average doses are similar (INCB).  Again based on one dose per
day, the annual requirement is about 1600 tons of drug.  Weighted for the estimated number of users of amphetamine and the number
of methamphetamine users worldwide, the requirement for amphetamines is estimated at some 516 tons (184 tons of amphetamine, and
332 tons of methamphetamine) [users in Europe (3.3 million) vs. users in North America and Asia (2.9 million + 22.5 million)].  Breakdown
of overall mean (amphetamine and methamphetamine) of 410 tons used on a pro rata basis.
Ecstasy: Taking into account occasional, moderate and heavy use, studies show that, on average, the eight million ecstasy users consume
about three tablets per week.  This amounts to an annual requirement for up to 1250 million tablets, or 100 tons to 125 tons of drug
(each tablet contains 80mg to 100mg).
** Drug seizures
Amphetamine and methamphetamine: Law enforcement officials estimate that seizures generally account for some 10% of the drugs
available.  Based on that estimate, and average global seizures over the last three years, where data are available, about 34 tons, the
clandestine market would amount to 340 tons.  Other more specific estimates have been made of interdiction successes, suggesting that
only about 7% of the drug is actually seized.  Using that information, estimated production amounts to about 490 tons.
Ecstasy: Similarly, based on average global seizures over the last three years of about 5 tons, the total production of ecstasy would amount
to 50 tons, rising to about 75 tons using the lower estimate for the interdiction rate.
*** Precursor seizures
Using a similar approach to that for drug seizures, estimates of the market for amphetamine and methamphetamine based on precursor
seizures range from 290 tons to 410 tons; and for ecstasy from 130 tons to 200 tons.
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Estimates produced by UNODC for its Ecstasy and
Amphetamines Global Survey 2003 were based on
seizures of the drugs, the precursors required for their
manufacture and estimates of consumer demand. These
estimates put annual production of ATS at around 520
tons (range: 390-641 tons) which is larger , in terms of
weight, than the global manufacture of heroin but
smaller than the global manufacture of cocaine. 
Production is dominated by methamphetamine, fol-
lowed by ecstasy and amphetamine 
Acknowledging for the complexity inherent in the pre-
cise breakdown of ATS production by substance, all
available indicators suggest that methamphetamine
accounts for the bulk of global ATS production, fol-
lowed by ecstasy and amphetamine. 'Amphetamines' -
i.e. methamphetamine and amphetamine together -
account for some 80%, and ecstasy for some 20% of
global ATS production. At least two thirds of the
'amphetamines' manufacture  is accounted for by
methamphetamine. (This ratio could go as high as 80%
based on a breakdown of amphetamines seizures over
the 2001-2002 period).    
Global ATS production increased over the last decade
The overwhelming portion of reported seizures of ATS
concerns substances produced in clandestine laborato-
ries. One indicator for the trends of illicit manufacture
is the number of clandestine laboratories detected and
seized. Based on ARQ data, about 11,900 clandestine
laboratories of all drug types were dismantled in 2002,
of these more than 80% (some 9,800) produced ATS.
This proportion was less than 20% in the early 1990s.
Although the size of clandestine laboratories can vary
significantly, the increasing number of dismantled ATS
laboratories over the last decade reflected a rise in global
ATS production. However, there are also indications
that the growth of seizures of clandestine laboratories
may have prompted global ATS production to stabilize
in 2002. Seizure and consumption data for some coun-
tries where such laboratories were closed down, point in
this direction.  
Most clandestine laboratories detected  produce
methamphetamine
Most dismantled ATS laboratories produced metham-
phetamine (about 95% in 2001 and 2002). Laborato-
ries producing a combination of ATS (mostly
methamphetamine, methcathinone, amphetamine and
ecstasy) came next (3%), followed by those producing
only amphetamine (1% in 2001) and only 'ecstasy'
(close to 1% in 2002). Only 0.2% of the dismantled
laboratories produced other synthetic stimulants.
Detections of ATS laboratories indicated a shift from
amphetamine to methamphetamine production over
the last two decades. In 1985, 26% of seized ATS labo-
ratories produced amphetamine, in 1990 17% and in
2002 only 1%. Meanwhile the proportion of metham-
phetamine laboratories increased from 69% in 1985, to
88% in 1990 and 95% in 2002.  (It should be noted,
however, that these trends are heavily weighted toward
the reported data provided by the USA, because the
large majority of all detections of ATS laboratories are
in the USA.)
Fig. 136: Detections of clandestine laboratories at the global level, 1990-2002
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2.4.1.1.  Methamphetamine 
A record number of methamphetamine laboratories and
methamphetamine precursor chemicals were seized in
2002
More than 9,300 clandestine laboratories producing
methamphetamine were dismantled in 2002 (up 14%
from a year earlier). In addition, 160 tons of pseu-
doephedrine and ephedrine, the 'raw materials' for the
manufacture of methamphetamine, were seized at the
global level in 2002 (up from 31 tons in 2001). This was
potentially enough to produce some 110 tons of
methamphetamine in 2002. Even discounting the pos-
sibility of multiple orders in anticipation of some ship-
ments being intercepted, seizures in 2002 of
methamphetamine precursors were much more impor-
tant in reducing global supply than seizures of metham-
phetamine as such (15 tons).  Most ephedrine and
pseudo-ephedrine continues to originate in the East &
South-East Asia region and in South Asia.   
Most methamphetamine laboratories are dismantled in
North America 
The largest number of clandestine methamphetamine
laboratories were dismantled in North America over the
last two decades. The USA undertook 97% of all
reported methamphetamine laboratories detections in
2002. North America also accounted for 95% of all
methamphetamine precursor seizures in 2002 (up from
72% in 2001).  These seizures increasingly involved
pseudo-ephedrine (96% of all methamphetamine pre-
cursor seizures made in North America in 2002), which
was often smuggled into the USA via Canada.
(Improved legislation introduced in Canada in 2003
should make such diversion of precursor chemicals
more difficult in the future). The US authorities
reported the detection of 9,024 methamphetamine lab-
oratories in 2002 (up from 7,990 in 2001). Fourteen
clandestine methamphetamine laboratories were dis-
mantled in Canada in 2002 (13 in 2001) and 10 in
Mexico (19 in 2001).  The efforts to dismantle metham-
phetamine laboratories in North America in recent years
seem to have had a positive impact despite the fact that
most of them are small-scale production units. The
decline in availability is reflected in the estimated 30%
decline in the annual prevalence of methamphetamine
use among 12th graders between 1999 and 2003, a wel-
come sign after having increased throughout the 1990s. 
The largest number of ATS laboratories dismantled in
East and South-East Asia was reported from China (13),
Myanmar (4) and the Philippines (4) in 2002. The
number of dismantled laboratories in East and South-
East Asia fell in 2002 as compared to a year earlier (44
in China, 10 in Thailand, 5 in Myanmar, 3 in the
Philippines and 1 in the Republic of Korea in 2001).
Though the dismantled laboratories in this region tend
to be significantly larger than those (usually) seized in
the USA, detections are not that numerous. This leaves
large portions of methamphetamine available for traf-
Fig. 138: Dismantling of methamphetamine
laboratories, 1985-2002
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Fig. 137: Detected ATS laboratories, 1985-2002
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ficking across the region.  Thus, over the 2001-2002
period,  87% of global methamphetamine seizures took
place in this region. Moreover, China, Myanmar and the
Philippines repeatedly reported seizures of ephedrine
through 2002.  India also reported some seizures of
ephedrine.
The largest number of clandestine methamphetamine
laboratories dismantled in Europe was in the Czech
Republic (104 in 2002, up from 28 in 2001). Germany
dismantled two clandestine methamphetamine labora-
tories. The only detection of a clandestine metham-
phetamine laboratory operating in Africa took place the
same year in South Africa.    
2.4.1.2.  Amphetamine
Ongoing rise of detection of clandestine laboratories in
2002
The number of detected amphetamine laboratories has
increased again in recent years after falling in the 1990s.
A number of countries do not report the specific kind
of ATS produced by detected laboratories ('combined
ATS'). It can be assumed that a number of these labo-
ratories produce amphetamine. The number of detec-
tions of amphetamine and 'combined ATS' laboratories
rose by 5% in 2002. This was more than 6 times higher
than a decade earlier. 
Concentration of amphetamine production in Europe 
The Russian Federation and other European countries
(the Netherlands and Poland, followed by Germany,
Belgium, Bulgaria, the Baltic countries, the UK and
France) reported the dismantling of amphetamine labo-
ratories in 2002.  More than 80% of all P2P seizures (1-
phenyl-2-propanone, also known as BMK), the main
precursor for the production of amphetamine, were
made in Europe in 2002. 
With a shift of production towards Eastern Europe 
A shift of production from Western Europe towards
Eastern Europe has been noticed since the mid 1990s.
The number of dismantled amphetamine laboratories
continued to rise in Eastern Europe in 2002, while
falling in Western Europe. Nonetheless, the Netherlands
remained the most frequently mentioned source coun-
try for amphetamine in 2002 (cited by other countries),
followed by Poland and Belgium.     Fig. 139: Seizures of methamphetamine-precursors
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Fig. 140: Detected amphetamine laboratories, 
1985-2002
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Fig. 141: Detection of amphetamine* laboratories in 
Europe
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2.4.1.3.  Ecstasy
Number of dismantled clandestine ecstasy laboratories
rises almost 3-fold over 1992-2002 period   
The number of dismantled ecstasy laboratories declined
slightly in 2002 but was still almost 3 times higher than
a decade earlier.  While in the late 1980s and early
1990s laboratories producing MDA, and to a lesser
extent  MDEA and other ecstasy-type substances,  still
played a role, almost all laboratories seized in 2000 and
subsequent years produced MDMA (ecstasy). 
Most ecstasy laboratories are still dismantled in Europe,
but production is rising in Asia  
Over the 2000-2002 period 56% of all ecstasy labora-
tories were dismantled in Europe (of which 98% in
Western Europe), 27% in North America,  13% in Asia
(mainly East and South-East Asia) and 4% in other
parts of the world (notably in the Oceania region and in
southern Africa). In 2002 most ecstasy laboratories were
dismantled in the Netherlands (18), followed by China
(11), the USA (9), Canada (8), Belgium (4), the UK
(3),  and Indonesia (2).  The Netherlands also contin-
ues to be the country most frequently identified by
other countries as the main source country for the
ecstasy found on their markets.  
The most striking trend in recent years has been the
increase of ecstasy production in East and South-East
Asia. While the number of dismantled ecstasy laborato-
ries declined in Europe, and  remained more or less
stable in North America, it increased strongly in Asia.    
Ecstasy precursor seizures rose in 2002 
Global ecstasy precursor seizures (expressed in MDMA
equivalents) increased by 17% in 2002 and were 76
times higher than a decade earlier, another indicator
that global production of ecstasy increased over the last
decade. Seizures of ecstasy precursor chemicals (which
reduced potential MDMA production by some 12 tons
in 2002) were higher than seizures of ecstasy as such (5
tons in 2002).  
The main ecstasy precursor is still 3,4-MDP-2-P (also
known as PMK). It accounts for 60% of all ecstasy pre-
cursor seizures. Eighty seven percent of all PMK was
seized in Europe in 2002. In 2001 and 2002 Dutch
authorities reported the largest seizures of PMK, while
in 2000 Belgium reported the largest seizures. A strong
increase in 2002 was reported for seizures of piperonal,
a 'pre-precursor'  for the manufacture of ecstasy (mainly
due to large seizures reported by Mexico).  Seizures of
safrole, another pre-precursor for ecstasy production
also rose in 2002, though levels remained under those
of 2000 (when record seizures were reported by the
Netherlands).  Ninety nine percent of all safrole seizures
in 2002 were made in Europe. Countries in South-East
Asia seem to be the main source for PMK and safrole. 
Fig. 142: Detection of laboratoriesproducting
substances of the ecstasy group, 1985-2002
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Fig. 143: Detection of laboratories producing
substances of the ecstasy group, regional
breakdown, 1985-2002
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Fig. 144: Seizures of 'ecstasy' precursurs in MDMA-
equivalents
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2.4.2.1. Overview
Following massive increases in the 1990s, ATS seizures
declined in 2002… 
Amphetamine-type stimulants (ATS) seizures showed a
marked upward trend in the 1990s, particularly in the
second half of the decade, and peaked in the year 2000.
This was consistent with a general trend of increasing
ATS production, trafficking and consumption. From
2001 to 2002, however, ATS seizures declined by 7%,
mainly due to a fall of methamphetamine seizures in
China.
Over the 1992-2002 period, China reported the high-
est ATS seizures, followed by Thailand, the USA, the
UK and the Netherlands. In 2001 and 2002, the high-
est ATS seizures worldwide were reported from Thai-
land, followed by China. 
Over the last decade, ATS seizures increased much more
rapidly than those of heroin or cocaine, despite the fall
in 2001 and 2002 described above.  Using 1990 as a
base line, ATS seizures rose more than ten-fold till the
year 2000. Though they declined in 2001 and 2002,
they were still higher than in 1998 and some six times
larger than in 1990. 
In 2001/2002, more than 60% of global ATS seizures
were of methamphetamine and close to 20% were of
ecstasy.  The majority of the remainder was ampheta-
mine seizures (14%). For 6% of all ATS seizures no pre-
cise identification, beyond the general category of ATS,
was possible.   
2.4.2. Trafficking
Fig. 145: Seizures of amphetamine-type stimulants
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Fig. 146: Changes in ATS, heroin and cocaine
seizures (Index: 1990 = 100)
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Fig. 147: Breakdown of ATS seizures in 2001 and
2002 (N = 30 tons p.a.)
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… with concentrations in East/South-East Asia, fol-
lowed by Western Europe and North America
In recent years, ATS seizures have been concentrated in
East and South-East Asia, followed, at some distance, by
Western Europe and North America.  East and South-
East Asia accounted for 55% of all ATS seizures in
2001/2002, up from 39% in 1991/1992.  Most of this
increase took place in the late 1990s. Europe accounted
for 25% and North America for 12% of total ATS
seizures in 2001/2002.   A mere 8% of global ATS
seizures were recorded outside these three areas.  
In 2002 ATS seizures continued to decline in East and
South-East Asia.  They also declined strongly in North
America, probably a consequence of the large-scale dis-
mantling of ATS laboratories in the USA that reduced
domestic supply and thus trafficking within North
America. Significant increases, however, were reported
from Western Europe.   
2.4.2.2.  Methamphetamine 
Methamphetamine seizures peaked in 2000 following
strong increases in the 1990s. Since 2000 they have fol-
lowed a downward trend, falling by 27% in 2002.  The
trafficking of methamphetamine continues to be con-
centrated in two sub-regions: East & South-East Asia
(87% of all seizures in 2001/2002) and North America
(13%). In both sub-regions, however, seizures declined
in 2002. The North American decline is likely to have
been a result of an intensified dismantling of laborato-
ries in the USA. National student surveys confirm a
reduction of methamphetamine availability in 2002.
The decline in East and South-East Asia was mainly a
consequence of ongoing declines of methamphetamine
seizures in China following record ones in 1999 and
2000. Methamphetamine seizures also declined in the
Philippines and Myanmar in 2002.  Forty countries
reported seizures of methamphetamine in 2002. The
world's largest ones were reported from Thailand (56%
of global seizures), China (21%), the USA (7%), Myan-
mar (6%), Japan (3%) and Mexico (3%).  Thailand
reported a small increase in seizures in 2002. This seems
to have been due to intensified enforcement efforts
rather than an increase in trafficking activities. In 2003
Thailand stepped up its anti-trafficking efforts leading
to forceful crackdown on the methamphetamine
market.
Eighteen countries were identified as sources of
methamphetamine in 2002. The main source countries
Fig. 148: Geographical distribution of ATS seizures 
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Fig. 149: ATS seizures in 1991/92 (N = 4 tons)
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were Myanmar (for Thailand), China and the Philip-
pines. Some of the methamphetamine exported from
the Philippines originated, however, in China.  Chinese
authorities reported that 18% of the methamphetamine
on their market actually originated in Myanmar. The
Democratic People's Republic of Korea (North Korea)
has been repeatedly identified as a source country (or at
least as a major transit country) by the Japanese author-
ities. The main source countries for North America are
the USA and Mexico and, to a lesser extent, the Philip-
pines. The main sources for methamphetamine found
in Australia were identified as China and, to a lesser
extent, Thailand and the Philippines.  
2.4.2.2.  Amphetamine 
Fifty-eight countries reported seizures of amphetamine
in 2002. Though significantly smaller than those of
methamphetamine, seizures of amphetamine showed an
ongoing increase in 2002 (+25%). In 2001/2002 almost
90% of global amphetamine seizures took place in
Europe and, within Europe, more than 90% in Western
Europe.  Amphetamine seizures outside Europe were
mainly reported from the Near and Middle East, North
Africa and North America. Over the last few years, the
world's largest amphetamine seizures have been made in
the UK (accounting for more than a third of global
seizures aj), reflecting the country's position as the
world's largest amphetamine market. The next largest
seizures in 2002 were reported from Belgium (11%) the
Netherlands (10%), Germany (8%) and Sweden (7%).
Amphetamine seizures increased in Western Europe
and, to an even greater extent, in Eastern Europe, but
declined in the rest of the world in 2002.    
Fig. 151: Global methamphetamine seizures
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Fig. 152: Distribution of methamphetamine seizures,
2001-2002 (N = 18.2 tons p.a) 
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Fig. 153: Methamphetamine seizures in 2001 and
2002
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aj) At the time of writing,  since the UK has not yet reported seizure data for 2002, it is assumed, for the purposes of this analysis, that seizure levels
in 2002 were similar to those reported in 2001.  
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Twenty-one countries were identified as sources of
amphetamine in 2002. The main source country con-
tinues to be the Netherlands: 40% of all countries
reporting a source of the amphetamine they seized
identified the Netherlands as the main source country.
Authorities in the UK estimate that 90% of their
imported amphetamine originates in the Netherlands.
Authorities in Sweden estimate that 65% of their
amphetamine comes from the Netherlands. The French
authorities identified 46% of the amphetamine on their
market as having originated in the Netherlands and
33% in Belgium. The next most frequently identified
source countries for amphetamine exports were Poland
and Belgium, followed by the Baltic countries (Estonia
and Lithuania).
Fig. 154: Global amphetamine seizures
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Fig. 155: Seizures of amphetamine in 2001-2002 
(N = 4.3 tons p.a.)
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Fig. 156: Origin of amphetamine in 2002* 
Source: UNDODC, Annual Reports Questionnaire Data/DELTA.
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Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Metric tons 4           5           11         7           10         15         14         33         44         26         
 * metric ton equivalents. 1 unit assumed to be equivalent to 30mg. 
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AMPHETAMINES (excluding 'Ecstasy') 
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2.4.2.3.   Ecstasy 
Strong increase in seizures in 2002 
Seizures of ecstasy showed a clear upward trend in the
1990s, followed by a temporary stabilization between
1999 and 2001, and a renewed upward trend in 2002,
when they were 42% higher than the previous year.  It
should be noted that a separate reporting category for
the 'ecstasy' group of substances (MDMA, MDA,
MDEA) was only introduced in 2000, when the Annual
Reports Questionnaire, the main source of data from
Governments, was revised.  Prior to that, ecstasy seizures
were reported under the category of  'other hallucino-
gens'. Analysis of seizure data shows that the bulk of the
substances reported under the category of 'other hallu-
cinogens' is accounted for by ecstasy (95% in
2001/2002).  This category therefore seems to be a rea-
sonably good proxy for tracing the trend of ecstasy
seizures over the last decade. 
Concentration in Europe, but increases in other regions 
In the early 1990s ecstasy trafficking was almost exclu-
sively concentrated in Europe. In recent years, however,
it has spread throughout the world. The European pro-
portion of ecstasy seizures thus fell from 80% of world
seizures in 1993/1994 to 62% in 2001/2002. More
than 95% of these were made in Western Europe. The
regional distribution of ecstasy seizures in the rest of the
world, in 2001/2002, were 19% in North America, 9%
in Oceania region, 6% in East and South-East Asia, 2%
in South America (including the Caribbean) and 1% in
the Near and Middle East.  In 2002, ecstasy seizures
increased strongly in Oceania, South America, the
Caribbean, the Near and Middle East and Europe, but
declined - for the second year in a row - in North Amer-
ica.
Seizures of ecstasy were reported by 79 countries in
Fig. 159: Ecstasy seizures, 1993-2002
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
Fig. 160: Ecstasy seizures, 1993-2002
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Fig. 161: Distribution of ecstasy seizures, 1993-94 
(N = 0.9 tons p.a.)
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Fig. 162: Distribution of ecstasy seizures, 2001-2002
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2002, up from 67 in 2001, 37 in 1995 and 20 in 1992.
The largest seizures worldwide were reported from Bel-
gium and the Netherlands with 25% and 24% of global
seizures, respectively. Significant ecstasy seizures also
took place in the UK, the USA, Germany, China,
France, Spain, Israel, Canada and South Africa.   
'Internationalization' of trafficking despite concentra-
tion of production
Slightly less than 70% of countries reported that the
ecstasy found on their markets in 2002 originated in the
Netherlands, down from 75% in 2001. Although
Dutch criminal groups manufacture ecstasy, they do not
appear to be significantly involved in its international
traffic. In recent years Israeli and Dominican criminal
groups were found to have been behind many transat-
lantic shipments of ecstasy from the Netherlands and
other European countries to the USA, and several Chi-
nese criminal groups became involved in smuggling
ecstasy from the Netherlands to South-East Asia. The
second most frequently mentioned source of ecstasy was
Belgium, reflecting a shift of some criminal groups as
controls were tightened in the Netherlands. The UK
reported that 80% of ecstasy imports originated in the
Netherlands and 20% in Belgium. France reported that
65% of seized ecstasy originated in the Netherlands and
9% in Belgium. Authorities in Italy identified almost all
of the ecstasy on their market as coming from either the
Netherlands or Belgium. Croatia reported that 60% of
its ecstasy seizures originated in the Netherlands and
10% in Belgium. 
Other frequently mentioned European sources of
ecstasy were Germany, the UK and a number of East
European countries, including Estonia, Poland, Bul-
garia, the Czech Republic and Hungary. In Asia, Thai-
land, China and Indonesia were the most frequently
reported sources. The USA and Canada were the most
frequently identified sources in North America; and
Colombia, Suriname and Mexico in Latin America.  In
Africa, the Republic of South Africa was the most fre-
quently reported source of ecstasy. Though a country
identified/reported as a source need not necessarily be
the actual source of the drugs, it should be noted that
most of the countries cited here as sources have, in fact,
dismantled ecstasy laboratories in their territories over
the last few years.  In practice, however, it may not
always be easy to differentiate between ecstasy produced
in the Netherlands and Belgium. 
Fig.163: Origin of ecstasy* 
4%
7%
11%
13%
16%
13%
16%
18%
24%
69%
0% 10% 20% 30% 40% 50% 60% 70%
South Africa
South America
North America
Asia
other Western Europe
United Kingdom
Germany
Eastern Europe
Belgium
Netherlands
* Number of times a country/region was identified by other countries as a 
source country for  ecstasy,  expressed as a proportion of countries providing 
such information in 2002 (N = 45).  
Sources: UNODC, Annual Reports Questionnaire Data, C/INTERPOL/WCO, Individual Seizures Database.
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Fig. 164: Global seizures of Ecstasy*, 1993 - 2002
*
* data refer to 2001.
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Use of Amphetamine-type stimulants 
Amphetamine-type stimulants (ATS), as defined by
UNODC, consist of (i) ‘amphetamines’ (amphetamine,
methamphetamine), (ii) a number of other synthetic
stimulants such as methcathinone, phentermine,
fenetylline, etc. and (iii)  ‘Ecstasy’ (MDMA; related
products such as  MDA and MDME, grouped together
with MDMA under the heading of 'ecstasy-group sub-
stances'). These substances are chemically or pharmaco-
logically related, and consumed by similar user
populations in several countriesak.  While consumption
of 'amphetamines' and of  'ecstasy'  can be regarded as
increasingly global in nature, most of the other synthetic
stimulants only play a role at the regional level (e.g.
methcathinone in the countires of the former Soviet
Union and in the USA or fenetylline in countries of the
Arabian peninsula).
The typical user 'profiles' of the various ATS are differ-
ent. In most countries, ecstasy is consumed by youth
and young adults in a recreational setting, often linked
to dance events. In developing countries its consump-
tion is mainly associated with youth of the upper class
while in developed countries consumption is spread
across all social classes. Other ATS are consumed by
both youth and adults.  Consumption by adults tends
to be more prevalent amongst those of the lower income
levels (‘poor man's cocaine’). A number of countries
suffer from serious methamphetamine problems and
related issues of violence, serious health degradation and
treatment demand. Methamphetamine is in general
more potent than amphetamine and thus causes more
serious health problems (including paranoia and
strokes) and problems of drug related violence. 
2.5.3.1.1. Amphetamines
Amphetamines account, on average, for some 10% of
treatment demand at the global level. The highest pro-
portion of treatment demand for ATS abuse is found in
Asia (17%), ahead of Australia (14%), Europe (10%),
Africa (7%) and the Americas (5%), including 11.5% in
the USA. In a number of countries in East and South
East Asia, particularly Thailand, the Philippines, Japan,
the Republic of Korea and, to a lesser extent, in Taiwan
Province of China, methamphetamine is the main prob-
lem drug and plays a role similar to opiates in Europe or
cocaine in the Americas.  In parallel, a strong spread of
recreational use of amphetamines took place in a large
number of countries in the 1990s. 
Amphetamines are used by an estimated 30 million
people or 0.7% of the global population age 15-64. In
addition, some 8 million people are estimated to take
ecstasy. Use of amphetamine-type stimulants at the
global level is thus more widespread than use of opiates
(15 million people, or 0.4%) or cocaine (more than 13
million people, or 0.3%). 
More than 60% of the users of amphetamines (mostly
methamphetamine) are found in Asia, with East and
South East Asia accounting for the bulk of ATS use
(more than 95% of all users in Asia). The prevalence
rate of ATS use (excluding ecstasy) in East-and South-
East Asia is 1.3% of the population age 15-64, almost
twice the global average. The world's highest levels of
methamphetamine consumption, prior to the crack-
down on its methamphetamine market in 2003, were
reported from Thailand: annual prevalence of 2.4% of
the population age 12-65 according to household survey
results in 2001. According to other official estimates
which derived the total number of methamphetamine
users through indirect methods, 5.6% of the Thai pop-
ulation age 15-64 used methamphetamine (or 'ya-ba' as
it is locally known) at the beginning of the millennium.
The next largest proportions of ATS use among the gen-
eral population are found in Oceania (2.8%), notably in
Australia (4% of the population age 15-64 in 2001) and
New Zealand  (3.4% in 2001). Over the last decade a
2.4.3. Abuse
2.4.3.1. Extent
ak) UNDCP, Amphetamine-type Stimulants: A Global Review, Vienna 1996. 
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shift from amphetamine to the more potent metham-
phetamine has taken place in this region.     
The Americas and Europe together account for a quar-
ter of global use of amphetamines. Use of ampheta-
mines in North America affects 1.3% of  the population
age 15-64 and is thus clearly above average in the Amer-
icas (0.9%). Annual prevalence of stimulants use in the
USA affected  1.4% of the population age 12 and above
in 2002,  equivalent to 1.65% of the population age 15-
64. About half of all ATS use is linked to methamphet-
amine.
The highest levels of amphetamines use in Europe have
been reported from the countries of Western Europe
(0.6% of the population age 15-64), notably from the
UK (1.6% in 2003), Ireland (1.6% in 2002), Denmark
(1.3% in 2000) and Spain (1.2% in 2001). The highest
levels among the new EU member countries are found
in the Czech Republic (1.1% in 2002), Estonia (1%)
and Poland (0.7%), i.e. countries which also happen to
be among the largest ATS producers in Central and
Eastern Europe.  Most of the ATS use in Europe con-
cerns amphetamine. The only exception is the Czech
Republic where the main ATS of abuse is methamphet-
amine.
While supply of amphetamines in North America,
Europe and Asia is largely from clandestine sources,
supply in South America and Africa is still mainly diver-
sion from licit channels. There are, however, indications
that in a number of countries in South America use of
licit ATS has been curtailed over the last decade. 
The highest levels of ATS use in Africa have been
reported from Western Africa, followed by countries in
Southern Africa. Various parallel markets, at the local
level, supply the demand for ATS in Africa. In South
Africa, in addition, some clandestine production of ATS
has emerged to supply the local markets. 
Number of  people in % of  population
(in million)     age 15 - 64
OCEANIA 1.94 2.78
EUROPE 2.37 0.44
- West Europe 1.79 0.58
- East Europe 0.59 0.25
AMERICAS 4.96 0.89
- North America 3.46 1.25
- South America 1.50 0.54
AFRICA 2.13 0.44
ASIA 18.16 0.76
GLOBAL 29.56 0.73
            Abuse above global average
            Abuse close to global average
            Abuse below global average
Table 13: Annual prevalence estimates of consumption of amphetamines: 2001-2003
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
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Map 22: Use of amphetamine-type stimulants 2001 - 2003 (or latest year available)
> 1% of  population
Level of Abuse (Annual prevalence)
0.3 - 0.5% of  population
0.1 - 0.3% of  population
0.5 - 1%  of  population
Main manufacturing  areas
< 0.1%  of  population
Data not available
Map 23: Ranking of amphetamine-type stimulants in order of prevalence in 2002 (or latest year available)
(1992)
2
1
Ranking
(1 = most prevalent drug)
7 or more
No data provided
4 - 6
3
2000
Sources: UNODC Annual Reports Questionnaires data,  National Household Surveys on Drug Abuse, UNODC Rapid Assessement Studies,
Council of Europe, ESPAD.
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More than 8 million people or about 0.2% of the global
population age 15-64 consume ecstasy. Rates signifi-
cantly above the global average have been reported from
countries in Oceania, Western Europe and North Amer-
ica. More than a third of global consumption is con-
centrated in Europe and more than 40% in North
America, a result of strong growth rates in the late
1990s. North America, Western Europe and Oceania
together account for some  80% of global ecstasy use.  
The highest levels of ecstasy use were reported from
Australia (3.4% of the population age 15-64 in 2001),
followed by Ireland (3.1% of the population age 18 and
above in 2002), the Czech Republic (2.5% of the pop-
ulation age 15-64 in 2002), New Zealand (2.2% of the
population age 15-64 in 2001),  the UK (2% of the
population age 16-59 in 2003), Spain (1.8% of the
population age 15-64 in 2001), the province of Ontario
in Canada (1.8% of the population age 18 and above in
2000), the USA (1.3% of the population age 12 and
above, equivalent to 1.6% of the population age 15-64)
and the Netherlands (1.5% of the population age 15-64
in 2001).    
Ecstasy use is spreading to Eastern Europe as well as to
developing countries, notably in the Americas, Southern
Africa, the Near and Middle East and South-East Asia.
A number of school surveys in countries outside West-
ern Europe, North America and Oceania confirm the
increasing importance of ecstasy as the drug of choice
among youth. 
Importance of ATS use compared to other drugs
The relative importance of ATS use (including ecstasy)
is strongest in the East and South-East Asia and Ocea-
nia, where it is ranked as either the 1st or 2nd drug of
choice. Methamphetamine is the main ATS of abuse in
most of East & South-East Asia and in the Oceania
region.  ATS were reported as the main substances of
abuse by the authorities of Thailand, Japan, the Repub-
lic of Korea and the Philippines and as  the 2nd most
widespread substance of abuse by China, Myanmar,
Indonesia and Australia. 
Amphetamine and ecstasy are ranked as the 2nd most
widespread drug in several countries of western Europe,
including the UK, Ireland, Spain, Germany, Switzer-
land, Austria, Belgium and Iceland and 3rd in the
Netherlands after cannabis and cocaine. In the Nordic
countries and in several Central and East European
countries ATS are ranked 3rd after cannabis and seda-
tives (mainly benzodiazepines). 
Number of  people in % of  population
(in million)      age 15 - 64
OCEANIA 0.54 2.23
EUROPE 3.02 0.56
- West Europe 2.45 0.80
- East Europe 0.57 0.24
AMERICAS 4.00 0.75
- North America 3.56 1.28
- South America 0.45 0.17
AFRICA 0.11 0.02
ASIA 0.59 0.02
GLOBAL 8.26 0.21
            Abuse above global average
            Abuse below global average
Table 14: Annual prevalence estimates of consumption of ecstasy: 2001-2003
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
2.4.3.1.2. Ecstasy 
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In most countries of the Near East, ATS (mostly
fenetylline, locally known as captagon) are ranked 3rd
after cannabis and sedatives or cannabis and opiates. In
Israel and in Jordan ATS rank 2nd. In contrast to other
countries in the region, the main ATS encountered in
Israel is ecstasy. 
In Africa and in the Americas ATS are ranked either 3rd
or 4th. While in North America methamphetamine is
the main ATS of abuse,  most countries of South Amer-
ica and Africa reported amphetamine (or related stimu-
lants contained in medicaments)  as the main ATS.  
> 1% of  population
0.3 - 0.5% of  population
0.1 - 0.3% of  population
0.5 - 1%  of  population < 0.1%  of  population
Data not available
Level of Abuse (Annual prevalence)
Map 24: Use of ecstasy 2001 - 2003 (or latest year available)
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The number of countries reporting trends in ATS con-
sumption almost tripled between 1992 and 2002,
reflecting the rising importance of ATS use across con-
tinents. A majority of the countries reporting on ATS
trends saw an increase in consumption levels over the
1992-2002 period. Thus UNODC's Drug Abuse Trend
Index reveals a clear increasing trend, notably in the late
1990s and in the first two years of the new millennium.
Most of the increase in 2002 was related to the use of
ecstasy. In contrast, more than half of all countries
reporting on methamphetamine saw a stabilization in
the use of that drug. 
The overall increase of ATS use in 2002 was, however,
less significant than a year earlier. The number of coun-
tries reporting increases in ecstasy, amphetamine and
methamphetamine use declined in 2002 (from two
thirds of all countries reporting on ecstasy in 2001 to
about half of the countries in 2002; and from about half
of the countries reporting on amphetamine and
methamphetamine in 2001 to about a third in 2002).
In parallel, the number of countries reporting declines
of ecstasy, amphetamine and methamphetamine con-
sumption increased in 2002. 
2.4.3.2. Trends
Fig. 165: Global ATS consumption trend based on
national experts' perceptions
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 166: Trends in ATS consumption in 2002
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Fig.167: Trends in ATS consumption in 2002
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Fig. 168: ATS consumption trends in 2001 and 2002
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2.4.3.1. 'Amphetamines' consumption trends
For the purposes of this section, amphetamine and
methamphetamine have been combined and are dealt
with under the heading of 'amphetamines'  (ATS
excluding ecstasy). A subsequent section will then cover
ecstasy use.
ASIA
Though overall use continued rising in 2002, a number
of countries in East and South-East Asia are reporting
some stabilization/decline in consumption levels 
Over the last decade, on average, increases in the use of
amphetamines (methamphetamine and amphetamine)
were more pronounced in Asia than increases at the
global level.  Two thirds of all countries in Asia report-
ing trends on amphetamines in 2002 were located in
East- and South-East Asia -- the sub-region known to
have the highest levels of methamphetamine use in the
world.
Large increases in the use of methamphetamine were
reported from China and Singapore in 2002; some
increases were reported from Myanmar and the Repub-
lic of Korea. Japan reported that consumption levels had
remained stable and the Philippines, Hong Kong SAR
of China and Indonesia reported falling levels of
methamphetamine use.
One national study among ATS (methamphetamine,
ecstasy and ephedrine) users across the People's Repub-
lic of China (conducted by the National Institute on
Drug Dependence and the School of Public Health over
the February 2001 - January 2002 period) confirmed
that ATS use was a rather recent phenomenon in China.
Eighty percent of those currently consuming ATS only
started to do so in 1997 or later; more than a quarter of
the ATS users only started in 2001. Concentrations of
ATS use are still in the southeast coastal areas of China,
though ATS use is spreading to inland regions. ATS use
was found to be fairly common in public areas of enter-
tainment (such as dance halls) in large and middle-sized
cities. The study also suggested MDMA, growing faster
than methamphetamine use, emerged as the main ATS
in China, which is a rather startling result as ecstasy was
not encountered in China until 1997. Methampheta-
mine is mostly in the form of 'ice' (domestically pro-
duced, notably in Guangdong and Fujian provinces),
though significant imports of methamphetamine pills
from neighbouring Myanmar, destined for markets in
north-eastern China,  were also reported in 2003.
Against the background of a rapidly expanding ATS
market, Chinese authorities launched major operations
over the August 2003-January 2004 period to disman-
tle trafficking rings (focussing on the Fujian and Guang-
dong provinces) and to prevent ATS use in dance halls
and other entertainment locationsal.          
Some of the strongest increases in recent years were
reported from Thailand where the proportion of people
admitted to treatment for abusing methamphetamine
Fig. 169: Amphetamines consumption trend in Asia 
based on national experts' perceptions 
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 170: China: Year in which ATS were used for the
first time (n = 1345 ATS users)* 
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Source: National Institute on Drug Dependence (Peking University)
and School of Public Health (Peking University, "Characteristics
and Consequences of Amphetamine-type Stimulants Abuse in
China", in Centre for Drug Research, Universiti Sains Malaysia,
Report of the Asian Multicity Epidemiology Workgroup 2002.
al) China National Narcotics Control Commission, 2003 Annual Report on Drug Control in China.
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rose from 2.1% in 1995 to 50.5% in 2001. (Out of
39,931 admissions for treatment of substance abuse,
20,157 patients consumed methamphetamine in 2001.)
In recent years, close to 80% of all reported violations
against the drug laws were related to methamphetamine.
Estimates provided by the authorities suggest that the
total number of methamphetamine users rose 6-10 fold
between 1993 and 2001, giving Thailand one of the
highest methamphetamine prevalence rates in the
world: affecting between 1 and 2½ million peopleai in
2001 (2.4%aj to 5.6% of the general population age
15-64) depending on estimates. Against the background
of a major methamphetamine epidemic, the Thai
authorities launched large operations (February 1 to
April 30, 2003) to crack down on the local ATS market.
The operations were successful insofar as 43,000 drug
dealers and 285,000 methamphetamine consumers
reported themselves to the authorities. Of these 175,000
were sent to treatment. Overall more than 90,000 drug
traffickers were arrested. Methamphetamine prices rose
3-4 fold over the first two months following the market
crack-downak.  Though prices fell again to some extent
in subsequent months, local supply did not fully
recover. It can be assumed therefore that overall
methamphetamine use declined in 2003. Few new users
are thought to have started to experiment with metham-
phetamine and the number of various drug related
crimes such as burglaries and robberies has declined.
Some 2,600 homicides were reported during the time of
the operations (roughly double the 'normal level').
About half of these deaths were considered by the police
to have been 'drug-related'.  There were also reports that
drug traffickers in neighbouring Myanmar, facing diffi-
culties selling their product in Thailand, targeted the
Indian market instead, which resulted in rising levels of
methamphetamine use in the eastern states of India.     
Another important market for methamphetamine in
South-East Asia is the Philippines. Since 1992,
methamphetamine (locally known as shabu) has been
the prime drug of abuse for those seeking treatment.
Close to 90% of all violations against the drug laws are
related to methamphetamine. Youth surveys, conducted
in the mid 1990s and in 1997/98, found a clear increase
in life-time prevalence rates from 7% (1.4 million) to
10% (2.1 million) of those aged 15-30. A Rapid Assess-
ment Study,  conducted in 3 locations (Antipolo, Cainta
and Tanay) in Rizal province, located to the East of the
ai) The number of all drug users was estimated at 2.65 million people by the authorities, 90% among them were methamphetamine users (derived
from the number of drug addicts who applied for treatment in 2001). (Office of the Narcotics Control Board, Thailand Narcotics Annual Report
2002, p. 9.)  
aj) Thailand also published results of a household survey, conducted in 2001.  According to this survey, 1,092,500 people used Ya-ba
(methamphetamine tablets) within the last year, equivalent to 2.4% of the population age 12-65. Annual prevalence of all illicit drug use concerned
1.9 million people. Life-time prevalence of Ya-ba concerned 3.5 million people, equivalent to 7.8% of the population age 12-65. Past month
prevalence of Ya-ba concerned about half a million persons, or 1.1% of the population age 12-65. (ONCB in collaboration of Assumption
University, Chiang Mai University, Chulalongkorn University, Khon Kaen University, Rajapat Institute Pibulsongkram, Rajapat Instittue Uttaradit
and Songkhla University, "Preliminary Report of Estimation of Population Related with Substance Abuse", quoted in ONCP, Thailand Country
Report, February 2003.)  
ak) ONCB, "War on Drugs" Concept and Strategy, Bangkok, Dec. 2003.
Fig. 171: Methamphetamine use in Thailand,
1993-2001
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Fig. 172: Methamphetamine abuse in Thailand: 
Proportion of drug addicts using  methamphetamine
over the last 30 days prior to entering treatment
(Number of patients in 2001: 39,931)
Source: ONCB, Thailand Narcotics Annual Report 2002 and
previous years
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capital Manila in June 2003, found a life-time preva-
lence rate of shabu of 5.7% among youth (age 16-25
year olds), less than for the use of marijuana (8.6%), but
more than for the use of any other drugam.  Estimates
of the overall number of regular methamphetamine
users in the Philippines range from 500,000 people
(1.1% of the population age 15-64), according to the
National Drug Law Enforcement and Prevention
Center for the late 1990s, to close to 1.8 million people
according to the Dangerous Drugs Board. The latter
figure refers to overall regular drug use. Based on the
number of people in treatment and other indicators
(seizures, arrests), it can be estimated that 70 to 90 per
cent of drug abuse is methamphetamine related. Based
on this, UNODC estimates that about 1.3 million
people, or 2.8% of the population age 15-64, may be
using methamphetamine. For 2002 and 2003, however,
the authorities reported a significant decline in metham-
phetamine use as a consequence of successful supply
reduction measures. Indeed, the above mentioned
Rapid Assessment Study among youth revealed that for
14% of the youth shabu was perceived to be difficult or
impossible to get, while only 9% considered shabu to be
easy to procure.   
Japan is another important methamphetamine market
in East Asia. Close to 90% of all reported violations
against the drug laws are related to methamphetamine.
Japan was the first country affected by methampheta-
mine abuse epidemics. These occurred in the early
1950s, in the 1970s, in the early 1980s, and again in the
second half of the 1990s. Over the last few years,
methamphetamine use appears to have stabilized
according to prevalence surveys undertaken by the Min-
istry of Health. Arrest and seizure statistics even point
to some decline in 2003.
am) UNODC, Primary Prevention of ATS Abuse among Youth in the Philippines, October 2003. 
Fig. 173: Reported violations against the stimulants law in Japan, 1950-2003
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Sources:  Ministry of Health and Social Welfare; National Policy Agency of Japan; UNODC, ARQ data; Headquarters for the Promotion of
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Fig. 174: Japan, Methamphetamine use among the
general population (age 15 and above) 
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Source: Ministry of Health, Labour and Welfare, National Resident
Survey on Drug Use, 2001.
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A combination of a broad range of preventive and
supply control measures appears to have been responsi-
ble for this success. These measures may also have pre-
vented Japan from suffering the same increases in
methamphetamine use experienced by several other East
and South-East Asian countries in recent years. While
the trend in Japan towards stabilization/moderate
decline in use is generally accepted,  prevalence esti-
mates continue to differ significantly depending on the
methods used to establish them. Prevalence estimates
range from 300,000 persons (0.3% of the population
age 15 and above or 0.4% of the population age 15-64)
based on household surveys conducted by the Japanese
Ministry of Healthan and reported to UNODC, to 2.8
million (3.2% of the population age 15-64) derived
from indirect methods, based on other Japanese sources,
regularly cited in the US International Narcotics Con-
trol Strategy Reports. According to the latter estimates,
the number of methamphetamine addicts is around
600,000; the number of casual users is about 2.18 mil-
lion. Based on the latter estimates, the Japanese author-
ities estimated the methamphetamine market to be
between 10 and 20 metric tons per year (INCSR 2004).
This would be equivalent to a wholesale value between
$300 and $600 million and a retail value between $4
and $8 billion, making Japan, in financial terms, the
most lucrative methamphetamine market in East and
South-East Asia.
OCEANIA
Stabilization of amphetamines use in the Oceania
region 
Australia and New Zealand are the main markets for
amphetamines (notably methamphetamine) in Oceania.
According to national household survey data from Aus-
tralia, 3.4% of the population age 14 and above (or 4%
of the population age 15-64) used amphetamines
(methamphetamine and/or amphetamine) in 2001, the
Fig. 175: Japan, Methamphetamine abuse among
lower secondary school students 
(age 13-15) 
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Source: Ministry of Health, Labour and Welfare, National Survey
on the Awareness and Actual Conditions of Drug Abuse among
Junior High School students", 2002.  
Fig. 176: Australia, Annual prevalence of amphetam-
ines use (population age 14 and above)
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an) The lower numbers seen in household surveys  may, however, also reflect the  stigma associated with methamphetamine use and the fear that the
personal acknowledgement of methamphetamine use could entail negative personal consequences. 
Fig. 177: Australia: Percent testing positive for
amphetamines among male police
detainees*, 2000-2002 
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second highest rate worldwide after Thailand (or the
largest rate if only estimates from household surveys are
compared; cross-country comparisons, however, may be
partly misleading because the tendency to under-report
drug use in Australia is less than in other parts of the
world). The strong upward trend, reported over the
1995-1998 period, did not continue in subsequent
years, and gave way to a period of stabilization. 
The DUMA surveys ('Drug Use Monitoring in Aus-
tralia' testing police detainees for drug consumption
based on urine analysis) showed that, in the course of
2001, amphetamines use increased for a short period of
time - reflecting substitution effects resulting from the
heroin shortage in 2001 - before declining again in
2002. Similarly, data collected among injecting drug
users (IDUs) showed a temporary increase in abuse in
2001 followed by a decline in 2002.  The use of
methamphetamine seems to be highest in South Aus-
tralia and in Queensland. 
AMERICAS
Some increase in the Americas … 
UNODC's Drug Abuse Trend Index showed some
increase in the use of amphetamines in the Americas as
of the mid 1990s. The increase was, however, signifi-
cantly less than in Asia.
… with  mixed results reported from North America … 
Results of surveys in North America over the last few
years have been mixed. Use of amphetamines among the
general population remained relatively stable over the
last decade, though fluctuations were observed in indi-
vidual years. Overall use of stimulants affected 1% of
the general population age 12 and above in 1991 and
1.1% in 2001. Results for 2002 - which are not directly
comparable with those of previous years - showed a
prevalence rate of  1.4%. Half of the stimulant use was
related to use of methamphetamine (0.7%). 
The number of people treated for amphetamines abuse,
however, more than quadrupled over the 1992-2001
period, mainly due to methamphetamine abuse. More
than 80% of all stimulant related treatment demand in
2001 was caused by methamphetamine, up from 66%
in 1992.  Data also show that over the last decade
methamphetamine abuse gradually spread from the
western states towards the rest of the country. Nonethe-
less, abuse is still highest in the western and south-west-
ern parts of the country and rather low in the eastern
states of the USA. 
There were also positive trends to report. In both the
USA and in Canada (Ontario) use of amphetamines
among high-school students peaked at high levels
around 1996/97 and has been showing a  downward
trend since, including in 2003.  In the USA, use of
amphetamines in 2003 was some 20% lower among
high school students than in 1996.  In Ontario  it was
some 25% less than in 1997. For 2003, a decline in the
use of amphetamines (in general, as well as for metham-
phetamine) in the USA was reported among 8th, 10th
and 12th graders. Methamphetamine use among high-
school students declined for the fourth year in a row.     
Fig. 178: Amphetamines consumption trends 
in the Americas, based on national experts'
perceptions 
Source: UNODC, Annual Reports Questionnaire Data.
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Fig. 179: Stimulants abuse in the USA among the
general population (age 12 and above)
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A basically stable level of amphetamines use was
reported from Mexico.  In both 1998 and 2002, 0.1%
of the population used amphetamines. In Mexico,
slightly more than 90% of all  amphetamines use takes
place in urban areas and - in contrast to other drugs -
most amphetamines are used by women (close to 60%).  
and some increase reported from South America …
In contrast to overall stable trends in North America,
some increases in amphetamine use were reported in
2002 from countries in the southern cone of South
America: Argentina, Chile and Paraguay. In Brazil, the
largest South American country,  the annual prevalence
of the use of amphetamines amounted to 0.3% of the
general population (age 12 and above) in 2001. This
was slightly lower than in Chile (0.4% in 2000) and
lower than in Argentina (0.7% in 1999).
Fig. 180: Primary methamphetamine/amphetamine
admission rates in the USA by State per
100,000 population aged 12 and above
Source: SAMHSA, Treatment Episode Data Set (TEDS), 1992-2001,
December 2003.     
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Fig. 181: Amphetamines abuse related treatment
admissions in the USA
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Fig. 182: Annual prevalence of amphetamines use in
the USA and Ontario (Canada) among high-
school students
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Fig. 183: Average per capita consumption of licit
stimulants in Latin America* in defined
daily doses (DDD) per capita  
3.10
2.86
2.17
1.55 1.41 1.36 1.44 1.51
1.80
5.3 5.2
3.2
2.8
2.6 2.6 2.8
3.7
4.3
0
1
2
3
4
5
6
92-
94
93-
95
94-
96
95-
97
96-
98
97-
99
98-
00
99-
01
00-
02
D
D
D
 p
er
 c
ap
it
a
unweighted average
average (weighted by population)
* average is based on information from 14 countries
Sources: Centre for Addiction and Mental Health, Drug Use
Among Ontario Students, 2003 and NIDA, Monitoring the Future
2003.
187
2. Trends Amphetamine-type stimulants
Clandestine manufacture of amphetamines - sofar - has
only played a minor role in this region. Only small
amounts of amphetamines have been seized, with no
reports of ephedrine, pseudo-ephedrine or P-2-P seized,
and few reports of detected laboratories (the first offi-
cially reported dismantling of an amphetamine produc-
ing laboratory to UNODC concerned Chile in 2002).
It can be assumed, therefore,  that most of the synthetic
stimulants used in the countries of South America
remain pharmaceutical preparations diverted from licit
channels (often marketed as anorectics or as medication
to treat Attention Deficit Disorder (ADD)). The calcu-
lated per capita consumption of licit stimulants, after
having declined strongly in the early 1990s, stabilized in
the mid 1990s and has shown an upward trend over the
last few years.     
EUROPE
Stabilization of amphetamine consumption in Western
Europe 
Following massive increases in the consumption of
amphetamines (mainly amphetamine) in the 1990s, the
overall trend for Western Europe as a whole was basi-
cally stable over the 2000-2002 period. In 2002 this was
the net result of  declines reported from the UK and Ire-
land, stable trends reported from Sweden, France,
Netherlands, Italy, Spain and Portugal and increases
reported from Germany (though no further increases
were observed in 2003), Austria and Denmark. 
The most impressive decline in the use of amphetamine
over the last few years was reported from the UK,
Europe's largest amphetamine market. Annual preva-
lence of amphetamine use - after having increased
strongly in the early 1990s - fell from 2.9% in 1996 to
1.6% in 2002, according to the British Crime Survey
data. Similarly, the National Health & Lifestyle Surveys,
conducted in the Ireland showed a strong decline in
annual prevalence rates of amphetamine use from 2.6%
in 1998 to 1.6% in 2002.
In Sweden, one of the first countries in Europe affected
by a serious amphetamine epidemic, surveys undertaken
among military recruits found declining levels of
amphetamine use in the 1970s and in the 1980s. This
was followed by strong increases in the early 1990s,
which reached a peak in 1998. Since then the trend has
been towards stabilization and - over the last few years -
decline. Preliminary data for 2003 suggest that the
lowest level since 1996 was reached. A general popula-
tion survey (age 15-75) conducted in 2000 showed an
annual prevalence of amphetamine use of less than
0.5%.
Fig. 184: Amphetamines consumption trend in
Western Europe: based on national experts'
perceptions 
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 185: United Kingdom, Amphetamine abuse
among the population age 16-59
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Source: Home Office, British Crime Surveys 2001/02 and previous
years.
Fig. 186: Ireland: Amphetamine abuse among the
general population age 18 and above
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Trends in amphetamine use in Norway, as reflected in
annual youth surveys conducted since the late 1960s,
have been similar to those observed in Sweden.  Fol-
lowing declines in the second half of the 1970s and the
1980s, amphetamine use increased again in the 1990s.
Since the late 1990s prevalence rates have been falling
in Oslo and since 2001 they have basically stabilized in
Norway (though in 2003 they were higher than in the
previous year). The overall levels of amphetamine use
are, however, higher in Norway (1.2% in 1999 among
the general population, age 15-64 ) than in Sweden. 
In France, general population survey data showed an
increase in the 1990s, but a stabilization in recent years.
Annual prevalence of amphetamine use among the gen-
eral population (age 15-64) was - as reported to
UNODC - 0.2% of the population age 15-64 in 2002,
the same level as in 2000. The number of 'interpella-
tions' (reports/arrests by the police) for amphetamine
use declined between 1998 and 2002. Following
increases in the early 1990s, investigations among youth
showed a relatively stable level of amphetamine use over
the 1995-2002 period (except for low levels reported in
one study in 2000).  
Fig. 187: Life-time prevalence of amphetamine use among military recruits in Sweden (1976-2003)
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Fig. 188: Norway, Amphetamine use among youth
(age 15-20)
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Fig. 189: France, annual prevalence of amphetamine
abuse among the general population
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Questionnaire Data.
Fig. 190: France, Life-time prevalence of
amphetamine use among youth 
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In Italy, life-time prevalence of amphetamine use among
those aged 15-19 showed increases in the early 1990s. It
declined over the 1999-2001 period. Between 2001 and
2002 the reported levels remained unchanged. Similarly,
data on drug use amongst those in military service,
showed an increase in amphetamine use until 1998 and
a decline/stabilization thereafter. With regard to people
in treatment for amphetamine abuse,  increases (from
very low levels) were noticed until 1996. Between 1992
and 2002, the number of people undergoing treatment
for amphetamine abuse declined. Practically no change
was observed between 2001 and 2002. Overall, 0.1% of
the population age 15-44 was found to use ampheta-
mine in Italy in 2002.
In Germany, the annual prevalence of amphetamine use
increased strongly in the 1990s. The number of first
time registered amphetamine users peaked in 1998, and
remained largely stable over the 1998-2003 period.
Hardly any change was observed between 2002 and
2003. The highest per capita arrests for the posses-
sion/consumption of amphetamines have been reported
from some of the states close to the Benelux countries
(Rheinland-Pfalz and Saarland) and towards the east, by
Bavaria, Thüringen and Sachsen, i.e. states close to the
Czech Republic. The main synthetic stimulant found in
Germany continues to be amphetamine (95%); close to
5% of all stimulants related violations against the
German narcotics law concerned methamphetamine in
2003. Methamphetamine use is concentrated (80%) in
the two states which border the Czech Republic, Bavaria
and Sachsen.    
Amphetamines consumption in Eastern Europe stabi-
lized in 2002
Following years of reported increases, countries of East-
ern Europe reported - for the first time - largely stable
levels of amphetamine consumption in 2002. Out of 13
East European countries, 8 countries reported a stable
level of amphetamine use in 2002 (up from 5 countries
in 2001 and 2 in 2000). No Eastern European country
reported a strong increase in 2002. Most of the increase
in amphetamine use in 2002 was concentrated in the
Balkan region. Trends among the new EU countries
were mostly stable.  
Poland, the main illicit amphetamine producing coun-
try of Eastern Europe and the largest market overall in
Fig. 191: Italy: Life-time prevalence of amphetamine
abuse among youth, (age 15-19)
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Fig. 192: Italy: Number of people treated for
amphetamine abuse
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Fig. 193: Germany: Amphetamine use (1987-2003)
0.2%
0.6%
0.5%
6654 6588
0
2,000
4,000
6,000
8,000
87 89 91 93 95 97 99 01 03
n
u
m
b
er
 o
f 
fi
rs
t 
ti
m
e 
re
g
is
te
re
d
 
u
se
rs
0.0%
0.2%
0.4%
0.6%
0.8%
an
n
u
al
 p
re
va
le
n
ce
 in
 %
Annual prevalence in % (age 18-59)
No. of first time registered users
Sources: UNODC, Annual Reports Questionnaire Data,
Bundesministerium für Gesundheit, Repräsentativerhebung 1997,
L. Kraus and R. Augustin, Repräsentativerhebung zum Gebrauch
psychoaktiver Substanzen bei Erwachsenen in Deutschland 2000,
Sucht, Sonderheft 1, Sept. 2001, and Bundeskriminalamt,
Rauschgiftjahresbericht 2002 and BKA, Jahreskurzlage Rauschgift
2003.
190
World Drug Report 2004 Volume I. Analysis
the region, reported some decline of local amphetamine
consumption in 2002. Annual prevalence of ampheta-
mine use among the general population (age 16 and
above) amounted to 0.6% in Poland in 2002,  equiva-
lent to 0.7% among the general population age 15-64.
The prevalence rate was thus less than methampheta-
mine use in the neighbouring Czech Republic (1.1%
among the general population in 2002) or use of
amphetamine in Estonia (1% in 1998). It was, however,
higher than in neighbouring Slovakia (0.2% in 2002),
and higher than amphetamine use in Hungary or Slove-
nia (life-time prevalence of 1.7% or 2% among 15-64
year olds in Poland, versus 1.6% in Hungary and 0.4%
among 15-64 year olds in Slovenia). As compared to
countries in Western Europe annual prevalence of
amphetamine use in Poland (0.7%) was less than in the
UK (1.6% in 2002), Ireland (1.6% in 2002), Denmark
(1.3% in 2000), Spain (1.2% in 2001) or Norway
(1.2% in 1999). It was similar to the levels reported
from Germany (0.6% in 2000) and the Netherlands
(0.6% in 2001) and higher than amphetamine use in
Finland (0.5%), Sweden (<0.5% in 2000),  France
(0.2% in 2002), Italy (0.1% in 2001), Greece (0.1% in
1998)  or Portugal (0.1% in 2001).    
AFRICA
Stabilization of amphetamines use in Africa in 2002 … 
In Africa there appears to have been a stabilization in the
use of amphetamines in 2002 with five African coun-
tries reporting an increase, six a stabilization and four a
decline. Though consumption of various amphetamine-
type stimulants is widespread in Africa, relatively few
countries reported consumption trends regarding
amphetamines in 2002.  This could be because the use
of these substances is a matter of only secondary impor-
tance, for the authorities in several African countries,
and/or that the control mechanisms introduced at the
international level over the last few years to reduce
diversion from licit channels to illegal markets are show-
ing positive effects. The main source of the various
amphetamine-type stimulants in Africa are parallel mar-
kets, where legal medicines are diverted and sold with-
out prescription. The only country where clandestine
manufacture of amphetamine-type stimulants has
repeatedly been reported in recent years, is the Repub-
lic of South Africa.    
… despite increases in Southern Africa
Amphetamine use in Southern Africa appears to have
increased in 2002. Though use of amphetamines is
hardly noticeable among the general population and
treatment demand for the use of amphetamines is still
very low, use among youth was found to be already
rather high. (The life-time prevalence of 5% among
youth  (mean age 17 years) in Thukela district of Kwa
Zulu-Natal Province, South Africa in 2002 is higher
than  the corresponding rates for cocaine (3.7%) or
heroin (2.7%)). There have been also reports regarding
the emergence of crystal methamphetamine ("ice") in
Cape Town and of an increasing availability of meth-
cathinone (locally known as "CAT") in Cape Town and
Gauteng (Johannesburg, Pretoria) in 2002.   
In contrast, most of the countries in Eastern Africa and
Northern Africa saw amphetamine use stabilize or
decline. In Western Africa the situation was mixed.
Fig. 194: Amphetamines consumption trend in
Eastern Europe: based on national experts'
perceptions 
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 195: Amphetamines consumption trend in
Africa: based on national experts'
perceptions 
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Source: UNODC, Annual Reports Questionnaire Data.
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2.4.3.2.2.  Ecstasy 
Ecstasy use continues rising, but at a much lower  pace
than in previous years
Global ecstasy consumption has increased consistently
over the last decade. Ecstasy has been treated separate
from amphetamines only since the revised Annual
Reports Questionnaire was introduced in 2001. Any
trend data analysis prior to this year is thus potentially
misleading.
The following review will concentrate on trend data
received for the years 2001 and 2002. In 2001, two-
thirds of the countries reporting ecstasy trends (n = 56)
reported an increase in ecstasy use.  In 2002 half of the
countries reporting ecstasy trends (n = 53) perceived
increases in consumption. In parallel, the countries
reporting declines rose from 10% in 2001 to 17% in
2002.
Global ecstasy consumption thus appears to have con-
tinued rising in 2002, though at a significantly slower
pace than in 2001. The ongoing popularity and conse-
quent spread of ecstasy use in many developing coun-
tries continued. In several of the largest ecstasy markets
of Europe and North America, where massive increases
were experienced in the 1990s, ecstasy consumption sta-
bilized or showed signs decline.
EUROPE
Following years of massive increases, several countries
saw signs of stabilization in 2002/2003
In contrast to previous years when practically all coun-
tries reported strong increases, 10 out of 15 West Euro-
pean countries reported a stabilization of ecstasy
consumption trends in 2002, suggesting that demand
and supply reduction interventions, undertaken over
the last few years, are starting to show positive results.
Only 4 countries (UK, Ireland, Spain and Denmark)
continued to report an increase. In Eastern Europe 5 out
of 11 countries reported that ecstasy use remained stable
or declined, while 6 countries reported ongoing
increases (most of them in south-eastern Europe).   
Within Europe, Western Europe was the first to be
affected by rapidly rising levels of ecstasy consumption.
Beginning in Spain and the UK (late 1980s) consump-
tion then spread to the rest of the continent. In the
second half of the 1990s, overall ecstasy use continued
to increase. This was reflected in the ESPAD (European
School Survey Project on Alcohol and Other Drugs)
studies, which were conducted among 15 to 16 year
olds in some 30 countries on behalf of the Council of
Europe. The overall increase in the second half of the
1990s was, however, mainly due to rapidly growing
levels in the East European countries, notably Latvia,
Lithuania, the Czech Republic, Slovenia, Estonia and
Hungary. In contrast, a number of West European
countries, including the UK, Ireland, the Netherlands,
Italy, Iceland and Cyprus reported falling levels of
ecstasy use over the 1995-1999 period. 
In Spain, annual prevalence of ecstasy use increased
until the mid 1990s, declined between 1995 and 1999
but rose again  between 1999 and 2001 from 0.8% to
1.8% of the population age 15-64, one of the highest
levels in Europe. The number of people in treatment for
ecstasy abuse exhibited a similar pattern. The propor-
tion of emergency room visits due to ecstasy abuse rose
from 2.4% of all drug related emergency room visits in
1999 to 4.4% in 2001. 
Fig. 196: Global ecstasy consumption trends, 2001 
(n = 56)
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 197: Global ecstasy consumption trends, 2002 
(n = 53)
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Source: UNODC, Annual Reports Questionnaire Data.
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National surveys on illicit drug use conducted in the
Netherlands revealed a significant increase in the annual
prevalence of ecstasy use between 1997 and 2001.
During this period ecstasy use almost doubled, from
0.8% to 1.5% of the general population (age 15-64). In
Amsterdam, prevalence of ecstasy use rose 5-fold over
the 1990-2001 period. The Dutch authorities, however,
did not observe any further rise in 2002. 
General population surveys in the UK revealed an
upward trend over the 1992-2002 period, including
over the 1998-2002 period. Annual prevalence of
ecstasy use of the population age 16-59 was found to be
2.2% in England and Wales in 2002, up from 1.6% in
1998. In 2003, however, the ecstasy prevalence rate
declined slightly to 2%. Similar kind of stabiliza-
tions/declines also appear to have taken place in some
other European countries.  
The National Health & Lifestyle Surveys conducted in
Ireland (based on a mail survey) showed a clear increase
in the annual prevalence of ecstasy use from 2.4% in
1998 to 3.3% in 2002. A peak in ecstasy use, however,
may have been reached. A household surveyao, con-
ducted in Ireland and in Northern Ireland (through
face-to-face interviews) towards the end of 2002 and
Fig. 198: Spain: annual prevalence and persons
treated for ecstasy abuse 
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sobre Drogas, Noviembre 2003.   
Fig. 199: Netherlands: annual prevalence of ecstasy
use among the general population
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Fig. 200: England & Wales: Ecstasy use among the
general population age 16-59, 1994-2003
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Fig. 201: Ireland: ecstasy use among the general
population age 18 and above
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ao) National Advisory Committee on Drugs (NACD) and the Drug and Alcohol Information and Research Unit (DAIRU) , Bulletin 1 - Drug Use in
Ireland & Northern Ireland, first Results from the 2002/2003 Drug Prevalence Survey, October 2003.      
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early 2003, revealed a significantly lower annual preva-
lence rate of 1.1% among the general population (age
15-64) in the Republic of Ireland (about half the level
reported from the UK). Ecstasy use in Northern Ireland
affected 1.7% of the population age 15-64. The manner
in which methodological differences (face-face-to-face
interview versus mail questionnaire) and actual changes
in prevalence may respectively have influenced the
results needs to be further examined.
Data for Sweden showed an upward trend in ecstasy use
until 2002. In 2003, however, ecstasy use (based on life-
time prevalence of ATS use among military recruits) fell
to its lowest level since 1999. Annual prevalence among
the general population was less than 0.5% in 2000. 
In Norway the annual youth surveys revealed massive
increases of ecstasy use in the 1990s, consistent with
trends in the rest of Europe. In 1999 annual prevalence
of ecstasy use was found to affect 0.7% of the popula-
tion (age 15-64). As in Sweden, increases in the 1990s
were followed by a stabilization in the first years of the
21st century. Youth surveys as well as test results from
people driving under the influence of drugs revealed
such a pattern. In 2003, however, the prevalence rates
for ecstasy use increased again and were slightly higher
than in 2000 or 2001. 
After having increased strongly in the first half of the
1990s, general population and youth surveys in Ger-
many revealed a small decline in ecstasy use between
1997 and 2000/2001. Annual prevalence of ecstasy use
in the general population (age 18-59) fell from 0.8% in
1997 to 0.6% in 2000. This was the result of two
opposing trends: ecstasy use declined in the 'old
provinces' (former West-Germany), but  increased in
the 'new provinces' (former East Germany). It is  the
only drug which is already more widespread in the new
provinces than in the old. The number of persons regis-
tered for ecstasy use rose in the 1990s, but fell by 22%
in 2002 and by 29% in 2003, reaching the lowest levels
since 1999.
Fig. 202: Life-time prevalence of ecstasy among
military recruits in Sweden (1994-2003)
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Source: Centralförbundet för alcohol och narkotikaupply-sning,
Drogutvecklingen I Sverige - Rapport 2003, Trends in Alcohol and
other Drugs in Sweden,  Report 2003.
Fig. 203: Norway: Life-time prevalence of ecstasy
use among  youth (age 15-20), 1994-2003
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Fig. 204: Germany: Ecstasy use among youth and in
the general population, 1997 and
2000/2001*
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Similar trends were also reported from Italy. Ecstasy use
showed strong increases in the early 1990s, but appears
to have levelled off in subsequent years, as shown by
data of the Italian ESPAD school-surveys. A national
household survey conducted in 2001 found the overall
level of ecstasy use to be 0.2% of the general population
(age 15-44),  less than in most other European coun-
tries.
Surveys undertaken in France indicated strong increases
in ecstasy use in the 1990s basically stabilizing among
the general population (age 15-64) over the 1999-2002
period (0.2% according to data provided to UNODC).
(There are, however, indications that ecstasy use among
young adults continued rising).  
AMERICAS
Following years of massive increase,  declines were
reported in North America for 2002 and 2003 
Ecstasy use in the Americas was first reported in the
early 1980s in the USA. The national control of
MDMA began in 1985 and was followed by interna-
tional control a year later. The spread of ecstasy was sub-
sequently halted for several years. The next wave of
expanding ecstasy use was only identified in the 1990s,
mainly among youth. The increase of ecstasy use in the
1990s is reflected - inter alia - in the tripling of life-time
prevalence rates among the general population between
1994 (1.3%) and 2001 (3.6%). The upward trend,
however, did not continue in subsequent years. Annual
prevalence of ecstasy use, first recorded in 2001,
declined from 1.4% in 2001 to 1.3% in 2002. Given
methodological changes which reduced under-reporting
and thus led to higher numbers for the year 2002, the
actual decline between 2001 and 2002 was probably
more important than indicated by existing data. During
that period ecstasy use among the general population
continued to be less widespread than use of cocaine
(2.5%).  It was about the same level as the consumption
of stimulants (1.4%), and more widespread than use of
LSD (0.4%) or heroin (0.2%). Despite the decline of
ecstasy in 2002, ecstasy use is more widespread in the
USA than in Western Europe. In Europe levels surpas-
sing those of the USA were only reported from the UK,
Spain and the Netherlands.
Fig. 205: Germany: newly registered ecstasy users
and annual prevalence of ecstasy use in
population age 18-59
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Fig. 206: Italy: life-time prevalence of ecstasy use
among students, age 14-20
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Fig. 207: France: ecstasy use 
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The Monitoring the Future surveys among young adults
(age 18-30) found an almost tenfold increase in the
annual prevalence rates of ecstasy use between 1991
(0.8%) and 2001 (7.5%). In 2002, however annual
prevalence declined, and a further decline can be
expected for 2003.  The average annual prevalence of
ecstasy use among high-school students (8th, 10th and
12th grades)-- which had doubled (from 2.9% to
6.3%) between 1998 and 2001-- fell to  5.1% in 2002
and to 3.2% in 2003, the lowest such rate since 1998.
Thus, between 2001 and 2003 ecstasy use among high-
school students fell by almost 50% (by more than 50%
among 8th and 10th graders and by 40% among 12th
graders).
The strong decline in the prevalence of ecstasy use over
the 2001-2003 period took place in parallel to increases
in the perceived harmfulness of ecstasy (trying MDMA
once or twice is a great risk)  and reduced availability
(‘easy or fairly easy to get’).  It is worth noting that pre-
vention activities in the second half of the 1990s helped
to raise the public's perception of the  risk associated
with ecstasy experimentation. Unfortunately, a strong
increase in availability offset all progress made in pre-
vention efforts over the 1998-2001 period. Once avail-
ability stopped rising, the prevention efforts succeeded
in lowering ecstasy consumption.  This was the case over
the 2001-2003 period.
The Monitoring the Future survey results also revealed
that ecstasy use is still more widespread in the north-
easternap parts of the United States (more than a third
higher than the national average in 2002), possibly
reflecting closer links with Europe where most of the
ecstasy originates.  Another finding was that ecstasy
users come from the middle class, in contrast to, for
instance, crack-cocaine, heroin or crystal methamphet-
amine users who usually are from poorer population
segments (measured in terms of the parental education
level of high school students).  
Fig. 208: USA: Ecstasy use among the general
population, age 12 and above 
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Fig. 209: USA:  Ecstasy use among high-school
students and young adults*, 1991-2003
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Fig. 210: USA:  perceived availability, harmfullness
and prevalence of ecstasy among 12th
graders
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Trends reported from Ontario, Canada showed almost
an identical pattern as that observed in the USA. Fol-
lowing a tripling of ecstasy use among high-school stu-
dents over the 1995-2001 period,  ecstasy use fell by a
third over the 2001-2003 period, the strongest decline
for any substance (from 5.8% to 3.8%). Similar to the
USA, the perceived availability of ecstasy in Ontario
declined between 2001 and 2003 (from 27% to 20% of
the 7th -11th graders), while the perceived risk of using
ecstasy increased (from 33% to 40% of the 7th -11th
graders). The use of ecstasy among high-school students
in Ontario (3.2%) is now less widespread than cocaine
(5.1%) or methamphetamine use (3.6%) but more
widespread than LSD (2.9%) or heroin (1.4%). In 2000
(and thus prior to falling ecstasy use levels in Canada),
ecstasy use among the general population of Ontario
was found to affect 1.8% of those age 18 and above,
more than in the USA or in Western Europe.  
While ecstasy use in Southern America continues to
expand, though at a lower pace ...
Out of nine countries reporting on ecstasy trends in
southern America (including the Caribbean and Central
America) in 2002, five countries (Colombia,
Guatemala, El Salvador as well as the Dominican
Republic and Trinidad & Tobago) reported some
increase and four countries reported a stable level of
ecstasy use. This suggests that the expansion of ecstasy
in the region continued, though at a lower pace than a
year earlier. In 2001, 13 out of 19 countries reported
increases in ecstasy use (including seven countries
reporting strong increases) and five countries reported a
stable level. 
Ecstasy was almost unknown in most Latin American
countries until the mid 1990s. By 1999, however, stud-
ies in Colombia already found a life-time rate of ecstasy
use among youth (age 10-24) of 1.8%. A further rise to
2.2% took place by the year 2001. The consumption of
ecstasy is thus still less widespread than cocaine (4.5%)
but more widespread than basuco (1.2%), ampheta-
mines (1.1%) or heroin (1.1%). Above average levels of
ecstasy use were reported, inter alia, from Medellin and
Cali while ecstasy use in Bogota was close to the
national average. Prevalence rates were found to be
higher among university students than among high-
school students, which seems to reflect the status of
ecstasy in Colombia and other Latin American coun-
tries as a drug for youth from rather well-off families.
Most of the ecstasy is imported from Europe. 
A number of high-school surveys, conducted in
2001/2002 as part of the Inter-American Drug Use
Data System (SIDUC) confirmed that ecstasy use is
now encountered throughout the region, though in gen-
eral, it is still less widespread than other drugs. Rela-
tively high levels - close to those reported from
Colombia - were encountered in countries in the vicin-
ity of Colombia, i.e. Ecuador (1.9%), followed by
Guatemala (1.6%),  Venezuela (1.5%) and Panama
(1.4%). Relatively low levels, in contrast, are still found
in Paraguay and Uruguay.  Use of ecstasy among the
general population, however, is still low. One survey
conducted in Chile in 2000 reported a life-time preva-
lence of ecstasy use of 0.2% among the general popula-
tion.
Fig. 211: Ecstasy use among high-school students in
Ontario (Canada) and in the USA
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Fig. 212: Colombia: Ecstasy use among youth (age
10-24)
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OCEANIA
Confronted with highest levels of ecstasy use worldwide,
but rate of increase appears to be losing momentum  
The highest levels of (admittedaq) ecstasy use world-
wide, are found in the Oceania region. Australia had an
annual prevalence rate of 3.4% of the population age
15-64 in 2001. (Some of the reported ecstasy use in
Australia consists of methamphetamine / mixed ingre-
dient tablets (‘pseudo ecstasy’), sold as ecstasy. Conse-
quently actual ecstasy use may be over-reported in
Australia). In New Zealand in 2001, 3.4% of those age
14-45 used ecstasy in the previous twelve months, up
from 1.5% in 1998 and 0.4% in 1990. Expressed as a
percentage of the population age 15-64, the standard
age range for international comparisons, ecstasy use
affected 2.2% of the general population in 2001.
Expressed as a proportion of the population age 14 and
above (the scale used  for surveys in neighbouring Aus-
tralia), the rate would be 1.9%. 
In Australia the 2001 national household survey
revealed an annual prevalence rate of 2.9% among the
general population age 14 and above (equivalent to
3.4% of those age 15-64), higher than the correspon-
ding rates for the UK (2.2%) or Spain (1.9%) and more
than twice the rate of ecstasy use reported from the USA
(1.3% of the population age 12 and above in 2003).
Over the 1995-2001 period ecstasy use tripled in Aus-
tralia, from 0.9% to 2.9%. A further rise was reported
by the authorities for the year 2002 (ARQ).
Most of the increase, however, took place over the 1995-
1998 period. Subsequently, the rate of increase has
started to flatten. The "National Study of Party Drug
Trends", conducted by the National Drug and Alcohol
Research Centre in 2003, found that the availability of
ecstasy remained largely 'stable' in Australia in 2003 (as
reported by 64% of regular ecstasy users). These per-
ceptions were also in line with the stability of ecstasy
prices in 2003 (around Aus$35 in New South Wales),
in contrast to the price declines reported over the 1997-
2001 period (from Aus$50 to Aus$35 in New South
Wales). The study also revealed that regular ecstasy users
are increasingly inclined to experiment with other drugs
as well, including cannabis and amphetamines (mainly
Ecstasy Cocaine Inhalants Stimulants Maijuana Any illicit drug
Ecuador 1.9% 2.4% 2.6% 3.5% 8.6% 12.3%
Guatemala 1.6% 3.2% 2.4% 5.3% 5.7% 9.8%
Venezuela 1.5% 1.0% 2.7% 6.4% 1.0% 6.0%
Panama 1.4% 0.8% 2.2% 5.9% 6.9% 9.6%
Nicaragua 1.1% 2.7% 2.4% 10.4% 6.9% 11.2%
Uruguay 0.5% 2.7% 1.7% 6.2% 12.5% 13.5%
Paraguay 0.4% 1.6% 0.7% 5.9% 4.3% 5.6%
Unweighted 
average
1.2% 2.1% 2.1% 6.2% 6.6% 9.7%
Table 15: Life-time prevalence of ecstasy and other drug use among high-school students in selected Latin
American countries, 2001/2002 (age 12-18)
Source: Organización de los Estados Americanos (OAS) , CICAD, Resumen Estadistico sobre Drogas, Décima Edición, 2003.
Fig. 213: Australia: Ecstasy use among the general
population (age 14 and above), 1993-2001   
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Source: Australian Institute of Health and Welfare (AIHW),
National Drug Strategy Household Survey 2001 and previous
years.
aq) The level of drug use shown in self-response household surveys (or school surveys) is not only a function of the actual  level of drug use in a country
but also of the readiness of drug users to admit their habit. The high levels of ecstasy use  found in household surveys in Australia and New Zealand
can be thus the result of high levels of ecstasy use and/or of a general climate in which ecstasy users (in contrast to other countries) are not afraid to
openly admit their drug taking behaviour.   
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2. Trends Amphetamine-type stimulants
methamphetamine powder in Australia), as well as crys-
tal methamphetamine, cocaine, ketamine, GHB, ben-
zodiazepines, LSD etc. Poly-drug use has become the
norm among regular ecstasy users (close to 90% of reg-
ular ecstasy users also experimented with other drugs).
Regular ecstasy users tried, on average, about 9 drugs
during their life-time (out of 19 drugs known to be used
in Australia) and used more than 6 different drugs over
the six months prior to the interviews ar.   However, the
study has also shown that, thus far,  there have been rel-
atively few regular users of other drugs among regular
ecstasy users.   
ASIA
Ongoing rise in 2002, but less dramatic than in previ-
ous years 
Although still limited overall, ecstasy use in Asia has
been growing rapidly in a number of countries of East
and South-East Asia in recent years, notably in China,
Hong-Kong, SAR of China, Thailand, Indonesia and
Vietnam.  Consumption has also been expanding in the
Near East, notably in Israel and in the Lebanon. 
Ongoing increases in ecstasy use were reported from
Israel and from the Lebanon for the year 2002 and
2003. Over the last couple of years a number of  crimi-
nal Israeli groups have specialized in the international
ecstasy trade, shipping ecstasy from the
Netherlands/Belgium to overseas markets (North Amer-
ica, Oceania etc). A knock on effect of this has been the
expansion of the domestic market, mainly among
youth. In Lebanon the ecstasy market is primarily
geared towards high-income recreational users.
The strong increases of previous years reported from
countries in East and South-East Asia, in contrast, did
not continue in 2002/2003. Though authorities in
China reported rising levels of ecstasy use, there were
also reports of intensified efforts to crack down on local
ecstasy laboratories and on dance halls and clubs where
ecstasy was known to have been used. This appears to
have had some positive consequences for neighbouring
Hong Kong. Authorities in Hong Kong reported a large
decrease of ecstasy use in 2002 - following  years of
increasing consumption. Declines in ecstasy use were
also reported from Indonesia following the dismantling
of a major ecstasy laboratory which had supplied local
and regional markets.
Despite the impact that these successes in supply reduc-
tion have had on demand in 2002/2003, it seems to be
too early to speak of a trend towards a sustained stabi-
lization of ecstasy use in East and South-East Asia.  As
the market for ecstasy is far from saturated in this part
of the world, a serious concern is that the past few years'
upward trend in the use of ecstasy is likely to resume
again shortly. 
AFRICA
Ecstasy use in Africa is still limited. It tends to be con-
centrated in the southern parts of the continent, mostly
affecting the local white minority and, to a lesser extent,
South-Asian communities. Some of the ecstasy appears
to be locally produced (South Africa) though most is
still imported from Europe. Increases in ecstasy use for
the year 2002 were reported from South Africa,
Namibia and Zimbabwe.  Though just 1% of those in
treatment in South Africa reported ecstasy as their pri-
mary substance of abuse, 9% reported the drug as their
secondary drug of abuse in 2003.  
Increases were also reported from Mauritius and the
Seychelles, while Kenya and Somalia reported  falling
levels of ecstasy use. In western Africa only Gambia
(2001) and Cameroon (2002) reported some increase.
In most of the rest of Africa ecstasy is virtually
unknown.   
ar) National Drug and Alcohol Research Centre, Party Drug Trends, Bulletin, December 2003. 
Fig. 214: New Zealand: Ecstasy use among the
general population 1998-2001   
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Zealand Drug Statistics, Wellington 2001.   
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The analysis of world drug markets presented in this report highlighted some positive elements.  Affecting less than
5% of the age group 15 to 64, the prevalence of illicit drug use at the global level remains much lower than for
tobacco, which affects close to 30%. As far as the two main problem drugs - heroin and cocaine - are concerned,
the prevalence only amounted to about 0.5% of the same age group in 2002. Global  production of opium is now
some 80% less than at the beginning of the 20th century, prior to the introduction of an international drug control
system.
Though considerable progress has been recorded, there is no room for complacency. Drug use remains at an unac-
ceptable level and continues to bring misery to mankind. It also finances criminal and, to some extent, terrorist activ-
ities. Too many young people across the globe still die every year because of drugs, either as a direct result of drug
abuse, or indirectly from exposure to infectious diseases, primarily HIV, transmitted by contaminated injection para-
phernalia.   
In the Political Declaration, adopted at the 1998 UNGASS,  Governments decided to achieve significant progress
in the reduction of illicit drug supply and demand by the year 2008.  Information and data presented in this report
show mixed results so far: 
• Clear advances were made with regard to the global production of cocaine, which fell by 30% between
1999 and 2003, and 18% between 2002 and 2003. This decline was largely due to major control
efforts in Colombia, the world's largest producer of cocaine. Global cocaine production is now at its
lowest levels since the late 1980s. In the USA, the world's largest cocaine market, 2003 student sur-
veys showed levels of consumption some 23% lower than in 1999, and more than 60% lower than in
1985. There was, however, an increase of cocaine consumption in South America and Western Europe
over the last few years, but this trend may have started to lose momentum in 2003.
• In the case of opiates, progress were made in South-East Asia, the world's second largest source of illicit
opium. There, opium production fell by 35% between 1998 and 2003, and by more than 50%
between 1990 and 2003. These advances were unfortunately over-shadowed by developments in
South-West Asia. In Afghanistan, opium production was virtually eliminated in 2001, leading to a
66% decline of global opium production in that year. This had positive consequences on the demand
side. In several parts of Asia and Europe abuse of opiates stabilized in 2002. Drug related deaths
declined in Western Europe by some 20% between 2000 and 2002 and the number of new IDU
related HIV cases fell in Central Asia and Eastern Europe in 2002. However, Afghan opium produc-
tion rebounded during the last two years. In 2003, it was already one third higher than in 1998 and
there are indications that 2004 production could climb even further, resulting in plentiful supplies of
opium and heroin on the international market. 
• Available data for cannabis is less precise than for the other two plant based drugs. Nonetheless, all
available indicators suggest that the cannabis market continued to increase over the last few years.
Conclusion
Cannabis production as well as global cannabis seizures rose over the last decade and are now back to
the levels of the late 1980s. UNODC's Drug Abuse Trend Index showed an ongoing increase of
cannabis use over the last decade and even some acceleration over the 2000-2002 period. Cannabis
trend data suggested an increase in Europe, South America, Africa and in a number of countries in
Asia. The market stabilized in North America, Oceania and some countries of South-East Asia. 
• Data for amphetamine-type stimulants showed a mixed picture. The number of ATS laboratories dis-
mantled clearly increased during the last decade, including over the 1998-2002 period. Seizures of
amphetamines also showed a strong upward  trend in the 1990s, but declined between 2000 and 2002.
Similarly, UNODC's Drug Abuse Trend Index indicated, for the first time in years, a stabilization of
consumption in 2002. Increases in methamphetamine use, however, continued to be reported from a
number of countries in East- and South-East Asia. In North America and in Western Europe, follow-
ing years of increases in the 1990s, the amphetamines market has remained largely stable in recent
years. 
• The trend was less favourable with regard to ecstasy. Seizures continued to rise.  In many parts of the
world, ecstasy use increased further in 2002. Nonetheless, there were signs that the upward trend
might be losing momentum. While it continued to increase in many developing countries, ecstasy use
stabilized in several West European countries and declined in the USA and in Canada in 2002/2003. 
Conceptual developments in recent years offer prospects of reinvigorated drug control strategies.  They reflect, for
instance, the need to address the drug problem in a broader sustainable development context. A more integrated
response to the twin sectors of drugs and crime is also emerging. The new paradigm of human security encapsulates
this broader view of the problem. Finally, efforts are also under way to improve the understanding of drug epidemics,
as well as the structure and functioning of drug markets, with a view to design more synergetic, dynamic and cost-
effective interventions. 
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An estimated 3 % of the global population, or 185 million people
consume illicit drugs annually. Among this population are people
from almost every country on earth and from every walk of life.
Countless more people, around the world, are involved in the
production and trafficking of illicit drugs, and still more are
touched by the devastating social and economic costs of this
trade. These people live in both developed and developing
countries, are rich and poor, healthy and unhealthy, citizens and
refugees. Illicit drugs are a truly global phenomenon. Partially a
consequence of this pervasiveness, and partially a consequence
of the illicit and hidden nature of this trade, reliable analysis and
statistics on the production, trafficking and consumption of illicit
drugs are rare.
In cooperation with Member States, the United Nations Office on
Drugs and Crime (UNODC) has endeavoured to fill the gaps. 
In this first edition of the new two volume World Drug Report,
UNODC presents more quantitative data than ever before in an
effort to increase the amount of factual evidence available in 
a field which is so notoriously difficult to quantify. This year, 
the analysis of trends, some going back ten years or more, 
is presented in Volume 1. Detailed statistics are presented in
Volume 2. Taken together these volumes will provide the most
complete picture yet on today's illicit drug situation.
